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Mupirocin (Pseudomonic acid A) has long been used against Methicillin Resistant 
Staphylococcus aureus MRSA, yet bacteria have developed resistance, threatening 
future use. Structurally similar to mupirocin is thiomarinol A, a natural compound 
produced by the marine bacterium Pseudoalteromonas spp, which possesses stronger 
antibacterial activities. However, it differs from mupirocin by four distinct differences and 
among these are extra 4-hydroxylation and joining to pyrrothine. Studying these 
differences should enhance our understanding of the molecular assembly and 
biosynthesis machinery. 
Complementation and mutagenesis studies identified the tmuB gene to be responsible 
for the 4-hydroxylation as a final tailoring step. In vivo and in vitro studies on purified 
TmuB revealed that it can hydroxylate diverse pseudomonic acids but is inhibited by 
molecules with an 8-hydroxyl group, which primarily affects catalysis rather than binding. 
Molecular modelling plus docking and mutagenesis provides increased understanding of 
both TmuB potential to modify other substrates and how mupirocin activity can be 
modulated by 4-hydroxylation. This study also expressed holA, purified its gene product, 
a non-ribosomal polypeptide synthetase (NRPS), and assayed its activity by 
pyrophosphate release. It presents a proposed pathway for pyrrothine biosynthesis 
catalysed by HolA, which exhibits the unusual ability to join two cysteine molecules by a 
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1.1. Overview of antibiotics and antibiotic resistance   
Antibiotics (anti: against, bio: life) are chemical metabolites produced by microorganisms 
such as bacteria and fungi, and have the ability to kill or inhibit the growth of other 
microorganisms at low concentration. The noun “Antibiotic” was first suggested by soil 
microbiologist Selman A. Waksman in 1942 (Waksman, 1947).  
Before antibiotic development, infectious diseases were the major cause of death. This 
changed after 1929 when the British microbiologist Alexander Fleming discovered the 
first antibiotic by detecting the inhibition of the Staphylococcus aureus growth around a 
Penicillium notatum mold colony (Torok et al., 2009). However, although Fleming named 
this active substance penicillin, because of technical difficulties he did not extract it for 
human administration. Fortunately, about one decade later, Ernst Chain and Howard 
Florey developed a method to isolate penicillin and used it during the Second World 
War. This discovery changed the history of medicine and provided the inspiration to 
others to develop many types of antibiotics. Thus, the Noble Prize in medicine was 
awarded to Fleming, Chain and Florey in 1945 (Lloyd, 2009). 
Since the invention of the first antibiotic, public health has improved dramatically and 
average life expectancy has witnessed a significant rise (Todar, 2008). However, this 
improvement did not persist for a long time as a new problem developed which may 
render antibiotics to lose their efficacy. The first prediction about antibiotic resistance 




 “It is not difficult to make microbes resistant to penicillin in the laboratory by 
exposing them to concentrations not sufficient to kill them, and the same thing has 
occasionally happened in the body… …and by exposing microbes to non-lethal 
quantities of the drug make them resistant.”(The Nobel Lecture, 1945).  
This prediction was correct when the first antibiotic resistance developed by S. aureus 
against penicillin was observed in 1947. During several decades, antibiotic resistance 
increased steadily and nowadays seventy percent of nosocomial infections are resistant 
to at least one most commonly used antibiotic (Todar, 2008). The well-known bacteria 
that are resistant to a wide range of antibiotics and cause high mortality and morbidity 
are methicillin resistant Staphylococcus aureus (MRSA) and Multidrug Resistant 
Tuberculosis (MDR-TB). According to the Office for National Statistic data in England 
and Wales, 12% of all deaths in 1993 were due to MRSA and this rate rose significantly 
to 66% in 2002, although it had fallen back to 16% in 2014 (Office for national statistic, 
2004 & 2015). Regarding MDR-TB, a WHO report (2011) points out that this disease 
causes about one hundred thousand deaths annually. In addition to health risk, the 
economic impact is another reason to make this problem serious and globally 
concerning. For example, in the United States, Institution of Medicine report (1998) 
shows that diseases caused by antibiotic resistant bacteria cost about four billion US 
dollars annually. Therefore, the antibiotic resistance problem is considered as an issue 




1.1.1. Antibiotic classification 
There are several schemes to classify antibiotics into groups according to the type of 
activity, potency spectrum, chemical structure and the mode of action. Regarding the 
type of activity, antibiotics can be divided into bactericidals, which kill bacteria, and 
bacteriostatics, which inhibit bacterial growth. The potency scheme divides antibiotics 
into the broad spectrum (against a wide range of bacteria) and the narrow spectrum 
(against few types of bacteria) (Madigan et al., 2012). Based on the chemical structure, 
antibiotics with similar structure can be classified into groups, for example, β-lactams, 
macrolides, aminoglycosides, quinolones, tetracyclines (Figure 1.1). Cell wall synthesis, 
cytoplasmic membrane structure and function, protein synthesis, folic acid metabolism 
and nucleic acid (DNA and RNA) synthesis are the main targets in the cell that classified 
antibiotics into groups (Figure 1.2).  
The antibiotics which target the bacterial cell wall are highly selective as the cell wall is a 
unique feature for bacteria. A group of antibiotics targets this part of the cell using 
different mechanisms to inhibit or disrupt the cell wall. For example, β-lactams antibiotics 
inhibit cell wall synthesis by binding and reacting with transpeptidase enzymes (penicillin 
binding proteins) which are responsible for cross-linking of two glycan-linked peptide 
chains. Vancomycin inhibits cell wall synthesis by blocking transpeptidation via binding 
to the terminal D-Ala-D-Ala peptide (Madigan et al., 2012). Polymyxins act on the 
bacterial outer membrane and bind with lipid A moiety of the Lipopolysaccharide (LPS) 





































































































































































































Daptomycin, a cyclic lipopeptide, targets cytoplasmic membrane, inserts into and forms 
pores in the lipidbilayer causing rapid depolarization of the membrane (Robbel & 
Maraheil, 2010). The antibiotics that target protein synthesis can be divided into three 
subgroups and within the same subgroup, the mechanism of action for each antibiotic is 
different. Erythromycin, clindamycin and chloramphenicol inhibit protein synthesis by 
interaction with the 50S ribosomal subunit while gentamycin, kanamycin and tetracycline 
interact with the 30S ribosomal subunit. Puromycin and mupirocin inhibit protein 
synthesis in different ways from these two subgroups. Puromycin occupies the A site on 
the ribosome and therefore the growing chain of the peptide binds to puromycin instead 
of aminoacylated tRNA causing premature chain termination (Madigan et al., 2012). 
Mupirocin inhibits protein synthesis by binding specifically to isoleucyl-tRNA synthetase 
and prevents incorporation of isoleucine amino acids into bacterial proteins (Hughes & 
Mellows, 1978; Eriani et al., 1990). Folic acid in bacteria is produced from p-
aminobenzoic acid (PABA) via two enzymatic reactions. Tetrahydrofolic acid (THF) 
formation is essential for thymidine synthesis in bacteria and inhibition of THF formation 
means inhibition of bacterial DNA synthesis (Brown, 1962). Both trimethoprim and 
sulfonamides interfere with folic acid metabolism. Sulfonamides inhibit dihydropteroate 
synthetase, an enzyme that converts PABA to dihydropteroic (DHT), while trimethoprim 
inhibits the formation of THF from DHT by binding with the enzyme catalyzing this 
reaction (Brown, 1962 and Brogden et al., 1982). Quinolones such as ciprofloxacin and 
nalidixic acid inhibit bacterial DNA gyrase while rifampin affects transcription by binding 




al., 2012). Understanding the mode of action of antibiotics helps us to understand the 
mechanism of antibiotic resistance and how bacteria acquired resistance.  
 
1.1.2. Mechanisms of antibiotic resistance 
Microbes that produce antibiotics must naturally be resistant to the molecule(s) they 
produce while other microbes acquire resistance by a combination of genetic processes 
and selective pressure. The origin of the genes that play a role in the resistance could 
Figure 1.2. Classification of antibiotics according to the target. Each group of 
antibiotics targets a particular component of the cell. For example, cell wall collects 
penicillins and cephalosporins in one group (Figure taken from Madigan et al., 2012 




be chromosomal genes and mutation or they could be acquired by transferrable 
elements like plasmids. Bacteria use the following mechanisms to avoid being affected 
by antibiotic activity.  
Antibiotic modification and inactivation: resistance to penicillin and cephalosporin is 
often due to production of β-lactamase enzymes that cleave the essential β-lactam ring 
rendering the antibiotic inactive. Resistance to chloramphenicol and aminoglycosides is 
due to R plasmids which encode enzymes that modify the antibiotic molecules through 
phosphorylation, acetylation and adenylation (Mingeot –Leclercq et al., 1999 & Madigan 
et al., 2012). 
Modification of antibiotic targets: mutations in the genes, generally chromosomal, 
modify the binding site or active site geometry so that the antibiotic no longer inhibits the 
enzyme. For example, resistance to rifampin can be due to mutation of the RNA 
polymerase β-subunit (Wehrli, 1983). Modification of lipid A moiety of the 
Lipopolysaccharide (LPS) in gram-negative bacteria leads to polymyxin resistance 
(Olaitan et al., 2014).   
Alternative biochemical pathway: some bacteria depend on exogenous precursors to 
build up the essential molecules. For example, a mutation in the thymidylate synthetase, 
which catalyzes THF conversion to thymine (see above), results in thymine requiring 
bacteria (thy-) that depend on an exogenous source of thymine, and such bacteria are 




sulfonamides develop a resistant biochemical pathway that depends on exogenous folic 
acid from the environment (Madigan et al., 2012)          
Efflux pumps: Most bacteria use various transport proteins to extrude harmful 
substances, including antibiotics, out of the cell. These pump systems can transport 
either specific single molecules or a wide range of antibiotics leading to multidrug 
resistance (MDR). Resistance to fluoroquinolones due to this mechanism has been 
reported in a number of clinically important bacteria such as Staphylococcus aureus, 
Streptococcus pneumoniae and Escherichia coli (Webber & Piddock, 2003 and Sun et 
al., 2014).    
Cell permeability and antibiotic uptake: Bacteria use different techniques to reduce 
antibiotic uptake from the surrounding environment. Gram-negative bacteria develop 
permeability barriers to resist β-lactam antibiotics. Some mutations lead to modifications 
of lipid-mediated or porin-mediated pathways of the outer membrane permeability which 
reduce antibiotic uptake. Hydrophobic antibiotics such as kanamycin, gentamycin and 
erythromycin enter the cell through lipid-mediated pathways and modification of this 
results in resistance against these drugs. Some clinically important pathogens such as 
Escherichia coli, Neisseria gonorrhoeae, Pseudomonas aeruginosa and Klebsiella 
pneumoniae develop resistance against hydrophilic antibiotics such as β-lactams and 
chloramphenicol via porins modification. Other bacteria change proton motive forces to 
reduce the inner- membrane permeability (Delcour, 2009 and Torok et al., 2009) 




1.1.3. Tackling antibiotic resistance 
The wrong administration policy of antibiotics is the most important factor that 
predisposes to antibiotic resistance. Inappropriate and overuse of antibiotics in 
medicine, agriculture and veterinary medicine are the leading causes for development of 
antibiotics resistance. In the United States, in one year more than twelve tons had been 
prescribed for humans and about eighteen tons in agriculture (Torok et al., 2009; Todar, 
2008). However, this may be different between developed and developing countries 
(Torok et al., 2009). Regarding European countries, the European Surveillance 
Antimicrobial Consumption (ESAC) report (2009) shows that since 2005, the 
antimicrobial usage has risen. This may be evidence that antimicrobials still perform a 
mammoth task in fighting infectious diseases. However, the increasing consumption of 
antibiotics may be the main cause of antibiotic resistance, a serious problem that will 
face the future use of antibiotics. In response to the steady increase of antibiotic 
resistant bacteria and its impact both on health and economic sectors, many 
governments, health organizations and scientific institutions have taken steps to tackle 
antibiotic resistant bacteria and many strategies have been suggested. Many well-
known organizations such as the World Health Organization (WHO) and Centers for 
Disease Prevention and Control (CDC) had issued guidelines and policies to tackle this 
worldwide problem. These include hygienic and preventive measures, public education, 
awareness about antibiotic usages in heath and agriculture, alternative therapy such as 
bacteriophages and probiotics, and new antibiotics development (annual reports from 




The strategy to produce new antibiotics following the 1990s has failed as new antibiotic 
discovery and development had decreased steadily (Figure 1.3). The current situation 
with a lack of newly licensed antibiotics can-not fulfill the demand created by the fast 
development of antibiotic resistance. Therefore, many initiatives have been announced 
by health-care professionals and relevant scientific agencies. An initiative was 
announced in 2009 by the Infectious Disease Society of America to develop 10 new 
antibiotics by 2020 (Piddock, 2012). This was followed by British Society for 
Antimicrobial Chemotherapy action regarding solutions for the lack of new antibiotics 
(Piddock, 2012).  
 
New antibiotic analogues production can be often more effective than totally new 
antibiotics. First, the mechanism of action of the current antibiotics is confirmed. Second, 
a minor modification does not affect the structure backbone which is critical for activity. 
Finally, the modification may improve some features of the compounds such as potency, 
Figure 1.3. Number of new antimicrobials produced over the last three decades 




bioavailability and stability (Madigan et al., 2012). β-hydroxylation of an antimalarial 
compound by FrbJ enzyme, an Fe(II)/α-ketoglutarate dependent hydroxylase, improves 
activity and bioavailability (DeSieno et al., 2011).   
Because of dramatic developments in genetic techniques and chemical sciences, one 
can predict the molecular assembly of the antibiotic at the genetic level. This enables us 
to manipulate the genetic cluster of the producing microorganism to obtain novel 
derivatives. Many antibiotics are made naturally by bacteria using an assembly line of 
enzyme complexes like polyketides synthases (PKSs) and non-ribosomal peptide 
synthetase (NRPS). Understanding the mechanism of enzymatic system and the 
biosynthesis pathway of products may allow one to rebuild them to produce novel 
derivatives. 
   
1.2. Polyketides  
Polyketides are large classes of biologically active natural compounds produced by a 
wide range of living organisms such as bacteria, fungi, plants and animals. Because of 
their diverse pharmaceutical properties and biological activities, polyketides became the 
subject of many scientific studies and intensive research. They are the most important 
microbial metabolites in medicinal fields as they are used as antibiotics (for example 
erythromycin A and rifamycin S), antifungals (for example amphotericin B), anticancer 




immunosuppressants (for example rapamycin) (Figure 1.4) (Weissman & Leadlay, 
2005). 
  
Figure 1.4. Examples of clinically important polyketides (adapted from Weissman 
& Leadlay, 2005). 




1.2.1. Polyketide biosynthesis  
Polyketide biosynthesis is catalyzed by multi-domain enzymes called Polyketide 
Synthase (PKS) which catalyze repetitive decarboxylative condensation reactions in a 
similar pattern to the fatty acid biosynthesis, fatty acid synthase FAS (Figure 1.5).  
Based on protein structure and mode of synthesis, polyketide synthases are classified 
into three types: Polyketide synthase type I, type II and type III (Table 1.1). Type I PKSs 
are large multidomain proteins carrying all active sites required for polyketide 
biosynthesis. According to the mode of action of the enzyme system, Type I PKSs can 
be subdivided into two types: modular and iterative (Khosla et al., 1999). To carry out 
one decarboxylative condensation reactions in modular type I PKSs, each module 
should at least consists of three catalytic domains; Acyltransferase (AT), Acyl carrier 
protein (ACP) and Ketosynthase (KS). In addition to these three domains, the terminal 
module houses a Thioesterase (TE) domain which is responsible to release the product 
(Helfrich & Piel, 2016). 
The Acyltransferase (AT) of the PKS system is either located and integrated within each 
module and referred to as cis-AT PKS or as a stand-alone Acyltransferase (AT) domain 
and referred to as tran-AT PKS (Dunn et al., 2014). The ACP domain carries a 
prosthetic group (4-phosphopatetheine) arm which is attached to highly conserved 
Serine residue. This arm is a post-translational modification of the ACP domain 
catalyzed by 4-phosphopantetheinyl transferase (PPTase) (Figure 1.5). This arm works 




Figure 1.5. Mechanism of polyketide synthetase. A: 4’-phosphopantheinylation of 
ACP by PPTase. B: a starter unit loading to the AT and PCP domain, and C: the 








The number of ketide units of the product can be predicted by the number of modules 
because each module is responsible for the incorporation of one ketide unit (-CH2-CO-) 
to the polyketide chain (Khosla et al., 2007; Keatinge-Clay, 2012). 
The starter and extender units are activated as Co-A thioesters before loading to the AT 
domain. Many Co-A derivatives of carboxylic acids can be utilized as starter and 
extender units. However, the main starter units are acetyl-CoA and propionyl-CoA while 
malonyl-CoA and methylmalonyl-CoA are the most common extender units (Hranueli et 






This catalyzes the transfer of the acyl moiety to the thiol group of the 4- 
phosphopantetheine arm on the ACP domain. The AT domain loads the extender units 
to the second module in the same way to ACP. The KS domain catalyzes the 
condensation reaction between the starter unit and the extender unit to yield a β-
ketoacetyl 4C (if the starter is acetate and the extender is malonate). This elongation 
reaction continues until it reaches the terminal module which releases the forming chain 
by the TE domain (Hopwood & Sherman, 1990). In addition to the essential domains 
stated above, PKS modules contain other domains that catalyze extra reactions such as 
ketoreductase (KR), dehydratase (DH), methyltransferase (MT) and enoylreductase 
(ER) (Helfrich & Piel, 2016).   
Erythromycin, rapamycin and rifamycin are examples of the polyketides that are 
produced by modular type I PKSs. To understand the mode of enzymatic action, the well 
characterized and intensively studied example is the 6-Deoxyerythronolide B Synthase 
(DEBS) which is responsible for biosynthesis of erythromycin (Khosla et al., 1999). The 
DEBS consists of three large polypeptides (about 350 kDa each) referred to as DEBS1, 
DEBS2 and DEBS3. Each DEBS unit houses two modules and each module holds a set 
of domains required to catalyze one round of polyketide chain extension (Staunton & 
Weissman, 2001) (Figure 1.6). 
In addition to the three essential domains (ketosynthase, KS; acyltransferase, AT and 
acyl carrier protein, ACP) which exist in each DEBS, DEBS 1 contains an extra small 
module called loading didomain, LDD, which comprises the AT and ACP domains 






The AT domain in module 1 introduces the extender unit, methylmalonate and transfers 
it to the prosthetic group (4-phosphopantetheine) arm of ACP domain. The KS domain in 
the same module accepts the starter unit from the previous module and catalyzes the 
decarboxylative condensation reaction with the substrate bound to the ACP domain arm. 
Then, the growing polyketide chain passes from one module to the next until it reaches 
Figure 1.6. The modular type I PKS of 6-deoxyerythronolide B synthase (DEBS) 
showing the linear organization of the domain, each module houses essential 
domains KS, AT and ACP for one round extension (Figure adapted from Staunton 




the last module which houses the thioesterase TE domain responsible for releasing the 
final product. While passing from one module to another, the polyketide chain can 
undergo some extra reactions such as ketoreduction, dehydration and enoyl reduction 
by ketoreductase KR, dehydratase DH and enoyl reductase ER domains respectively. 
(Staunton & Weissman, 2001; Khosla et al., 2007). 
In contrast to the modular type that contains many active sites which are used only 
once, the protein structure of iterative PKS is composed of several monofunctional 
proteins each with only one active site that is re-used repeatedly. After the required 
number of iteration cycles, the polyketide chain is released by the TE domain (Frandsen, 
2010).  
 
1.2.2. Polyketide diversity  
The diversity of the products depends on the type and number of the building block 
units, secondary rearrangement of the product backbone such as cyclization and a 
broad range of the the tailoring modifications (Figure 1.7).   
Although there are many genetic, structural and mechanistic similarities between PKSs 
and FASs, there are some differences that make polyketides more diverse, active and 
complex. The polyketides differ from fatty acids by the complete or partial absence of 
reduction and dehydration reactions that make the latter unfunctionalized alkyl chains 




extender units is another cause of polyketide complexity. Studies reported that the 
loading AT, KR, DH and ER domains in DEBS PKS, which is responsible for 
erythromycin biosynthesis, accept a wide range of substrates (Khosla et al., 1999). 
PKSs use a diverse range of starter and extender units which impart structure diversity 
to the product backbone. The iterative type III PKSs use non- acetate starter units, for 
example, in the biosynthesis of dihydroxybiphenyl, benzoyl is incorporated as the starter 
unit. Different malonyl-derivatives have been reported to be used as unusual extender 
units by modular PKS.  In zwittermicin biosynthesis, an antibiotic produced by type I 
PKS in Bacillus cereus, hydroxymalonylate and aminomalonate are incorporated as 
extender units (Hertweck, 2009). In vitro analysis revealed that the methyltransferase 
(MT) domain of fungal polyketide synthase CazF displays a promiscuity for the 
substrates and can transfer a non-natural cofactor as an extender unit onto growing 
polyketide chains imparting the structural diversity of the product (Winter et al., 2013).  
Other studies show that the tailoring gene clusters are required to produce active 
polyketides (Hothersall et al., 2007) which may involve modifications of functional groups 







1.2.3. Genetic approaches and combinatorial biosynthesis  
There are many encouraging factors that push toward the manipulation of the polyketide 
synthases to generate novel compounds with different activities. The therapeutic 
importance of polyketide compounds that are already used in clinical and veterinary 
Figure1.7. Gilvocarcin pathway illustrating the diversification of the polyketide product 





medicine and the increasing demand that has been placed on them, and the modular 
nature of the type I PKSs diversity raises the promise of opportunities to apply genetic 
engineering to manipulate their structure in ways which are inaccessible by standard 
synthetic chemical approaches (Kitttendorf & Sherman, 2006). 
Many genetic engineering strategies have been applied to modify modular polyketide 
biosynthesis. These include (i) deletion or inactivation of single domains or mutation that 
change the substrate specificity; (ii) insertion and substitution of the intact modules; (iii) 
mutational biosynthesis by feeding of synthetic precursors to mutant phenotype. These 
manipulations either target the enzymes responsible for backbone building or target the 
tailoring enzymes that are responsible for post-polyketide processing (Staunton and 
Weissman, 2001).       
Over two hundred new polyketide structures have been produced using two approaches 
that target the specificity and catalytic power of the PKSs: either by targeting individual 
catalytic domains via deletion, addition, substitution and inactivation, or by targeting 
intact modules via replacement, deletion and addition (Kitttendorf & Sherman, 2006). 
The possible modification of polyketide structures includes chain length modification, 
incorporating of different building blocks and introducing peripheral moieties (Floss, 
2006; Kitttendorf & Sherman, 2006). 
There are many studies that involved genetic manipulation of the PKS catalytic domain 
which leads to incorporation of different starter and extender units. The replacement of 




domain incorporated new starter units and resulted in erythromycin A, B and D analogs 
(Khosla, 1999). The alteration of an AT domain by site directed mutagenesis can 
change the specificity for an extender unit in 6-deoxyerythronolide B synthase (Reeves 
et al., 2001). AT domain inactivation from module 6 of DEBS can be recovered by 
malonylCoA:ACP transacylase (MAT) to produce 2-desmethyl-6-deoxyerythronolide B 
(Kumar et al., 2003). Zhang et al (2006) reported that the replacement of reductive 
domains dehydratase (DH) and ketoreductase (KR) domains of module 2 from the 
avermectin PKS in S. avermitilis Olm73-12 by the DNA fragment encoding the DH, 
enoylreductase, and KR domains from module 4 of the pikromycin PKS of Streptomyces 
venezuelae  produces only avermectin B instead of  avermectin A and oligomycin. 
A study revealed that the mutant strain of S. avermitilis accepts synthetic analogues of 
the diketide intermediate exogenously added to the culture media as starter units and 
lead to production of novel analogs of avermectin (Dutton et al., 1994). Some studies 
focus on the tailoring enzymes that decorate the backbone structure of the polyketides 
such as oxidation, glycosylation and methylation. These modifications, that are 
significant for biological activities and the chemical properties of the molecules, thus 
become the targets for the combinatorial biosynthesis that leads to new polyketides. 
Examples of these enzymes that exhibited broad substrate tolerance are 
glycosyltransferases, methyltransferases, P450 mono-oxygenases and nonheme-iron(II) 
and 2-oxoglutarate-dependent hydroxylases (Weissmann and Leadlay, 2005). Co-
expression of glycosyltransferase from the picromycin cluster with a library of plasmids 




and improved antibacterial activities (Tang and McDaniel, 2001). Genetic and 
biochemical analysis revealed substrate flexibility of P450 hydroxylase (PikC) from S. 
venezuelae to catalyze the hydroxylation of 12- and 14-membered ring macrolides (Xue 
et al., 1998).  Inactivation of nonheme-ketoglutarate-dependent oxygenase in Glarea 
lozoyensis ATCC 20868 abolished the pneumocandin A0 production and increased the 
yield of pneumocandin B0, the semisynthetic precursor of the antifungal drug, 
caspofungin acetate (Chen et al., 2015). Figure 1.8 shows a number of examples of 
modified natural products via genetic engineering.        
Despite the numerous investigations of polyketide compounds, there are many 
limitations and difficulties regarding genetic manipulation that must be overcome in order 
to discover further desired novel molecules. The extraordinary length of the PKS genes 
from 35 to more than 200 kb, make them difficult to be manipulated. Some of the natural 
polyketide producers are not amenable to genetic manipulation procedures. Some 
domains within the same PKS system exhibit a degree of specificity, so that 
manipulation of the upstream domains may abolish the products. Some relationships 
and interactions between domains within the same module and between modules are 
difficult to predict and work in a sequential fashion. Thus, any rational genetic 
engineering in the gene cluster of the PKS should consider these issues (Menzella et 






Figure 1.8. Examples of clinically important polyketide structures that have been 





Mupirocin is a polyketide produced by Pseudomonas fluorescens NCIMB 10586, a 
Gram-negative rod-shaped bacteria found in soil living in the vicinity of plant roots. 
Mupirocin was first described as pseudomonic acid in 1971 by Ernst Chain's laboratory 
(Fuller et al., 1971). Pseudomonic acid is a mixture of four types (pseudomonic acids A, 
B, C, and D). Pseudomonic acid A (PA-A) accounts for 90% of the mixture and is 
composed of two parts: monic acid a C17 molecule containing a pyran ring and 
saturated fatty acid, 9-hydroxynanoic acid. These two parts are joined by an ester bond. 
Pseudomonic acid B which accounts (8%) of the mupirocin mixture differs from PA-A by 
the presence of a hydroxyl group at C8. Pseudomonic acid C and D together account for 
< 2% of the mixture and differ by a double bond between C10-C11 instead of the 
epoxide group and unsaturated C-C bond in the fatty acid side chain at C4’-C5’ 
respectively (El- Sayed et al., 2003). Genetic manipulation of the mup cluster has 
generated many derivatives of pseudomonic acids (Figure 1.9). 
 
1.3.1. Mechanism of action  
Mupirocin exerts a broad spectrum activity against Gram-positive bacteria, particularly 
Staphylococcal and Streptococcal species that cause skin infection, and even against 
some Gram-negative Enterobacteriaceae bacilli particularly at high concentration (Table 
1.2). Mupirocin is bacteriostatic at low concentration but bactericidal at high 









Figure 1.9. Pseudomonic acids and derivatives produced by the WT and mutant 





It is used as a topical antibiotic to treat bacterial skin infections and as a nasal aerosol to 
clear the nasal passage in patients and hospital staff particularly to eradicate MRSA 
colonization, which is resistant to a wide range of antibiotics (Cookson et al., 1990). 
 
Table 1.2. Antibacterial activities of mupirocin (Thomas et al, 2010) 
Organism 
Mupirocin MIC  
(µg. ml-1) 
Gram-positive bacteria  
Streptococcus pneumoniae 0.12 
Bacillus anthracis 64 
Bacillus subtilis 0.12 
Clostridium difficile 32 
Corynebacterium sp. > 128 
Enterococcus faecalis 64 
Listeria monocytogenes 8.0 
Staphylococcus aureus  0.25 
Staphylococcus epidermidis 0.5 
Gram-negative bacteria  
Bacteroides fragilis > 6,400 
Bordetella pertussis 0.02 
Escherichia coli 128 
Haemophilus influenzae 0.12 
Neisseria meningitidis 0.05 
Pasturella multocida 0.25 








Mupirocin inhibits protein synthesis by binding specifically to isoleucyl-tRNA synthetase 
(IleRS) which is responsible for the specific aminoacylation of tRNAIle with isoleucine 
during ribosomal protein synthesis. IleRS belongs to the class I tRNA synthetases 
containing an ATP-binding Rossmann fold. As shown in Figure 1.10, in the first step, 
IleRS catalyzes a covalent linkage between the carboxyl terminus of isoleucine with the 
5'-phosphate group of ATP to form an aminoacyl-adenylate intermediate, after which the 
activated isoleucine is transferred to the 2'OH of the terminal adenosine of tRNAIle. 
(Hughes & Mellows, 1978; Eriani et al., 1990 and Marion et al., 2009). 
The crystal structure revealed that the IleRS structure can be divided into three regions 
according to the function (Figure 1.11): the Rossmann fold which is responsible for 
amino acid activation and transferring, the editing domain which removes incorrectly 
acylated amino acids and the region at the C- and N-terminus that recognizes an 
unusual anticodon loop conformation in the tRNA (Silvian et al., 1999). IleRS displays a 
proofreading activity using “double sieve” mechanism depending on the synthetic and 
editing catalytic sites. First, the synthetic active site refuses amino acids larger than 
isoleucine such as methionine and phenylalanine, and those with polar sidechains. 
However, valine, which is smaller by a single methyl group, can fit into the active site 
and consequently Valyl-AMP or Valyl-tRNAIle are synthesized. Thus, the second sieve is 
achieved by the editing site which hydrolyses these misloaded valines (Ibba and Söll, 
2000). 
Mupirocin acts as a bifunctional inhibitor for IleRS as it occupies both the isoleucine and 




of the monic acid mimics the side chain of isoleucine while the pyran ring and the region 
around C1–C3 mimics the ribose and adenine of ATP.  
 
 
Figure 1.10. Mechanism of action of isoleucyl-tRNA synthetase to activate 




In addition, this binding could be more stabilized by the 9-hydroxynonanoic acid part 
which sits in a hydrophobic groove (Hughes & Mellows, 1978; Thomas et al., 2010). 
The IleRS cannot use the proofreading activity described above to discriminate 
mupirocin binding, but uses an alternative “shuttle mechanism” in which the incorrect 
products have to travel between the synthetic and editing active sites in the same 
manner to DNA polymerase editing (Silvian et al., 1999). 
        
 
Figure 1.11. Crystal structure of the isoleucyl-tRNA synthetase as a complex with 
mupirocin. The structure is divided into three regions according to the function; 
Rossmann fold (synthetic site) (Green), editing domain (site) (Yellow) and N-terminus 
(anticodon) domain (blue). tRNA is shown as orange sticks and mupirocin as red 








1.3.2. Limitation and resistance 
There are many limitations which allow mupirocin to be used as a topical antibiotic but 
not as a systemic medication. The ester linkage, which holds both monic acid and 9-
hydroxynanoic acid together, is hydrolyzed in body fluids rendering it inactive and the 
majority binds with serum resulting in insufficient bioavailability. In addition, its biological 
activity is pH dependent and retained within pH 4-9 and outside these limits, the 
hydroxyl group at C7 attacks the 10, 11 epoxide producing two inactive cyclic ethers 
(Clayton et al., 1980; Thomas et al., 2010).  
Another problem associated with the use of mupirocin as an antibiotic is the 
development of resistance by bacteria. Bacteria use more than one mechanism to 
protect against mupirocin. Resistance was first recorded in 1987 and studies reported 
that this resistance is due to two types of mechanism. Low-level mupirocin resistance 
(MIC = 8-56 mg/ml) results from a point mutation in a single nucleotide in the ileS gene 
that encodes the IleRS (Cookson, 1998). The common mutations that occur at the 
synthetic site of IleRS indentified in resistant S. aureus are V588F, V631F and G593V in 
the vicinity of the KMSKS motif in the Rossmann fold. The substitution of valine 588 with 
the bulkier residues like phenylalanine distort the Rossmann fold and prevents 
mupirocin binding (Antonio et al., 2002). Other studies report a similar mutation but in a 
different residue Q612H which causes considerable disruption in the hydrophobic pocket 
in the Rossmann fold. Four more mutations (P187F, K226T, F227L and V767D) were 
identified in clinical isolates of MRSA with low-level mupirocin resistance. These 




interaction with mupirocin (Yang et al., 2006).  Because low-level resistance is non-
transferable, it is not currently considered a major threat to clinical use. However, the 
prevalence of low level resistance in S. aureus is more frequent than high-level 
resistance (Yun et al., 2003).     
High-level mupirocin resistance (MIC ≥ 512 mg/ml) is due to the production of a novel 
IleRS having sequence motifs in its active site similar to the eukaryotic IleRS which is 
naturally resistant to mupirocin. An evolutionary study identified that this type of IleRS in 
some bacterial species is acquired by horizontal gene transfer and closely related to 
archaeal and eukaryotic IleRSs (Brown et al., 2003). This type of IleRS in bacteria is 
encoded on conjugative plasmids (Hodgson et al., 1994; Yanagisawa & Kawakami, 
2003). The prevalence of high-level resistance in S. aureus is due to the presence of the 
mupA gene in transferable plasmids and is similar to the mupM gene in the mupirocin 
producer, Pseudomonas fluorescens, which is located on the chromosomal DNA (El-
Sayed et al., 2003). The prevalence of the high-level mupirocin resistance has been 
recorded by many studies which is the major threat to clinical use of the antibiotic 
(Thomas et al., 2010) 
Many gram-negative bacteria are resistant to mupirocin because of the effective 
permeability barrier of the outer membrane against hydrophobic antibiotics including 





1.3.3. Mupirocin gene cluster and biosynthesis  
The gene cluster that is responsible for mupirocin biosynthesis is known as the mup 
cluster and occupies 74 kb of the P. fluorescens NCIMB 10586 chromosome. The 
cluster contains thirty-five Open Reading Frames (ORFs) divided into two parts (Figure 
1.12). The first part includes six large ORFs encoding proteins known as mupirocin 
multifunctional polypeptides (mmp) from MmpA to MmpF.  
The mmpA gene encodes one non-elongating module and two elongation modules for 
monic acid backbone. The mmpB plus mupS, Q, E, mAcpD and mmpF encode the 
necessary domains for 9-hydroxynanoic acid synthesis. The thioesterase domain at C-
terminus is responsible for the release of the product from PKS. The mmpC gene 
encodes two acyltransferase domains responsible for starter and extender units loading 
to KS and ACPs (El-Sayed et al., 2003; Gurney & Thomas, 2011). The mmpD gene 
encodes the four elongation modules for the monic acid backbone. The mmpE encodes 
single KS/OR domains responsible for 10, 11-epoxide formation (Gao et al., 2014). The 
mmpF encodes single KS domain and the function remains unknown, but its deletion 
aborted PA-A production (Hothersall et al., 2007).   
The second part consists of twenty-six individual genes (mup and mAcp) known as 
tailoring genes required for the necessary modification of the product backbone. In 
addition to these two parts, the cluster also includes gene (mupM) responsible for self-
protection to mupirocin and the genes (mupX, mupR and mupI) for the regulation of the 






1.3.3.1. Monic acid biosynthesis  
The biosynthesis begins at MmpD which consists of the first four elongation modules for 
monic acid backbone and followed by MmpA which consists of three modules achieving 
the fifth and sixth elongation steps. Each module contains KS and ACP domains in a 
standard manner for type I PKS. The AT domains which are responsible for starter units 
(acetyl- CoA) activation or the extender unit (Malonyl-CoA) loading to the KS and ACP 
domains are proposed to be provided by MmpC, which contains tandem acyl hydrolase, 
in a pattern of trans-acyltransferase class modular PKS. The synthesis may start by 
transferring the activated acetyl-CoA to the 4'-phosphopantetheinyl arm of ACP in the 
first module of MmpD, which then transfers to the thiol group of active cysteine of KS, 
but this is just speculation at present. The extender unit is loaded to the 4'-
Figure 1.12. Mupirocin biosynthesis gene cluster in P. flourescens NCIMB 10586 




phosphopantetheinyl arm of ACP, then the condensation between starter and extender 
units is catalyzed by KS domain (El-Sayed et al., 2003; Gurney & Thomas, 2011).  
The four modules of MmpD perform four condensation reactions before the growing 
chain is transferred from MmpD to MmpA by the first module of MmpA, which contains 
KS and ACP, to complete the C14 backbone of monic acid. The KS in the first module of 
MmpA is inactive in terms of Claisen condensation because it lacks the two key 
histidines in the active site, so the function of this module is more likely to transfer the 
intermediate from the last module of MmpD to the second module of MmpA or it may be 
the location where 6-hydroxylation occurs as the result of a tailoring enzyme, currently 
suspected to be mupA (Figure 1.13). The first and third modules of MmpD have MT1 
and MT2 respectively, which catalyze the addition of the C16 and C17 methyl groups 
derived from S-adenosyl methionine (El-Sayed et al., 2003; Thomas et al., 2010).  
 
1.3.3.2. Hydroxynanoic acid biosynthesis 
The 9-hydroxynonanoic acid biosynthesis is assembled by mmpB. The starter unit of the 
9-hydroxynonanoic acid is 3-hydroxypropionate, suggested to be produced by mupQ, 
mupS and mAcpD, combined with the extender unit, malonate, is extended through 
three rounds of condensations catalyzed by mmpB which functions iteratively (Gurney & 
Thomas, 2011). Studies on mupirocin and thiomarinol, an analogue to mupirocin 
produced by Pseudoalteromonas spp, confirmed the isolation of truncated saturated 

































































































































































































This suggests that the fatty acyl side chains are built up by successive elongation and 
not by ligation of fully assembled 9-hydroxynanoic acid (Murphy et al., 2011).  
 
1.3.3.3. Tailoring genes activities  
The tailoring genes include twenty-six single open reading frames (mupC to mupZ, 
macpA to mapcE). Mutational studies show that all the tailoring genes are necessary to 
modify the intermediate structure to produce mupirocin. These modifications include 
pyran ring formation, epoxidation of C10-C11, incorporation of the methyl group at C3 
and hydroxylation at C6 (Gurney & Thomas, 2011). The Orf mupW is thought to be 
responsible for the oxidative activation of the C16 methyl group and its deletion 
produced a novel compound lacking the tetrahydropyran ring known as mupirocin W 
(Cooper et al., 2005a). Studies showed that MupC, MupF, MupO, MupU, MupV and 
mAcpE are required for the correct oxidation around the pyran ring and their deletion 
generates pseudomonic acid B (Table 1.3). Deletion of mupF leads to the production of 
mupirocin analogue with C7 ketone while a mupC deletion results in failure to reduce 
C8-C9. The addition of the C15 methyl group to C3 is introduced by 
hydroxymethylglutaryl-CoA synthase (HCS) cassette which consists of MupG, MupH, 






Table 1.3. Examples of some products produced by mutant strains of 
Pseudomonas flourescens NCIMB 10586 
ORF Proposed function  Mutant product  
mupC  Oxidoreductase Mupirocin C 
mupF Ketoreductase  Mupirocin F 
mupW Dioxygenase  Mupirocin W 
mupV Oxidoreductase Pseudomonic acid B 
mupO Cytochrome P450 Pseudomonic acid B 
mupU CoA synthase Pseudomonic acid B 
macpE Acyl carrier protein Pseudomonic acid B 
mupH HMG-CoA synthase Mupirocin H 
mmpE Oxidoreductase (C-terminus part)  Pseudomonic acid C 
mupE Enoylreductase  6’-7’ enoyl bond 
  
 
1.4.  Thiomarinols 
Thiomarinols are natural compounds produced by a marine bacterium, 
Pseudoalteromonas spp SANK 73390 and display antibacterial activity against both 
Gram positive and Gram negative bacteria (Table 1.4). Thiomarinols consist of two 
portions of independent antibiotics: marinolic acid, an analogue to pseudomonic acid 
produced by Pseudomonas fluorescens, and the pyrrothine core from holomycin 
antibiotic linked together via an amide bond (Shiozawa et al., 1993). At least seven 
thiomarinol structures have been isolated from the wild type Pseudoalteromonas spp 
SANK 73390 (Figure 1.14). Thiomarinol A was isolated as a major product while 
thiomarinol B, C, D, E, F and G were isolated as the minor products from the culture 




Table 1.4. Antibacterial activity of thiomarinol types A-G (Shiozawa et al, 1993; 1994 
and 1997). 
Test Organism MIC (µg. ml-1) 
 A B C D E F G 
Staphylococcus aureus MRSA <0.01 ≤0.01 ≤0.01 ≤0.01 ≤0.01 ≤0.01 ≤0.01 
Staphylococcus aureus 209P JC-1 <0.01 ≤0.01 ≤0.01 ≤0.01 ≤0.01 ≤0.01 ≤0.01 
Enterobacter cloacae 963 6.25 0.8 3.1 1.5 1.5 12.5 >200 
Enterococcus faecalis NCTC775 <0.01 0.05 0.8 0.2 0.05 0.2 3.1 
Klebsiella pneumoniae IID685  0.78 0.8 1.5 0.8 0.8 3.1 12.5 
Salmonella enteritidis G 3.13 0.4 1.5 0.8 0.8 3.1 25 
Serratia marcescens IAM 1184 25 3.1 6.2 6.2 6.2 25 >200 
Proteus vulgaris IID874 0.39 0.05 0.2 0.1 0.2 1.5 3.1 
Escherichia coli  NIHJ JC-2 3.13 0.8 3.1 1.5 1.5 6.2 >200 
Morganella morganii IFO3848 12.5 6.2 12.5 12.5 12.5 100 >200 
Pseudomonas aeruginosa PA01 0.39 0.8 0.4 0.4 0.4 6.2 12.5 
 
The marinolic acid of thiomarinol A (TMA) is structurally close to PA-C in which the 
10,11 epoxide is replaced by an alkene, but it differs by having an extra hydroxyl group 
at C4 and the fatty acid moiety is shorter by one carbon (Shiozawa et al., 1993). 
Thiomarinol B (TMB) varies from TMA by having two extra oxygen atoms attached to the 
pyrrothine moiety, while thiomarinol C (TMC) has one less oxygen atom at C4 
(Shiozawa et al., 1995). As shown in Figure 1.14, thiomarinol D (TMD) has one extra 
methyl group at C14, thiomarinol E (TME) has two more methylenes in the fatty acid 
chain while in TMF the hydroxyl group at C13 has been replaced by a ketone. 
Thiomarinol G is similar to PA-C and can be designated as 6-deoxy-8-hydroxymonic 
acid C (Shiozawa et al., 1997). All these minor products showed variable antibacterial 
activity against Gram positive and Gram negative bacteria (Table 1.4). Murphy and co-
workers isolated more minor products from the WT Pseudoalteromonas spp SANK 





Figure 1.14. Thiomarinols produced by WT and mutant strains of Pseudoaltermonas spp 




These include marinolic amide and the range of pyrrothine metabolites in which different 
fatty acid chain lengths are attached to the pyrrothine molecules and were named 
xenorhabdins. Later mutation experiments suggested that the marinolic amide is likely a 
degradation product of thiomarinol A (Murphy et al., 2011). Mutasynthesis experiments 
produced more thiomarinol derivatives. Thiomarinol H and J (Figure 1.14) were 
produced by feeding anhydroornithine and α-Aminobutyrolactone respectively to a 
∆NRPS strain (Murphy et al., 2011). 
        
1.4.1. Thiomarinol gene cluster and biosynthesis  
DNA sequencing of the circular plasmid pTML1 from Pseudoalteromonas spp SANK 
73390 identified the gene cluster (about 97 kb) responsible for thiomarinol biosynthesis. 
This gene cluster consists of trans-AT PKSs with forty-five ORFs, twenty-seven of them 
are responsible for marinolic acid production in a similar way to the mup cluster of 
mupirocin, and seven ORFs encoding production of the pyrrothine core with similarities 
to NRPS and tailoring enzymes responsible for holomycin biosynthesis in Streptomyces 
clavuligerus (Figure 1.15). Many genes in the thiomarinol gene cluster (tmp) are similar 
to those in the mupirocin (mup) cluster (Fukuda et al., 2011). The genes tmpA to tmpD 






In spite of the similarities between the tmp and the mup clusters, there are many 
differences. First, the tmp possess extra ACP domains in the third module of tmpD and 
in the last module of tmpA.  
Second, the tmpB gene varies from mmpB by encoding two modules, one with four ACP 
domains and one with a single ACP domain. Third, most of the tailoring genes in the tmp 
cluster have a counterpart in the mup cluster. However, depending on the direction of 
transcription and the presence of the rep/par interruption, the tailoring genes can be split 
into five transcription units; tmlT to tmlN, tmlM to tacpB, tmlA to tmlF, tmuA to tmlP and 
tacpA to holH (Fukuda et al., 2011). Fourth, the absence of mAcpE in the tmp cluster 
suggests that all the late tailoring steps are catalyzed by tmpB which contains extra KS 
Figure 1.15. Thiomarinol gene cluster on pTML1 (Figure taken from Fukuda et al., 




and ACP domains. Fifth, the presence of some orfs in tmp, but absence in the mup 
cluster such as tmuB. Finally, the tmp possesses seven orfs (hol genes) which encode 
the non-ribosomal peptide synthetase and tailoring enzymes responsible for pyrrothine 
molecule assembly (Fukuda et al., 2011).  
Suicide mutagenesis revealed that tmpD is equivalent to mmpD in the mup cluster and 
its deletion aborts thiomarinol and marinolic acid production, while the holA knockout, 
abolishes pyrrothine production and retains marinolic acid. This indicates that the 
marinolic acid and pyrrothine can be synthesized separately (Fukuda et al., 2011). To 
confirm joining the pyrrothine moiety marinolic acid as an intact unit, ∆NRPS SANK 
73390 strain was fed pyrrothine which resulted in thiomarinol A production. The 
pyrrothine unit is proposed to be formed from two molecules of cysteine via NRPS 
biosynthesis before linking to marinolic acid. Isotope labelling studies suggested that the 
assembly of the octanoate fatty acid of marinolic acid does not follow the standard 
polyketide pattern in which the acetate units incorporate in head-to-tail pattern, but FAS 
catalyzes two rounds extension of C4 precursor or incorporates C4 precursor to the 
polyketide and then elongates it by two C2 extensions (Murphy, et al., 2013). The joining 
of the marinolic acid and pyrrothine molecule is carried out by tmlU and holE. An in vitro 
study revealed that TmlU activates marinolic acid as acyl-CoA while HolE acts as an 
acyltransferase to join it with pyrrothine. TmlU displays substrate specificity while HolE 
accepts a broad range of the fatty acyl CoA derivatives which explain the xenorhabdins 
production (Dunn et al., 2015). Figure 1.16 shows the proposed thiomarinol biosynthesis 










































































































































































































































































































































1.5. Non-ribosomal peptide synthetases 
Nonribosomal peptides are natural products produced by multidomain modular enzyme 
assemblies known as Non-ribosomal peptide synthetase (NRPS). These compounds are 
structurally diverse with a broad spectrum of biological activities that can be applied as 
agrochemical agents or in the development of modern medicine including antibiotic, 
immunosuppressive and anticancer drugs (Finking & Marahiel, 2004; Winn et al., 2016). 
To highlight the importance of the NRPS system, some remarkable examples of 
nonribosomal peptides are shown in Figure 1.17. Vancomycin, a glycopeptide antibiotic 
active against Gram-positive bacteria including methicillin resistant Staphylococcus 
aureus is made by an NRPS (Wageningen et al., 1998). Cyclosporin, the powerful 
immunosuppressive drugs used to treat autoimmune disorders and in organ 
transplantation, is a cyclic NRP produced by Tolypocladium inflatum fungus (Weber et 
al., 1994). Bleomycin produced by Streptomyces verticillus has anticancer properties 
(Du et al., 2000) 
NRPS products characterized by distinctive features differentiate them from ribosomal 
peptides. Most of the NRPS products are cyclic or branched cyclic containing not only 
the common 22 amino acids but also non-proteinogenic amino acids, sugar, fatty acids 
and the unusual modifications in the peptide backbone connecting the amino acids by 
bonds other than peptide or disulfide bonds (Figure 1.17). These features impart NRPS 
products with chemical diversity associated with powerful bioactivity (Schwarzer et al., 




antibiotics, contain a different length of fatty acid chain. Non-proteinogenic amino acids 
such as D-phenylalanine and ornithine are incorporated into the structure of the 
antibiotic gramicidin S. The immunosuppressive agent cyclosporine A contains unusual 
amino acids, L-α-amino butyric acid and 2-butenyl-4-methyl-L-threonine. Many NRPs 
contain heterocyclic rings generated from cysteine, serine and threonine residues and 
the ring formed is named based on the oxidative state. Bleomycin A contains two thiazol 
rings generated by cyclization and oxidation of two cysteine residues (Finking & 
Marahiel, 2004).  
 
1.5.1. NRPS types and biosynthesis  
NRPSs are large multimodular megaproteins with repeating catalytic domains. Each 
module is responsible for incorporating one building block to the product, so that, the 
number of amino acids in the product can be predicted by the number of NRPS 
modules. According to the mode of biosynthesis, modular NRPSs are classified into 
three types: Linear (type A) in which the number and sequence of amino acids are 
correlated with the number and sequence of the NRPS modules, Iterative (type B), as an 
analogue to iterative PKSs, in which the catalytic domain is reused repeatedly and 
Nonlinear (type C), in which the arrangement of NRPS modules does not match the 





 Figure 1.17. Examples of clinically important non-ribosomal peptides (Collected from 




The minimal NRPS elongation module consists of three core domains: Adenylation (A) 
domain, Condensation (C) domain and Peptidyl Carrier Protein (PCP)(Figure 1.19). By 
consuming ATP, the Adenylation domain recognizes and activates the amino acid to 
form an amino-acyl adenylate. This intermediate transfers to and binds covalently to the 
thiol group of 4’- phosphopantetheinyl arm of the PCP domain. This moiety is 
approximately 20 Å in length, acts as a flexible arm that helps the bound substrate to 
shuttle between catalytic sites.    
 
 
Figure 1.18. Modular types of NRPS; Linear, Iterative and Nonlinear (Figure taken 




The condensation domain, which has two similar sub-domains, catalyzes the formation 
of the peptide bond between the amino acid bound to the phosphopantetheinyl arm of 
the PCP in the same module with that in the adjacent module and release of the 
phosphopantetheinyl arm (Figure 1.19) (Condurso and Bruner, 2012). 
The function of the first module (Initiation module) is just to activate the substrate 
because it lacks a C domain, while in the C-terminus the termination module contains 
the Thioesterase (TE) domain (Figure 1.19), which catalyses the release of the 
assembled peptide chain from phosphopantetheinyl thioester resulting in either a linear 
peptide or cyclic peptide using an internal nucleophile (Kohli and Walsh, 2003).  
 
Figure 1.19. The essential domains of NRPS model. A: adenylation domain, T: 
thiolation domain, C: condensation domain, TE: thioesterase domain (Figure taken 




In addition to the essential three core domains, there are auxiliary domains which act as 
tailoring enzymes and impart the NRPS products extra modifications. These 
modifications occur either to the individual residue before peptide bond formation or 
after the peptides have been synthesized (Hur et al., 2012). These domains include 
Epimerization (E), Cyclization (Cy) and Methyltransferase (MT) domains. The 
epimerization domain located at the C-terminus of PCP is responsible for Cα 
racemisation. The cyclization domain is responsible for heterocyclization of 
serine/threonine and cysteine residues. The methyltransferase domain uses S-
adenosylmethionine (SAM) as a cofactor to introduce N- or C-methylation of the building 
block. These tailoring enzymes either exist as the standalone enzyme, in trans, or 
inserted within the essential enzymes, in cis (Walsh et al., 2001).  
 
1.5.2. Biotechnology applications and challenges      
Engineered biosynthesis of NRPSs was applied to improve the pharmacokinetics and 
ADME properties of the NRP. The early work focused on introducing non-natural amino 
acids into the growing peptides via feeding experiments and mutasynthesis. 
Cyclosporine A was produced by feeding the WT Tolypocladium inflatum with D-serine 
which replaces the natural D-alanine at position 8. However, the problem associated 
with this approach is the competition between the natural and alternative substrate 
consequently leads to a low yield of the desired product (Winn et al., 2016). This 




which changes the preference of the catalytic domain toward the substrate. For 
example, the Lys278Gln mutation of the 10 model adenylation domain of CDA NRPS 
was fed with synthetic precursor Gly-mGln, and successfully incorporated into the 
product (Thirlway et al. 2012). This technique was not feasible in some NRPS because 
of the high fidelity of the downstream domains.     
The modular nature of the non-ribosomal peptide synthetase became the subject of 
many studies and intensive investigation to manipulate the biosynthetic pathway. Many 
approaches have been applied to achieve these purposes including domain swapping, 
module deletion or swaping and module fusion. Understanding the specificity and 
structure of the domains and modules is the key tool to generate new templates. In 
general, four strategies have been suggested to change individual domains to produce 
new products (Figure 1.20). 
 
 
Figure 1.20. Different strategies to create hybrid NRPS, a and b: domains fusion, 
c: module fusion and d: point mutation (Figure taken from Finking and Marahiel, 




These strategies include fusion between different domains and modules, and domain 
specificity alteration. The most remarkable feature that enhances the fusion is the linker 
regions that connect the modules. These regions consist of about 15 amino acids and 
display no conserved residues with small and hydrophilic amino acids rendering these 
regions to be the ideal positions for module fusions. Biochemical studies on the 
tyrocidine synthetase showed the possibility of module fusion between the second and 
ninth or tenth modules resulting in hybrid NRPS proteins (Figure 
1.20c)(Mootz, Schwarzer & Marahiel, 2000). In surfactin synthetase, deletion of the 
second module results in a fusion between the first and third modules producing a 
satisfactory amount of product shortened by one amino acid (Mootz, et al., 2002). The 
linker region between A and PCP domains gives the possibility to alter a single domain 
(Doekel & Marahiel, 2000). Point mutations can change the specificity of an A domain 
(Figure 1.20d) to produce a new compound, but this approach may be limited because 
of the specificity of the downstream C and TE domains (Eppelmann,  Stachelhaus, 
Marahiel, 2002 ; Challis and Naismith, 2004). 
Trans-expression of the tailoring enzymes in the heterologous host is another approach 
to modify NRP structure. Trans-expression of the ram29 gene, which is responsible for 
mannosylation of ramoplanin, in eduracidin-producing Streptomyces fungicidicus 
resulted in mannosylation of eduracidins (Winn et al., 2016).       
However, the manipulation approaches to reprogramming the NRPS and production of 
desired compounds is hindered by insufficient knowledge about protein interactions and 




the single domain as interdomain interactions play a major role in substrate recognition 
(Lautru and Challis, 2004). Another challenge is the high specificity of A domain which 
tolerates very little variation with the consequent reduction in the diversity of the 
products. Domain alteration and point mutation to change the substrate selectivity have 
been suggested to solve this problem. This faced another difficulty since the 
downstream domains, C and TE domains, also show substrate selectivity. Finally, the 
unknown role of the linker regions between modules and the different conformations of 
the products which depend on the nature of the TE domain should be investigated by 
structural and biochemical studies (Schwarzer, Finking and Marahiel, 2003; Challis and 
Naismith, 2004). 
 
1.6. Objectives of this study   
This study aims to understand and characterize PKSs and NRPSs which are 
responsible for mupirocin and thiomarinol biosynthesis in an attempt to create new 
derivatives with desired properties. Mupirocin (Pseudomonic acid A) is the topical 
antibiotic used against MRSA for decades. Resistance against mupirocin has been 
evolved by bacteria which may threaten its future use. Thiomarinol A is structurally 
similar to mupirocin but is more potent which makes it a good substitute. Since its 
discovery, thiomarinol has become the subject of much scientific research trying to bring 
it into clinical use. Although many studies showed that mutagenesis and mutasynthesis 




have potent antibiotic properties, there are a number of significant questions related to 
the biosynthesis of these compounds that need to be answered. This will clarify the role 
of each related element consequently paving the way to make the desired genetic 
manipulation which improve the products or increase the yield. This study aims to 
answer some of these questions in an attempt to add new aspects to the previous 
studies. 
The general backbone structures of mupirocin and thiomarinol are similar (Figure 1.21). 
The monic acid and the pyran ring are quite similar to those in marinolic acid. The 
molecular similarities between mupirocin and thiomarinol are consistent with the 
similarity between the gene clusters as revealed by DNA sequence analysis and their 
proposed biosynthetic pathways based on this information (Figure 1.22). These 
similarities between the products and gene clusters may be helpful to predict the 
function of unknown genes in the tml/tmp cluster depending on the mup gene cluster 
which already has been characterized and most of the gene function was identified. 
Despite similar structures between thiomarinol and mupirocin, there are also four distinct 
differences between product molecules. These include the absence of 10,11 
epoxidation, the presence of 4-hydroxylation, the shorter hydroxy-fatty acid and 
pyrrothine molecule attached to the hydroxyl group in thiomarinol (Figure 1.21). 
Mutagenesis and complementation studies identified genes responsible for 10,11 
epoxidation and pyrrothine molecule while the presence of 4-hydroxylation and why the 





Understanding these differences might allow modification of the core of mupirocin and 
other molecules in subtle ways which may improve their properties. Outside the pH 
range of 4-9, the 7-hydroxyl group attacks 10,11 epoxide irreversibly and reduces its 
activity (Thomas et al., 2010). Mutational analysis revealed that the gene knockout of 
Figure 1. 21. The similarity and differences between mupirocin (PA-A) and 
thiomarinol A. The similarity and the differences highlighted with blue and yellow 
shadow respectively. The differences include the absence of 10,11 epoxidation, 
the presence of 4-hydroxylation, the shorter hydrox-fatty acid and the hydroxyl 




















∆mmpE/OR results in pseudomonic acid C which lacks the 10,11 epoxide. This makes 
pseudomonic acid C more stable than pseudomonic acid A and may improve clinical 
usage. Feeding experiments with Pseudoalteromonas spp SANK73390 showed that the 
main component of mupirocin PA-A could be 4-hydroxylated (Gao et al., 2014). 
However, the enzyme responsible for this hydroxylation was not identified and the 
significance of thiomarinol hydroxylation was not investigated. Marion and co-workers 
proposed that the 4-hydroxylation may enable thiomarinol to form more hydrogen bonds 
with the target, and the addition of this OH to the analogues may improve the 
antibacterial activity (Marion et al., 2009). Chapter 2 therefore focuses on the 
investigation of the enzymes that direct the 4-hydroxylation of thiomarinol, studying their 
specificity and the ability to hydroxylate other analogues including pseudomonic acids 
via heterologous expression of the encoding genes, and the role of this hydroxyl group 
in thiomarinol and the hydroxylated version of the analogues activity. 
The pyrrothine molecule is a non-ribosomal peptide consisting of two cysteine residues 
which is assembled by seven orfs designated as holA to holG. HolA is similar to a non-
ribosomal peptide synthetase (NRPS). Pyrrothine imparts potency to thiomarinol and its 
removal reduced antibacterial activity significantly. The intriguing feature of holA gene, 
which is responsible for pyrrothine biosynthesis, is that it encodes only a single 
Adenylation (A) domain, Condensation (C) domain and Peptidyl Carrier Protein (PCP) 





   
 
This leads to the suggestion that HolA is a homodimer protein and works as an iterative 
NRPS in a similar manner to fungal NRPS (Fukuda et al., 2011). To investigate more 
about this kind of NRPS, Chapter 3 presents the in vivo and in vitro characterizations 
plus biochemical assays of HolA protein in an attempt to understand the assembly of the 
pyrrothine molecule by investigating the protein dimerization and activity.        
Thiomarinols display cytotoxicity in eukaryotic cells and effort has been made to explore 
this and to investigate the possible cell components which may be targeted by 
thiomarinols (Ahmed, 2010 unpublished). Untill recently, it is not clear which part of the 
thiomarinol is responsible for the loss of selectivity that was seen in PA-A. Thus, more 
Figure 1.22. The comparison between the gene cluster of thiomarinol (upper line) 
and the gene cluster of mupirocin (lower line) showing similarity and differences. 
The tmuB gene is indicated by a red arrow which has no counterpart in mup cluster. 
The box to the right represents the related NRPS cluster which is responsible for 
pyrrothine molecule assembly in Pseudoalteromonas sp. SANK 73390 (Adapted 
from Fukuda et al, 2011 after permission). See figure 1.12 and 1.15 for more details 




investigation on 4-hydroxylation and the pyrrothine molecule is needed in terms of the 
biological activity and cytotoxicity in eukaryotic cells. The overall work in this project 
includes genetics, bioinformatics and biochemical studies to understand the assembly of 


















2. INVESTIGATION OF 4-HYDROXYLATION IN THIOMARINOL 
2.1.  Introduction  
Hydroxylation is an essential step in many natural product pathways either as 
intermediate steps or as tailoring reactions. The hydroxylation of natural products 
contributes to structural diversification and alters their biological activity profiles. The 
hydroxylation of pseudomonic acid A at carbon 8 (as in pseudomonic acid B) reduces its 
anti-bacterial activity by around 60% compared to non-hydroxylated pseudomonic acid A 
(Cooper et al., 2005b). Other examples of hydroxylation modifying activity include 
cyclosporine losing its immunosuppressive activity after regio-specific hydroxylation at 
the 4th N-methyl leucine but retaining its hair growth side effect which might allow it to be 
used as a hair growth-stimulating compound (Lee et al., 2013). 
The common enzymes that introduce hydroxyl groups to the product backbone are 
cytochrome P450 monooxygenases (CYP450), flavin-dependent mono- and 
dioxygenases, and Fe(II)/α-Ketoglutarate dioxygenases (Rix et al., 2002; Wu et al., 
2016). In addition to hydroxylation, some of these enzymes catalyze more than one 
reaction with different consequences. For example, during clavulanic acid biosynthesis 
in Streptomyces clavuligerus, clavaminate synthase (CAS) performs three separate 
reactions including hydroxylation of β-Lactam, oxidative cyclization of proclavaminate 
and desaturation of dihydroclavaminate to produce clavaminate (Lloyd et al., 1999). 
As described in Chapter one section 1.6, one prominent difference between mupirocin 




identified the tmuB gene from the thiomarinol gene cluster, which lacks a homologue in 
the mupirocin cluster, as a potential candidate to perform the 4-hydroxylation of 
thiomarinol (Figure 1.15 and 1.22). The tmuB gene in the thiomarinol gene cluster 
encodes for a 29.5 kDa TmuB protein. As an initial prediction about TmuB function, 
protein-protein BLAST search was carried out which revealed that TmuB possesses 
sequence similarity to dioxygenase enzymes. Further screening of the thiomarinol 
cluster plus a protein-protein BLAST search predicted TmlZ (14.7kDa) as 
monooxygenase enzyme.    
The aim of this study is to determine whether these genes in thiomarinol gene cluster 
are responsible for 4-hydroxlation, to determine the potential role of this hydroxylation in 
terms of the biological activity of the compound and in terms of the production profile 
and the physiological character of the producer. It would also be of interest to determine 
what are the possible analogues that could be hydroxylated by these genes and how 
this might alter the properties of products. This investigation might thus allow 
modification of the core of mupirocin and other molecules in subtle ways. 
In an attempt to answer these questions, TmuB and TmlZ were subjected to 
complementation and mutational analyses followed by a combination of in vivo studies 
and in vitro biochemical characterization plus protein bioinformatics and structural 
modelling. The results shed new light on proteins of the phytanoyl-CoA dioxygenase 





2.2. Materials and methods 
2.2.1. Bacterial strains and plasmids 
The wild type thiomarinol producer Pseudoalteromonas sp SANK 73309 was used for 
DNA amplification of the tmuB and tmlZ genes, suicide mutagenesis and thiomarinol 
extraction. Wild type and mutant strains of Pseudomonas fluorescens NCIMB 10586 
(Whatling et al., 1995) were used for pseudomonic acids production and as the 
heterologous hosts. For plasmids transformation and gene cloning competent cell of 
E.coli DH5α (Hanahan, 1983) was used. E.coli S17-1(Simon et al., 1983) was used to 
mobilize expression vectors that hold the target genes to the wild type and mutant 




   Table 2.1. Bacterial strains used in this study. 
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F-, cya-99, araD139, 
galE15, galK16, rpsL1 
(Str r), hsdR2, mcrA1, 
mcrB1. 
Used as a detector 
bacterium to test 
protein-protein 
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F-, cya-854, recA1, 
endA1, gyrA96 (Nal r), 
thi1, hsdR17, spoT1, 
rfbD1, glnV44(AS). 
Used as a detector 
bacterium to test 
protein-protein 
dimerization in vivo 
Karimova 
et al, 2005 
Escherichia coli 
S17-1 
TpR SmR recA, thi, pro, 
hsdR-M+RP4: 2-Tc:Mu: 








P. fluorescens with 
mupV gene deletion 
Heterologus hosts and 






P. fluorescens with 
mmpE gene deletion 
Heterologus hosts and 
pseudomonic acid C 
production 




P. fluorescens with 
mupC gene deletion 
Heterologus hosts and 
mupirocin C production 
Hothersall 
et al., 2007 
NCIMB 10586 
∆mupF 
P. fluorescens with 
mupF gene deletion 
Heterologus hosts and 
mupirocin F production 
Hothersall 
et al., 2007 
NCIMB 10586 
∆mupO 
P. fluorescens with 
mupO gene deletion 
Heterologus hosts and 






P. fluorescens with 
mupU gene deletion 
Heterologus hosts and 






P. fluorescens with 
mupV gene deletion 
Heterologus hosts and 






P. fluorescens with 
mupW gene deletion 
Heterologus hosts and 




sp  SANK 73390 
Wild Type: Thiomarinol 
producing bacteria 
Thiomarinol extraction, 
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resistant strain used 
standardly by BSAC for 
susceptibility test  
Used as a detector 







2.2.2. Growth of bacterial strains and culture conditions 
Marine agar and marine broth for Pseudoalteromonas SANK 73390: provided by 
DificoTM were used to Pseudoalteromonas SANK 73390 propagation. These media 
contain all the nutritional requirements for Pseudoalteromonas SANK 73390 growth. The 
media were prepared according to manufacture instructions and sterilized by 
autoclaving (121 oC at a pressure of 15 pounds per square inch for 15 min).    
Minimal medium (M9 medium) for Pseudomonas fluorescens NCIMB 10586:  This 
medium was used as a selective medium to inhibit E.coli S17-I growth after conjugal 
mating with Pseudomonas flourescens strains. To prepare 400 ml of this medium, 200 
ml of 3% agar and 200 ml of M9 x2 medium were mixed and 400 µl of 0.1 M CaCl2, 400 
µl of 1 M thiamine-HCl, 400 µl of 1 M MgSO4, 400 µl of Tetracycline (100 mg/ml) and 
2ml of 40% glucose were added and poured into petri dishes.  
Secondary stage medium (SSM) was used to produce mupirocin from Pseudomonas 
fluorescens strains, per liter, 25g soya flour, 2.5g spray dried corn liquor, 5g (NH4)2 SO4, 
0.5g MgSO4 7H2O, 1g Na2HPO4, 1.5g KH2PO4, 6.25g CaCO3 were mixed with 850 ml 
distilled water, dissolved by stirring and heating, the pH adjusted to 7.5 by NaOH, the 
volume completed to 1 liter and autoclaved. Prior to setting up cultures, 40% sterile 
glucose was added.   
Luria (L) Broth and L agar were used to culture E.coli DH5α and E.coli S17-1. One liter 




agar media). The media was sterilized by autoclaving (121 oC at a pressure of 15 
pounds per square inch for 15 min). 
Table 2.2. Plasmids used and constructed in this study. 
Plasmid's 
name 
Features Usage Source 
pAKE604 
AmpR,  KanR, Bsac, 





AmpR, LacZα PCR 
cloning vector 




T7 promotor, His tag, 
KanR, LacZα, 
lacI,MCS,Ori 
Protein expression Novagen 
pJH10 
Low copy number, 
tetracycliner, 





tmuB gene cloned to 





tmlZ gene cloned to 





tmuB gene cloned to 
pET28a 
To overexpress TmuB 




tmuB gene cloned to 
pJH10 
To express TmuB 




tmlZ gene cloned to 
pJH10 
To express TmlZ protein 
in hetrologues strains 
This study 
pHHM06 
tmuB gene with point 
mutation I109N cloned to 
pJH10 
To express TmuB 
protein with this 




tmuB gene with point 
mutation I109N cloned to 
pAKE604 
To introduce point 




tmuB gene with point 
mutation I109N cloned to 
pET28a 
To overexpress TmuB 
protein with this 




tmuB gene with point 
mutation I109V cloned to 
pJH10 
To express TmuB protein 







tmuB gene with point 
mutation L141N cloned to 
pJH10 
To express TmuB 
protein with this 




tmuB gene with point 
mutation L141V cloned to 
pJH10 
To express TmuB 
protein with this 




tmuB gene with point 
mutation L141S cloned to 
pJH10 
To express TmuB 
protein with this 





tmuB gene with point 
mutation R69K cloned to 
pJH10 
To express TmuB 
protein with this 







tmuB gene with point 
mutation K105E cloned to 
pJH10 
To express TmuB 
protein with this 




tmuB gene with double 
point mutation 
R69K&L141V cloned to 
pJH10 
To express TmuB 
protein with this 





Low copy number, 
pSU40, lac promoter, 
Kanr, MCS, T25 





high copy number, 
pUC19, lac promoter, 
Ampr, MCS, T18 




Low copy number, 
pSU40, lac promoter, 
Kanr, MCS, T25 fused to 
leucine zipper 
Used as a positive 
control in B2H 
Euromedex 
pUT18-zip 
high copy number, 
pUC19, lac promoter, 
Ampr, MCS, T18 fused to 
leucine zipper 
Used as a positive 
control in B2H 
Euromedex 
pHHM16 
tmuB gene cloned to 
pKT25 
To test protein 
dimerization in vivo 
This study 
pHHM17 
tmuB gene cloned to 
pUT18 
To test protein 







tmuB gene cloned to 
pKNT25 
To test protein 
dimerization in vivo 
This study 
pHHM19 
tmuB gene cloned to 
pUT18C 
To test protein 
dimerization in vivo 
This study 




2.2.3. Polymerase Chain Reaction PCR 
Primers were designed manually and online software Netprimer and OligoAnalyzer 3.1 
were used to check primer quality. Restriction sites and extra three bases were added to 
the 5’ end of the primers to facilitate digestion and recombination. The primers were 
synthesized by Alta Bioscience in the University of Birmingham. The standard PCR 
reaction was carried out using high fidelity DNA polymerase from (Velocity provided by 




type bacterium was prepared using boiled cell preps. The primer sequences are listed in 
Table 2.4. 
 
Table 2.4.  Primers used in this study.  

























































to create insert 
with point 
mutation 



































FL141N To create 
insert with 
point mutation 

















































primer to clone 





*The Tm was calculated by online software NetPrimer from primer Biosoft. The PCR annealing 




The PCR reaction was carried out using SensoQuest thermocycler and set up with the 
following program: 




Denaturation step: 98 oC for 30 sec 
Annealing step: 50 oC for 30 sec*                   
Extension step: 72 oC for 30 sec* 
Extension step: 72 oC for 7 minutes          1 cycle 
* The annealing temperature and extension time varies according to primers, and DNA template length 
and G-C content.  
 
2.2.4. DNA isolation and manipulation 
2.2.4.1. DNA and plasmid extraction 
Chromosomal DNA was isolated using the boiled cell miniprep method and used as a 
DNA template in PCR reaction. About 10 colonies of the experiment bacterium were 
picked up by sterile pipette tip and resuspended in 50µl of sterile distilled water. The 
mixture was then boiled for 10 minutes and centrifuged for 5 minutes (1300 xg, at 4 oC). 
The resulting supernatant was transferred to a new sterile tube and kept on ice.  
Plasmid was isolated using the ISOLATE II Plasmid mini Kit provided by BIOLINE. A 
single colony was picked up and inoculated into 5 ml L-broth and incubated at 37 oC for 
16 hours with shaking at 200rpm. The principles include alkaline SDS lysis method 
(Birnboim and Doly 1979). The isolation procedure was carried out according to the 






lysis to release the DNA material, DNA binding to silica membrane, washing the column 
to eliminate salts and endonucleases, and finally collecting the DNA by elution buffer. 
 
2.2.4.2. Restriction enzyme digestion 
The restriction enzymes were purchased from New England Biolab (NEB). The total 
volume of the digestion reaction was 20µl-50µl depending on the downstream 
application. The amount of enzymes added to the reaction was 1µl per 1µg of DNA in 
accordance with the manufacture’s instructions. The mixture was incubated at 37 oC in a 
water bath for 2-3 hours. The restriction enzymes were deactivated either by heating or 
by gel purification depending on the type of enzyme.  
 
2.2.4.3. DNA ligation 
The ligation between DNA fragments and vectors was carried out using T4 DNA ligase 
provided by Invitrogen. The total volume of the ligation reaction was 20 µl, using 0.5 µl of 
the enzyme. The insert : vector ratio was 3:1 using WI /SI : WV /SV formula (W: DNA 
weight in ng, S: DNA size) to find the appropriate amount of DNA to add to the ligation 
reaction. The mixture was incubated overnight at 4 oC, then different amounts were used 





2.2.4.4. Agarose gel electrophoresis 
Agarose gel electrophoresis was used to examine the size of DNA (PCR product, 
digested DNA and plasmids) and for purification purposes. 1% agarose gel was 
prepared by dissolving one gram of agarose powder in 100 ml 1x TAE buffer (40 mM 
tris-acetate and 1mM EDTA pH8) with heating. The mixture was cooled down and 2 µl of 
ethidium bromide was added to enable DNA visualization under UV light. The gel tray 
was prepared, suitable combs were inserted and the gel mixture was poured gently, and 
left at room temperature to solidify. Before loading the DNA sample onto the gel, loading 
buffer (0.25% w/v bromophenol blue and 15% w/v ficoll in water) was added in a 1:5 
ratio of the DNA sample. 5 µl of marker DNA (1 kb) was loaded in the lane next to the 
samples to estimate the size of DNA samples. The gel was run for 45 minutes at 110 V 
in 1x TAE buffer. 
  
2.2.4.5. DNA extraction from gel 
GFX PCR and Gel Band Purification Kit from GE Healthcare was used to extract and 
purify DNA from the agarose gel using supplied solutions. The correct bands of DNA on 
the gel were cut with a scalpel under ultraviolet light and placed into a 1.5 ml microfuge 
tube. The gel slice was dissolved by adding 10 µl of capture buffer to each 10 µg of the 
gel slice and incubated at 60 oC in water bath for 15-30 minutes with mixing by inversion 
every 5 minutes. The capture buffer sample was transferred to a GFX microspin column 




minute at 16000 x g. The flow through discarded, the GFX microspin column washed 
using 500 µl by wash buffer and dried by centrifugation for 1 minute at 16000 x g. The 
GFX microspin column was transferred to a clean 1.5 microfuge tube, 30 µl of elution 
buffer was added to the column membrane, incubated at room temperature for 2 
minutes and centrifuged for 1 minute at 16000 x g. The GFX microspin column removed 
and the eluted sample stored at -20 oC. 
 
2.2.5. Preparation of the competent cells 
E. coli DH5α and S17-1 were used to prepare competent cells according to the calcium 
chloride method (Cohen et al., 1972). The E. coli was plated out on the LB agar and 
then a single colony was picked up and inoculated into 5 ml L-broth, incubated at 37 oC / 
200 rpm for 16 hours. From this, 1 ml was used to inoculate 100 ml of L-broth, incubated 
at 37 oC / 200 rpm. The growth was monitored and measured by spectrophotometer 
untill the cell density reached OD600= 0.4-0.6. The culture was centrifuged (5000 rpm, 7 
minutes at 4oC). The cell pellet was resuspended using chilled 100 mM calcium chloride 
(2 ml per 5 ml culture) then incubated on ice for 30 minutes. The resuspeneded cells 
were centrifuged again (as stated above) and the cell pellet resuspended in 100 mM 
CaCl2 15% glycerol. 100 µl of this was aliquoted into sterile 1.5ml microfuge tubes, 





2.2.6. DNA transformation 
The recombinant vector was transformed to the competent cells according to the 
standard heat-shock protocol (Cohen et al., 1972). 5 µl to 10 µl of ligation mixture were 
added to the 100 µl of competent cells in sterile 1.5ml microfuge tube and mixed gently. 
This mixture was incubated on ice for 30 minutes, then heat shocked at 42 oC in a water 
bath for 2 minutes. This enhances the entry of the recombinant vector into the 
competent cells. To recover the transformed cells, 1 ml of L-broth was added, gently 
mixed and incubated at 37 oC for 1-2 hrs. 100-150 µl of the recovered cells were plated 
out on selective media and incubated overnight at 37 oC. 
 
2.2.7. Bacterial conjugation 
E.coli S17-1 (donor) was used to mobilize the constructed vector to the recipient 
bacteria. One ml of overnight culture of each of the donor and recipient were mixed in 
universal bottle. This mixture was thenpassed through a sterile filter by syringe then the 
filter was placed on the appropriate agar plate without selection and incubated overnight 
at appropriate temperature. The bacteria from the filter were resuspended in one ml of 
(saline or broth according to the recipient bacteria) and serial dilutions were made from 
10-1 to 10-5. From each dilution 100 µl was plated out on appropriate selective media and 





2.2.8. A-Tailing of PCR product 
The blunt-end PCR product was ligated with pGEMT-Easy vector for sequencing 
purposes. This vector is sold as linear molecules with T-overhang, so an A-overhang 
was added to the PCR product by mixing 6µl DNA, 1µl MgCl2 (50mM), 1µl dATP(2mM), 
1µl 10x buffer (200 Tris-HCl, pH 8.4 and 500mM KCl) and 1µl of Invitrogen Taq DNA 
polymerase (5U/µl) in a clean 1.5 ml microfuge tube and incubated at 70 oC for 30 
minutes. 4µl of this was mixed with 1µl of pGEMT-Easy vector provided by Promega, 6µl 
buffer and 1µl ligase enzyme, and incubated overnight at 4 oC. This was transformed to 
competent E.coli DH5α and plated on selective media with IPTG and X-gal .  
 
2.2.9. DNA sequencing  
DNA sequencing was carried out by the Functional Genomics lab in the University of 
Birmingham using an ABI 3730 DNA analyzer. The procedure is based on the 
dideoxynucleotide chain termination method invented by Sanger et al., in 1977. The total 
volume of the sample was 10 µl (200-500 ng DNA, 3.2 pmol primer, SDW to 10 µl) and 
10 µl BigDye Reaction Mixture (Big DyeT Terminator v 3.1 Cycle sequencing kit) was 
added. The results of the DNA sequencing were visualized using Chromas software and 





2.2.10. Gene cloning and heterologous expression 
The tmuB and tmlZ genes were amplified by PCR (as describe previously) with primers 
TmuBF&TmuBR and TmlZF/TmlZR respectively (Table 2.4) using genomic DNA from 
the WT Pseudoalteromonas sp SANK 73309 as a template. The genes were cloned into 
pGEM-T Easy vector (Promega) as A-tailed inserts and transformed into competent 
DH5α as described previously. The DNA samples were sent for sequencing in 
Functional Genomic lab in the University of Birmingham using Big Dye Terminator kit 
(PE-ABI). The target genes with the identical sequences were ligated into the 
expression vector, pJH10, as EcoRI/XbaI inserts. These constructed vectors were 
moved to the heterologous hosts via conjugation using E.coli S17-1. 
  
2.2.11. Samples preparation for HPLC 
Pure single colony of transformed Pseudomonas flourescens with constructed vector 
was set up into L-broth supplemented with appropriate antibiotics and incubated 
overnight at 25 Co with shaking at 200 rpm. Secondary stage medium (SSM) was 
inoculated with 5% of the overnight culture (1.25 ml to 25 ml of SSM) and incubated at 
22 Co for 40-60 hours with shaking at 200 rpm. The culture was centriguged at 7000 x g 
for 7 min and the supernatant was transferred to 50 ml volume falcon tube. The pH was 





2.2.12. HPLC analysis 
HPLC was used to analyze products of Pseudomonas flourescens strains. Both solvent 
A (HPLC grade water) and solvent B (HPLC grade acetonitrile) were supplemented with 
0.01% formic acid and degassed properly. Gilson® 321 pump was used to pump the 
solvent and the flow rate was 1 ml/min. Unipoint LC system software was used to 
perform HPLC. 100 µl of the sample was injected into C18 column (15cm x 4.6mm, 
5µm) and 233 nm UV was used to detect the samples. 
 
2.2.13. Mass spectrometry and NMR 
The MS and NMR were done at the School of Chemistry, University of Bristol. 500 ml to 
1 L of culture was incubated for target product purification in the same manner as for 
HPLC analysis. The cells were removed by centrifugation at 22,000 ×g for 20 min. The 
supernatant was then extracted by ethyl acetate (1:1) once, followed by an extra ethyl 
acetate extraction after the aqueous was acidified to pH 5.0. The two extracts were 
combined and ethyl acetate was evaporated in vacuo. The residue was collected by 
methanol for LCMS analysis and all the samples were dissolved in 3.0 ml 
methanol.  Analytical samples were prepared by 10-fold dilution with methanol and 
analysed by LCMS using a Waters HPLC system (Waters 2545 Binary Gradient Module 
and Waters SFO System Fluidics Organizer). Detection was achieved by UV between 
200 and 400 nm using a Waters 2998 diode array detector, and by simultaneous 




detecting between 150 and 600 m/z units. Chromatography (flow rate 1 mL·min-1) was 
achieved using Phenomenex Kinetex column (5 μm, C18, 100 Å, 4.6 × 250 mm). 
Solvents were: A, HPLC grade water containing 0.05% formic acid; B, HPLC grade 
acetonitrile containing 0.045% formic acid. Analytical gradients were as follows: 0 min, 
5% B; 22 min, 60% B; 24 min, 95% B; 26 min, 95% B; 27 min, 5% B; 30 min, 5% B. 
LCMS purification of target compounds were performed on 
prep Phenomenex Kinetex column (5 μm, C18, 100 Å, AXIA 21.2 × 250 mm). Collection 
of target peaks was triggered by mass. Both positive (PI) and negative (NI) mode were 
employed for the characterization of the target compounds together with the UV 
absorption pattern. Comparative yields of target compounds were measured by ELS 
peaks. 
 
2.2.14. Bioinformatic analysis 
Bioinformatic analysis: DNA and protein sequences of tmuB were obtained from the 
GenBank database at NCBI (accession no. FN689524 & protein id: CBK62743). HHpred 
(http://toolkit.tuebingen.mpg.de/hhpred) (Soding, 2005) was used to identify homologous 
resolved protein structures. The first four structures with the highest identity score were 
PDB ID 4NAO (Havemann et al., 2014), 4NMI (Widderich et al., 2014), 4MHR (Hoppner 
et al., 2014) and 2AX1 (McDonough et al., 2005) with identity score (20%, 19%, 17% 
and 15%) respectively. DSSP (Joosten et al., 2011) was used to determine the 
secondary structure of the templates. The secondary structure prediction server 




(http://www.compbio.dundee.ac.uk/jpred) (Cole, 2008) were used to predict TmuB 
secondary structure. ClustalX (Jeanmougin et al., 1998) was used to set up the initial 
multiple alignments and the software Seaview (Galtier et al., 1996) was used to 
manually refine the alignment guided by the known and predicted secondary structure. 
Modeller version 9.12 (Narayanan et al., 2006) was used to generate a homology model 
of TmuB on the basis of the crystal structure of EasH (4NAO). The overall geometric and 
stereo-chemical qualities of the final modelled structure of TmuB were evaluated using 
multiple programs and online servers such as PROSESS (Wishart Lab, 
http://www.prosess.ca/index.php ), WHAT_CHECK (Hooft et al., 1997), and RAMPAGE 
(Lovell et al., 2003). Evolutionary Trace Annotation (ETA) servers (Amin et al., 2013; 
Erdin et al., 2013) and ESPript3 (Robert and Gouet, 2014) were used to identify the 
important residues for the protein catalytic function and those which are conserved or 
diverse and to find the suitable residues for mutation.  
 To predict the catalytic reaction of TmuB on the substrates, AutoDock4 and 
AutoDockTools 1.5.6 (Morris et al., 2009; Sanner, 1999) were used to dock the 
substrates into the active site of the modelled TmuB and to analyze the interaction 
between the protein and the ligands. Rigid docking was performed using the genetic 
algorithm with default docking parameters. AutoGrid was used to define the docking 
searching area in active site and the grid size set to 54 X 52 X 52 points, grid spacing of 
0.375 Å and grid center 71.5 X 30.09 X 34.89. Before running the AutoGrid and 




(http://www.pymol.org) was used to modify the substrate (PA-A to PA-B) and to visualize 
the predicted structure of TmuB protein. 
 
2.2.15. Point mutation using overlap extension 
The mutagenesis overlap extension method (Vallejo et al., 1994; Mergulhao et al., 1999) 
was used to create point mutations. A pair of overlapping primers was designed in which 
the point mutation was located in the middle of the primers RP1 
5'CCAATGCCACCGAACAGCTGAAC and FP2 5'GTTCAGCTGTTCGGTGGCATTGG. 
These two primers were used with previous external primers (Table 2.4) to generate two 
fragments each with point mutation at one end. To fuse these two fragments, a second 
round of PCR was run using TmuBF as a forward primer, downstream fragment as a 
reverse primer and the WT DNA genome as a template (The procedure illustrated in 
Figure 2.1). In this study, a modified method was used by designing one primer with the 
point mutation in the middle. This was used with normal forward or reverse primers to 
create a piece of DNA with the desired mutation. This DNA product was used with the 
forward or reverse primer to amplify the whole gene with the desired mutation (the 
procedure illustrated in Figure 2.2). The tmuB with the point mutation was cloned into 
the expression vectors and mobilized to P. fluorescens strains via conjugal mating using 





Figure 2.1. Overlap extension to create point mutation: step1, amplifying two 
overlapping fragments; step2, extension and joining the overlapped fragment 






Figure 2.2. Modified overlap extension to create point mutation: step1, amplifying 
a piece of the DNA template with desired mutation; step2, using this piece of 





2.2.16. Protein overexpression using pET28a 
The target gene was expressed using pET28a vector which carries an N-terminal His-
Tag and thrombin Figure 2.3. Both pET28a vector and the sequenced gene on pGEM-T 
Easy vector were digested with Ndel and Xhol restriction enzymes and purified by gel 
electrophoresis. The ligation between the gene and the vector was carried out as 
described in section 2.2.4.3 and transformed into competent E.coli DH5α and plated out 
on LB agar plus kanamycin (50µg/ml). The recombinant vector was isolated from grown 
colonies and was checked by restriction enzyme digestion and gel electrophoresis. The 
recombinant vector with the correct insert was transformed into competent E.coli BL21 
(DE3) strain and plated out onto LB agar plus kanamycin (50µg/ml). 
 
2.2.16.1. Small scale expression using IPTG induction 
Small scale expression was done to find an optimum temperature and IPTG 
concentration to produce soluble protein. Universal bottles of L-broth plus kanamycin 
(50µg/ml) were inoculated with single a colony of E.coli BL21 (DE3) strain which carries 
the recombinant pET28a vector and incubated for 16 hours at 37 oC with shaking at 200 
rpm. 25 ml of fresh LB- broth in 250 ml volume flask seeded with1:100 overnight culture, 
antibiotic was added and incubated at 37 oC /200 rpm till the OD600 reached 0.4-0.6.  
To induce protein expression, different concentrations of IPTG (0.0mM, 0.1mM, 0.5mM 




temperature (37 oC, 25 oC, 18 oC ). From each flask, 1ml was taken and centrifuged for 
10 minutes at 13000 x g / 4 oC. The supernatants were discarded and the pellets were 
washed with STE buffer (10mM Tris-HCl pH 8.0, 0.1 M NaCl and 1 mM EDTA) and 
analyzed by SDS-PAGE. 
2.2.16.2. Large scale expression using autoinduction approach 
Autoinduction was used to produce large amounts of soluble protein by preparing half 
strength L- broth. To prepare 400 ml of half strength L- broth, 4g tryptone, 2g yeast 
extract, 1.42g Na2HPO4, 1.36g KH2PO4 and 1.07g NH4Cl were added, dissolved by 
stirring and heating and autoclaved. To set up the autoinduction culture, to each 400 ml 
of half strength L- broth, 3.2ml of 60% glycerol, 20ml of 1% glucose/ 4% lactose/ and 
40mM MgSO4, 50µg/ml kanamycin and 1ml of trace metal solution were added, mixed, 
poured into sterile 2L volume flask, and 4ml of overnight culture was inoculated. This 
was incubated at 37 oC for 3.5 hours then moved to 18 oC for 16 hours. The cells were 
harvested by centrifugation for 10 minutes at 14000 x g at 4 oC using 500ml volume 
bottles in Beckman centrifuge using F10BA rotor. The supernatants were discarded and 







Figure 2.3. General features of pET28a vector and multiple cloning sites 
(From Novagen user manual, 2002). The tmuB gene was cloned between 




2.2.17. Cell lysis  
Different methods were used to lyse the cells and separate the soluble and insoluble 
protein fractions depending on the downstream application. 
2.2.17.1. Sonication 
 Sonication was used to disrupt the cells and check the solubility of the protein in small 
scale expression. The pellet was resuspended by lysis buffer (20 mM Tris-HCl pH7.5) 
and for each 1 gram of pellet 10 ml of lysis buffer was added. One tablet of EDTA-free 
protease inhibitor cocktail provided by Roche was added to each 50 ml of cell 
suspension.  The cell suspension was kept on ice for 1 hour and sonicated for 4 x 10 
seconds at 10 micron.  
2.2.17.2. Bugbuster® Master Mix 
Bugbuster® Master Mix provided by Novagen was used to disrupt the cells and check 
the solubility of the protein in small scale expression. For each 1 gram of the pellet 5 ml 
of Bugbuster solution was added and incubated at room temperature for 60 minutes to 
allow complete lysis of the cells. The soluble and insoluble fractions were separated by 
centrifugation at 20000 xg for 10 minutes at 4 oC. The supernatant was carefully 
transferred to a new tube and treated as soluble protein while the pellet was 




2.2.17.3. French press 
The French press is considered to be the first choice to obtain pure and intact protein 
from large scale expression. The pellet was resuspended in resuspension buffer (20 mM 
Tris-HCl pH7.5) and for each 1 gram of pellet 10-15 ml of lysis buffer was added. One 
tablet of EDTA-free protease inhibitor cocktail provided by Roche was added to each 50 
ml of cell suspension. The French press cell body and compartments were kept in fridge 
for 1 hour, the sample loaded (35 ml per run) and the cells were disrupted under 12000 
psi pressure. The soluble and insoluble fractions were separated by Beckman centrifuge 
at 30.000 x g for 20 minutes at 4 oC using AJ25 rotor. The supernatant was carefully 
transferred to new tube and treated as soluble protein and ready to be purified.  
 
2.2.18. Protein purification 
2.2.18.1. Affinity chromatography 
The soluble fraction of protein was purified using HisPur Ni-NTA Resin® provided by 
Thermo Scientific and following the manufactures instructions. To propylene column 
(Qiagen), an appropriate amount of the resin was added, left for 15-30 min to settle the 
nickel particles and the storage buffer was drained. The resin was washed three time 
with two resin-bed volumes of equilibration buffer (20mM Tris-HCl, 500mM sodium 
chloride, 10mM imidazole; pH 7.5). The protein sample was loaded on the column gently 
and the flow-through fraction was collected and reapplied again to maximize protein 




volumes with wash buffer (20mM imidazol, 20mM Tris-HCl, 500mM NaCl pH7.5) to elute 
the unbound proteins. The target protein was then eluted with elution buffer (20mM Tris-
HCl, 500mM NaCl, pH7.5) in steps containing different concentrations of imidazole 
(50mM, 100mM, 150mM, 200mM and 250mM). All fractions from flow through to final 
elution were collected separately and analyzed by SDS-PAGE to check the purification 
process. 
  
2.2.18.2. Gel filtration 
The protein purified from the affinity chromatography step was  further purified by gel 
filtration using a Superdex 200 26/60 column with 300 ml capacity. ÄKTAprime plus was 
used to inject the buffer and the sample. The running buffer (20mM Tris-HCl, 500mM 
NaCl pH7.5) was filtered and degassed using a 0.2µm filter under vacuum. The buffer 
flow rate was 3 ml/min with pressure 0.5 MPa, after 600 ml of buffer running, the flow 
rate was reduced to 1ml/min and 2 ml of protein sample (5 mg/ml) was injected. The 
absorbance scale was 280nm and the fractions (4ml/tube) were collected in 10 ml 






2.2.19. Sodium dodecyl sulfate- polyacrylamide gel electrophoresis (SDS-PAGE) 
Protein samples were analyzed using SDS-PAGE. 12% resolving gel (lower part) and 
5% stacking gel (upper part) were prepared as follows: 
 
 
A BioRad gel electrophoresis kit was used to set up the gel, the glass plates were fixed 
on the casting frame and checked for leaking by adding distilled water. The components 
of the resolving gel were mixed and poured between glass plates and the upper part 
was filled with isopropanol to level up the gel surface and eliminate air bubbles. After gel 
polymerization, the isopropanol was removed, washed three times with distilled water 
and dried with Whatman filter paper. The upper part between glass plates was filled with 
stacking gel mixture, the desired size comb was inserted and left to polymerize. 
The protein samples were prepared by adding an equal amount of loading dye (50 mM 




boiled for 5 minutes. The glass plates were assembled using clamping frame and 
electrode assembly, and placed into the running tank. The running tank was filled with 
1X Tris- glycine electrophoresis buffer (5X buffer: 25 mM Tris pH 8.3, 250 mM glycine 
and 0.1% SDS). The plastic combs were removed and 10 µl of protein sample and 
prestained protein marker were loaded into the gel wells. The electrodes were 
connected to power supply and run at 120V / 500mA for 2 hours. The gels were 
removed from the glass plates and stained with Coomassie Brilliant blue stain (5 tablets 
of Phastgel Blue R dissolved in one liter of 1:1 distilled water and methanol) for at least 
3 hours. The gels were destained by De-staining solution (30% methanol and 10% 
glacial acetic acid) untill the gels became clear and the protein bands were obvious. 
Finally, the gels were washed and equilibrated for 5 minutes in distilled water and fixed 
with cellophane sheets.  
 
2.2.20. Protein dialysis, concentration and storage 
The imidazole in the protein sample was eliminated either by gel filtration or dialysis. 
Dialysis buffer was prepared as the wash buffer used for affinity chromatography 
(section 2.2.18) but without imidazole or any other buffers were used according to the 
downstream application. The dialysis tubing Specta/Pro® supplied by SpectrumLabs with 
6,000-8,000 MWCO was used and prepared according to the manufacture’s manual. 
The tube was soaked in distilled water for 30 minutes, washed with 0.5% sodium 




followed by 2 ml of 0.4% of sulphuric acid per 50 ml of total solution for 1 minute and 
finally washed thoroughly with distilled water. To remove the heavy metal ions, the tube 
was soaked in 0.5 M of EDTA for 30 minutes and washed several times with distilled 
water to remove all EDTA and ions. One end of the tube was closed with the plastic clip 
and the sample was loaded by pipetting and the other end closed by clip. The sample to 
buffer ratio was 1:200 to maximize buffer exchange and the sample was dialysed with 
stirring at room temperature for 4 hours and then replaced with fresh buffer and dialysed 
for overnight at 4 oC. Amicon® Ultra Centrifugal Filter with 100,000 MWCO was used to 
concentrate the protein sample. The protein concentration was measured using a 
Nanodrop 1000 spectrophotometer. 25% (v/v) of glycerol was added to the protein 
sample, 250µl was aliquoted in 1.5 ml microfuge tube, flushed by liquid nitrogen and 
was stored at -20 oC. 
 
2.2.21. In vivo protein-protein interactions  
Bacterial Adenylate Cyclase Two-Hybrid System Kit was used to test protein-protein 
interactions in vivo. To amplify the tmuB gene, forward and reverse primers were 
designed with PstI and Xbal restriction sites respectively (Table 2.4). This allowed the 
gene to be cloned into the Two-Hybrid System vectors. 
pKT25, pKNT25, pUT18 and pUT18C vectors (Table 2.2) were used to create a fusion 
protein of the T25 and T18 domains of adenylate cyclase with the target protein. Control 




is fused to T25 and T18 domains respectively. The tmuB gene was sub-cloned in frame 
into the pKT25, pKNT25, pUT18 and pUT18C vectors using standard techniques. The 
recombinant plasmids were transformed into E.coli DH5α using the standard protocol 
and plated out on LB agar with the appropriate antibiotics (Figure 2.4). The recombinant 
vectors were checked for correct insertion by restriction enzyme digestion and gel 
electrophoresis. The two compatible recombinant vectors were co-transformed to the 
reporter strains, E.coli BTH101 and DHM1 (Table 2.1), which are adenylate cyclase 
deficient (cya)  and were plated out on both MacConkey agar containing 1% maltose, 
kanamycin and ampicillin, and LB containing IPTG, Xgal, kanamycin and ampicillin 
(Table 2.3). The plates were incubated at 30 oC for 2-3 days.  
The suspected colonies were further characterized by measuring the β-galactosidase 
activity using o-nitrophenol-β-galactoside (ONPG) as a substrate. The protocol 
procedure was carried out according to the manufactures instructions (Euromedex 
BACTH system kit) and described in detail by (Miller, 1992 and Karimova, 2005). Single 
pure colony was inoculated in 5ml LB broth supplemented with 0.5mM IPTG and the 
appropriate antibiotics, and incubated overnight at 30 oC. This was diluted 1:5 with M63 
medium and the optical density (OD) was measured at 600nm. To permeabilized 
bacterial cells, to each 5ml of the diluted bacterial culture, 60µl of each toluene and 
0.1%SDS were added in a glass tube, plugged slightly with cotton, vortexed for 10 
seconds and incubated at 37 oC with shaking for 40 minutes. Aliquots of 0.1 to 0.5ml of 
the permeabilized cells were added to 1ml of PM2 assay buffer (70mM 




100mM β-mercaptoethanol was added before use). The enzymatic reaction was set up 
by adding 0.1 ml of the permeabilized cells to 0.9 ml of PM2 buffer (in a 5 ml glass tube) 
and incubated in a water bath at 28 °C for 5 min. This was followed by adding 0.25ml of 
the substrate solution (4% ONPG in PM2 medium). A yellowish color developed as a 
result of the enzymatic activity and the reaction was stopped by adding 0.5 ml of the 
stop solution (1M Na2CO3). The OD for each tube was measured at 420nm. The β-
galactosidase activity is measured in units/mg of the bacterial dry weight (one unit 
equivalents to 1 nmol of ONPG hydrolyzed per min at 28°C). 
The following equation was used to calculate the enzyme activity, E (in Units/ml): 
E = 200 x OD420 / min of incubation) x Df.  
200: Is the inverse of the absorption coefficient of o-nitrophenol. 
Df: The dilution factor for the permeabilized cells which was 10. 
The result was converted to Units/mg, by considering that 1ml of culture at OD600 = 





Figure 2.4. General steps for identification in vivo protein-protein interactions using 





2.2.22. In vitro enzyme activity assay 
The initial hydroxylase TmuB activity was measured at 23 oC in 500 µl reaction volume 
which consists of 35µM TmuB protein, 0.25mM FeSO4 (Co-factor), 0.5mM α-keto 
glutaric acid (co-substrate) and 50µM pseudomonic acid A in 20mM Tris-HCl buffer, 
pH7.5 and 500mM NaCl. The reaction was set up in different time course and the 
reaction was stopped by adding an equal volume of 100% acetonitrile. The mixture was 
left for 5 minutes at room temperature, centrifuged at 13000 x g for 5 minutes, the 
supernatant was separated and analyzed by HPLC. Various conditions were used to 
reach the optimal reaction and to find the initial velocity of the enzyme activity. These 
variations included different temperature, time, and different concentrations of TmuB 
protein, the substrate, co-factor and co-substrate. Each assay point was triplicates to 
determine the mean standard error. The data were fitted to a Michaelis-Menton model 
using Prism graphpad software (http://www.graphpad.com/ scientific-software/prism).  
 
2.2.23. Suicide mutagenesis in Pseudoalteromonas sp. SANK 73390 
To inactivate TmuB activity in Pseudoalteromonas sp. SANK 73390, isoleucine 109 was 
changed to Asparagine via suicide mutagenesis. The tmuB gene with point mutation 
I109N was cloned into suicide vector pAKE604 as a SalI/XbaI insert. This was moved to 
the WT Pseudoalteromonas sp. SANK 73390 via conjugation using E.coli S17-1. 1ml of 
overnight culture of the donor and recipient were mixed, passed through 0.45µm filter, 




1 ml of marine broth, followed by serial dilutions (10-1 to 10-5), 200µl of each dilution 
being spread on marine agar supplemented with 100µg ml-1 kanamycin and incubated at 
23 oC for 3-4 days. Pure colonies (cointegrant clone) were selected and incubated at 23 
oC in marine broth without antibiotic to isolate strains in which the suicide plasmid had 
excised from the chromosomal DNA. From this, serial dilutions were plated on marine 
agar supplemented with 5% sucrose and the grown colonies were tested for kanamycin 
sensitivity. The colonies that were Kans and Sucr were selected and checked by PCR 
and DNA sequencing. Figure 2.5 illustrates the strategy of suicide mutagenesis. 
2.2.24. Antibiotic extraction and purification 
2.2.24.1. Thiomarinol from Pseudoalteromonas sp SANK 73309: 100 ml of marine broth 
was inoculated with 5 ml of overnight culture and incubated at 23 oC for 48 hours. To 
stabilize the thiomarinol compound, the pH was adjusted to 6.0 by HCl. An equal volume 
(100 ml) of acetone was added to the culture, mixed and incubated at 4 oC for 2 hours to 
decompose the cell wall.  
The acetone solvent was evaporated using a vacuum aspirator in the fume hood. An 
equal volume (100 ml) of ethyl acetate was added, mixed by shaking for 5 -10 minutes 
and transferred to separating funnel. The mixture was separated into two phases: 
solvent phase containing thiomarinol in the upper part and the water phase in the lower 
part. The latter was discarded by opening the funnel outlet slightly and the solvent phase 
transferred to the rotary evaporator. The dried extracted powder on the flask wall was 





Figure 2.5. The suicide mutagenesis technique using pAKE604 plasmid. This 





The product was analyzed by HPLC and the target peak was isolated using a fraction 
collector.             
2.2.24.2. Mupirocin from Pseudomonas fluorescens NCIMB 10586: 100 ml of secondary 
stage media (SSM) was inoculated with 5 ml of overnight culture and incubated at 22 Co 
for 40-60 hours with shaking at 200 rpm. The culture was transferred to 50ml Falcon 
tubes, centrifuged at 8,000 x g, the supernatant separated and the pH was adjusted to 
4.5 by HCl. An equal volume (100 ml) of ethyl acetate was added, mixed by shaking for 
5 -10 minutes and transferred to a separating funnel. The rest of steps were done as 
described in the previous section. 
 
2.2.25. Bioassay test 
2.2.25.1. Plate bioassay for mupirocin activity was carried out by spotting 10µl of 
Pseudomonas flourescens overnight culture onto 20 ml L-agar plates and incubating 
overnight at 30 oC. This was overlaid with 15 ml of molten agar at 45 oC seeded with 
overnight culture of Bacillus subtilis 1064 (40µl/ml) and 0.5 ml of triphenyl tetrazolium 
chloride TTC (5%). After incubation for 18h at 37 oC, the clear zones of inhibition around 
the bacterial spots were measured.  
2.2.25.2. Plate bioassays for thiomarinol using a disc diffusion assay to test the potency 
of thiomarinol compounds. The plate was prepared by pouring of 15 ml of LB agar into 




which was also left to solidify. The detection layer was prepared by mixing 4.75ml of 
melted LB agar 45 oC, 4.75ml pre warmed 45 oC LB broth, 100µl of TTC 5% and 400µl 
of the overnight culture of Bucillus subtilis 1064 in a Falcon tube. The discs paper with 
thiomarinol compounds were prepared by adding 40µl of the thiomarinol stock slowly, 
leaving it to dry and placing it over the overlaid layer. After incubation for 18h at 37 oC, 
the clear zones of inhibition around the paper disc were measured.  
 
2.2.26. Minimal inhibitory concentration 
Three flasks of L- broth were inoculated (1:100) with overnight cultures of detector 
bacteria (Bacillus subtilis or E.coli) and incubated at 37 oC with shaking untill the OD600 
reached to 0.4 - 0.6. This was diluted with L-broth to obtain OD600 0.08-0.10 (0.5 
McFarland standard) (McFarland, 1907), which contains approximately 108 CFU/ ml. 
This was diluted 1:100 to the working dilution (106 CFU/ml). A Costar® 96 well flat 
bottom plate was used to set up the tests. To each well, 100 µl of bacterial suspension 
and 100 µl of antibiotic dilutions were added. The plates were incubated at 37 oC with 
shaking at 200 rpm for 18-20hrs. A SPECTROstar Nano microplate reader was used to 
read the OD at 600 nm as raw data, and three combination wavelengths (600, 
900,977)nm were used to standardize the water content in the well. These data were 






2.3.1. Blast search to identify putative hydroxylase 
One prominent difference between mupirocin and thiomarinol structure is the extra 
hydroxyl group at C4 in monic acid (Figure 2.6). As mentioned in the Introduction to this 
Chapter, the alignment between the mupirocin and thiomarinol gene clusters, which 
were described previously (Fukuda et al., 2011) identified some genes in thiomarinol 
gene cluster that are absent from the mup cluster and might be responsible to catalyse 
4-hydroxylation of thiomarinol. To identify the potential candidate, the predicted amino 
acid sequences of these genes were used to perform BLAST searches against the NCBI 
GenBank protein database (Altschul et al., 1997). This identified TmuB as a putative 
phytanoyl-CoA dioxygenase with the identity score ranging from 42% to 33% and E-
value 1e-60 to 5e-45 respectively (Figure 2.7A) and TmlZ as putative monooxygenase 
with the identity score 46% and E-value 5e-34 (Figure 2.7B). Based on this, tmuB and 
tmlZ have been chosen as candidates that may encode the hydroxylase.  
 





Figure 2.7. The result of Blast (non-redundant protein sequence) search for the 






2.3.2. Gene amplification and recombinant vector construction 
The tmuB gene (795bp) was amplified by standard PCR and the product was run on the 
agarose gel which showed about 800bp. The purified DNA was cloned to pGEMT-Easy 
vector and was digested by relevant restriction enzymes to check that it is the right 
recombinant. The identical sequence insert was cloned to the expression vectors, 
pJH10 and pET28a (Figure 2.8). The same procedures were carried out to clone tmlZ 
into pJH10 plasmid.     
 
2.3.3. HPLC analysis of in trans expression of TmuB and TmlZ in heterologous 
hosts 
The constructed vectors (pHHM04 and pHHM05) were transferred to wild type and 
mutants of P. fluorescens NCIMB 10586 via conjugation and the culture supernatants 
were analyzed by HPLC to investigate the effect of genes expression. HPLC analysis 
showed that tmuB expression in WT P. fluorescens NCIMB10586 shifted the retention 
time (RT) of the pseudomonic acid A peak from 20.2min (PA-A) to give a new peak at 
18.2 min (Figure 2.9) while tmlZ expression did not show any activity. LCMS followed by 
NMR confirmed that this new product was the result of 4-hydroxylation.  
TmuB was expressed in the mutant strains that produce other derivatives rather than 
PA-A. P. fluorescens mutants ΔmacpE, ΔmupO, ΔmupU and ΔmupV were created 




these mutants did not show any change in metabolite profile of PA-B (RT 19.3min) 
(Figure 2.9). TmuB was expressed in other mutants of P. fluorescens which produce 
different pseudomonic acid derivatives: ΔmmpE/OR, ΔmupF and ΔmupC which produce 
PA-C, mupirocin F and mupirocin C respectively and ΔmupT and ΔmupW which 
produce mupirocin W. The HPLC profile for the mutant strains revealed that TmuB 
expression yielded some new major and minor peaks. 
As illustrated in Figure 2.9, expressing tmuB in the ΔmmpE/OR mutant gave a novel 
peak eluting at 20.2 min. Likewise, tmuB expression in the ΔmupF mutant yielded a new 
major peak at 19.6 min while the mupirocin F peak at 22.3 min increased by two-fold 
(Figure 2.9). However, there were no significant differences in the metabolite profile after 
TmuB expression in the strains producing mupirocin C (22.4 min) or mupirocin W (22.0 
min). The structures of the new derivatives were determined using LC-ESI-MS and NMR 
analysis. LC-ESI-MS identified the molecular weights of 516Da, 500Da and 514Da from 
WT, ΔmmpE/OR and ΔmupF respectively. The structures of these novel products were 
elucidated using NMR and were identified as 4-hydroxy PA-A, 4-hydroxy PA-C and 4-





Figure 2.8. The tmuB and tmlZ genes amplification and cloning. PCR 
product of tmuB (A), The tmuB gene (0.8kb) cloned to pGEM-T Easy as A-
tailed insert (B), pJH10 vector as EcoRl/Xbal insert (C) and pET28a vector 
as NdeI/XhoI insert (D), The tmlZ gene (0.38kb) cloned to pGEM-T Easy as 
A-tailed insert (E) and into pJH10 vector as EcoRl/Xbal insert (F). 
Constructed plasmids were digested with relevant restriction enzymes to 






Figure 2.9. HPLC analysis of culture supernatant from Pseudomonas 
fluorescens strains. TmuB modifies pseudomonic acid A and C but not B, that it 
has a hydroxyl at C8. Mupirocin F with a keto- rather than hydroxyl at C7 is also 





































































































































































































































































2.3.4. Bioinformatics analysis 
As described in the Materials and Methods section 2.2.14, the HHpred online program 
was used to identify the crystal structures of homologous proteins to be used as 
templates to create a homology model of TmuB. It has been found that all the templates 
belong to the nonheme-iron(II)/α-ketoglutarate(αKG)-dependent superfamily. Some 
enzymes in this group use α-ketoglutarate as a co-substrate to incorporate oxygen atom 




2.3.4.1.  Modelling  
TmuB secondary structure of TmuB was predicted using the secondary structure 
prediction server PSIPRED and Jpred3. This was aligned with the sequence and 
secondary structure of the templates in Seaview and refined manually (Figure 2.12). 
Figure 2.11. The hydroxylation reaction catalyzed by some enzymes belonging 




Modeller version 9.12 was used to generate a homology model of TmuB on the basis of 
the crystal structure of EasH (pdb 4NAO). Up to 10 models were generated, and were 
evaluated using a set of programs to choose the best model (see below). 
As illustrated in Figure 2.13, the core of the homology model of the TmuB protein 
contains a double stranded beta-helix (DSBH) or jelly-roll fold which is the characteristic 
feature that unifies the structures of the nonheme-iron(II)/2-oxoglutarate-dependent 
dioxygenase superfamily. This jelly-roll strucuture is surrounded by extra beta sheets 
and alpha helixes. The β-strand II and VII are disordered while the other strands are well 
determined. The cofactor (Fe+2 ion) is located in the center of the active site in the 
homology model and bound by three residues, His121 and Asp123 are located at the 
end of β-strand II and His191 is located on β-strand VII. The co-substrate αKG binds to 
Fe+2 ion in a bidentate manner via C1- carboxylate and C2-keto group while the C5-
carboxylate forms hydrogen bonds with Gln118 and Thr154 and electrostatic interaction 
with Arg202 (Figure 2.14). These residues are highly conserved among the enzyme 
family. The surface mode of the protein shows that the active site is identified as a long 
groove leading to the pocket where the cofactor and the co-substrate are bound. The 
docking process shows that this groove and pocket in the active site are consistent with 














































































































































































































































































α-h2 /β3 loop 
Figure 2.13. Homology model of TmuB (8th) illustrating the jelly-roll fold in the active 
site. The parts of the structure named based on previous crystal structures. Fe+2 
(orange sphere) and α-keto-glutarate (pink stick) are located in the centre of the jelly-
roll structure. The jelly-roll consists of eight β-strands arranged into four at each side. 
The strands I, VIII, III, and VI are in green color at one side while the strands II, VII, 
IV, and V in yellow color on the opposite side. Note that both strand II and VII are 
disordered. N-terminal in blue and C-terminal in red color. See Figure 2.21 for amino 




















Figure 2.14. Close insight into the active site of TmuB model. Fe+2 (orange 
sphere) is located in the centre of the jelly-roll structure and octahedrally 
coordinated by three conserved residues His121, Asp123 (at the end of strand II) 
and His19 (on strand VII), and the co-substrate α-keto-glutarate (pink stick) which 
is held by Gln118 (at beginning of strand II), Thr154 (on βIII/IV loop) and Arg202 






2.3.4.2. Homology model structure assessment 
The overall geometric and stereo-chemical qualities of the TmuB modelled structures 
were evaluated. WHAT_CHECK shows the residues packing score and the models 
quality, and the overall quality score of the models obtained by PROSESS (Table 2.6). 
All the models were checked and those with the highest score were selected.   
The Ramachandran plot for 8th model shows that all the residues around the active site 
are located within the favoured region. Only three residues (Val11, Ile13 and Lys254) 
are located within outlier regions which are far from the active site and located on the 
extreme N- and C-termini (Figure 2.15) which may not affect the catalytic activity. 
However, all models showed that the α-helix2/β3 loop has not been folded properly 
because it was missing from the crystal structure of the templates. Recently, two more 
proteins have been determined and were identified by HHpred with higher identity to 
TmuB, 21% for AsqJ (Bräuer et al., 2016) (PDB 5daw) and 23% for FtmOx1 (Yan et al., 
2015) (PDB 4y5t). It can be noticed that α-helix2/β3 loops in these proteins have been 
resolved and appear to be properly folded (Figure 2.16). Therefore, TmuB has been 
remodelled using these two proteins as the primary templates. The secondary structure 
of the TmuB was aligned with the templates and manually refined using Seaview (Figure 
2.17) and the TmuB structure was predicted according to AsqJ. Up to 6 models of TmuB 
were generated and were evaluated as described previously, and the quality scores 
were obtained (Table 2.6). As illustrated in Figure 2.18, in this model (15th) the α-
helix2/β3 loop has been folded and in combination with the βII/III loop covers the 









Figure 2.15. The geometric and stereo-chemical evaluation of 8th homology 






Figure 2.16. The structural model of TmuB and the crystal structures of the 
templates. Critical importance is the potentially mobile α-helix2/β3 loop that is 
missing from the EasH structure and is presents in AsqJ and FtmOx1 protein. A. 
TmuB model generated according to the structure of EasH protein (B) in which the 
loop is missing in the crystal structure (depicted as dash line). C and D. AsqJ and 



























































































































































































































































2.3.4.3. Receptor-ligand Docking 
The substrate PA-A was docked to the TmuB model to investigate the residues which 
should interact with the substrate, particularly around the pyran ring where the 8OH is. 
The 8th and 15th of the TmuB models were used as a receptor to dock the ligand, PA-A.  
The docking runs were repeated with different parameters to determine the most 
Figure 2.18. The structure of the TmuB model (15th) showing the α-helix2/β3 loop 
packing. A. The model was generated according to the structure of the AsqJ 
protein. B. The same model rotated 90o degree to right to show the active site. 
Note that the α-helix2/β3 loop and the βII/III loop partially cover the entrance of 











repeated and dominant conformations and orientations, and each run of the docking 
resulted in 50 docking conformations. With the 8th model, the majority of the docking 
results revealed that the monic acid of PA-A fits into the active site pocket while the 9-
hydroxyoctanic acid fits into the external groove (Figure 2.19 A&B). The target site, C4, 
is within 4.38 Å of the Fe ion in presence of the cofactor (Fe) and the cosubstrate (αKG) 
while in absence of the latter, the distance is 3.4 Å. The pyran ring is fitted at the 
entrance of the pocket surrounded by the residues Arg69 (on β1), Lys105 and Ile109 (on 
βI) and Met208 (on βVIII). However, the residues, which are involved in the interaction 
with the substrate around the pyran ring, include Arg69, Lys105 and Ile109, Leu141 (on 
βIII) and Ala206 on (βVIII) (Figure 2.19C&D). The hydrophobic groove, which 
accommodates the fatty acid chain, is formed by residues from βII/III loop, end of βVIII 
and the turn following the βVIII. 
The docking run was repeated using 15th model to test the effect of the loops and turns 
around the active site. These loops include the α-helix2/β3 loop, βII/III loop and the turn 
following the βVIII and are arranged as a triangle covering the active site. As a result, 
the docking conformation of the ligand to this model is quite differed from the 8th model 
and PA-A cannot fit into the active site, particularly the fatty acid chain. However, the 
location of the pyran ring near the pocket entrance and the interacted residues remained 
the same. The conformations obtained in this docking also suggest residues on α-
helix2/β3 loop to be involved into the interaction with the fatty acid chain rather than 






Figure 2.19. A&B. The 8th homology model of TmuB showing the PA-A docked into 
the active site. The fatty acid chain fits into groove along with interacting residues 
while the monic acid is inserting into the pocket, C. The residues in the active site 
which surround the pyran ring and were selected to be replaced, D. Homology model 
of TmuB showing the interaction between PA-A (Pink stick) and the residues close to 
the different substrate sectors in the active site. The target site C4 is 4.38 Å from the 
























2.3.4.4. In silico mutagenesis 
Arg69, Lys105, Ile109 and Leu141 residues were selected for mutation to smaller and 
more hydrophilic amino acids to create more space to accommodate a bulkier 
hydroxylated substrate (like PA-B) and interact with it. To find appropriate amino acids to 
substitute the current residues, the TmuB sequence was aligned against the sequences 
of nonheme-iron(II)/2-oxoglutarate-dependent dioxygenase superfamily. It has been 
found that Ile109 is conserved among these enzymes and might play an important role 
Figure 2.20.  The 15th homology model of TmuB showing the PA-A docked into the 
active site in presence of αKG (Green stick) and Fe. A. The surface mode showing 
the fatty acid chain interacting with the residues Lys54 and Ala67 on helix2/β3 loop. 
B. The residues interacting PA-A (Pink stick) and the residues close to the different 
substrate sectors in the active site. The target site C4 is 4.2 Å from the Fe II 










in enzyme activity while amino acids Arg69, Lys105 and Leu141 were at less conserved 
positions (Figure 2.21 & 2.22). Therefore, these residues were replaced with appropriate 
amino acids to create mutated model of TmuB and used as a receptor in the docking 
process. 
 
2.3.4.5. Receptor-ligand Docking (mutated TmuB)  
The mutated model of TmuB was used as a receptor to dock the ligands PA-A and PA-B 
using the same parameters used previously for PA-A with native TmuB model (Figure 
2.23A&B shows an example of the mutant TmuB models which were generated in 
silico). First, the ligand PA-A was docked to these mutated model to obtain 
conformations which are similar to those with WT model. Comparing the predicted 
conformations allowed us to choose mutations that might allow similar conformations to 
be achieved with PA-B. As illustrated in Figure 2.23C&D the docking of PA-B to the 
native and mutated TmuB model (I109N) was compared to obtain similar conformations 

















































Figure 2.21. The multiple sequence alignment of TmuB protein with homologue 
proteins. The conserved residues in the active site HXD/H which bind with Fe ion 
(red arrows) and those which bind with 2KG (blue arrows), and the residues that 





































Continue of Figure 2.21. The secondary structure of TmuB is shown on the top 
of the sequences. The beta strands of the jelly-roll depicted by Roman numerical 




































































































































































































































































Figure 2.23. Mutant model of TmuB showing the replaced residues in the active 
site and how it changed the shape of the pocket. A. The residue isoleucine 109 
was replaced with asparagine and this mutation inactivated TmuB both in vivo and 
in vitro. B. Double mutation in the active site, the residues arginine 69 and 
isoleucine 109 were replaced with lysine and valine respectively and this mutation 
did not change TmuB activity. C.PA-B (pink stick) docked into the native TmuB 
model and D.PA-B docked into the mutated TmuB (I109N) model. Criteria for the 
conformations are listed including binding energy and inhibition constant. The 




2.3.5. TmuB mutagenesis 
Modified overlap extension mutagenesis was used to create single and double point 
mutations in tmuB, cloned into expression vectors (Figure 2.24) and mobilized to P. 
fluorescens strains to test for hydroxylation of PA-B.  
The four candidate residues were replaced with a variety of amino acids (Table 2.7) and 
the metabolite profile was analyzed by HPLC. None of these mutations changed the 
specificity, no appearance of any ability to hydroxylate PA-B was observed and the 
ability to hydroxylate PA-A was decreased. The single mutations R69K and L141V did 
not change the product profile while L141S and I109V reduced the 4-hydroxylated 
product of PA-A by 25% and L141N by 75%. Both I109N and K105E mutations 
abolished 4-hydroxylation of PA-A completely. A double mutation R69K - L141V was 
created in an attempt to accommodate the bulky substrate like PA-B but again HPLC 






Figure 2.24. Strategy to create point mutation I109N in tmuB gene. The 
previously cloned pGME-T Easy (pHHM01) vector was used as a DNA 
template. The same strategy was used to create the rest of the point 





Figure 2.25. HPLC analysis of the culture supernatant of P. fluorescens 
transformed with point mutation (PM) TmuB in pJH10 vector. A: wild type 
P.fluorescens which produce PA-A (retention time 20.1min) and 4-hydroxylated in 
the presence of active TmuB protein (retention time 18.17min), B: ∆mupO 
P.fluorescens which produces PA-B (retention time 19.3min) and could not be 





2.3.6. TmuB protein expression and purification 
To purify TmuB the tmuB orf was inserted into pET28a, and expressed in E.coli BL21 
(DE3) with an N-terminal His-tag. For the point mutation (I109N) TmuB, the mutated 
insert which was created previously and cloned into the pJH10 vector, was used as a 
DNA template. Escherichia coli BL21 DE3 was cultivated at different temperatures and 
IPTG concentrations to check the initial expression. In small scale expression trials all 
the temperatures and IPTG concentrations induced sufficient expression of TmuB 
protein when analyzed by SDS-PAGE. However, it was found that the optimum 
expression of soluble protein can be achieved at 25 oC and with 0.5 mM of IPTG (Figure 
2.26). Therefore, this optimum growth condition was used for large scale expression. 
After large scale expression, the protein was purified from other protein components by 
affinity chromatography depending on the 6xHis-tag technique. The principle of this 
technique depends on the specific interaction of 6xHis-tag fusion protein with Nickel ion 
on agarose beads. This retains the tagged protein within the column while untagged 
protein can be washed out with buffer. The elution buffer contains imidazole which 
competes with histidine for nickel and releases the tagged protein. Buffers with gradient 
concentrations of imidazole (from 50 mM to 250 mM) were used to achieve this process. 
It was found that the most tagged protein was eluted at between 100 mM to 250 mM 
imidazole concentration. To collect as much pure protein as possible, the 100mM 





Despite the repeat purification by nickel affinity chromatography, the SDS-PAGE shows 
a secondary band. Therefore, gel filtration was performed using HiLoad 16/600 
Superdex 200pg column, the flow rate 1ml/min and 4ml per fraction, a single peak of 
TmuB protein comes out and the fractions from 43 to 50 were analyzed by SDS-PAGE 

















Figure 2.26. SDS-PAGE for TmuB protein overexpression to find the optimum 
temperature for soluble protein expression. 25ml cultures were induced by 0.5mM 
IPTG for 18 hours at different temperature. A: the cell pellet of the negative 
controls (Only BL21 and BL21 plus empty pET28a) and for the recombinant vector 
(pHHM03) all temperatures induced TmuB expression, B: The cell opened by 
sonication and the supernatant (soluble protein) separated from the cell pellet 
(insoluble). 25 oC and 0.5mM IPTG was appointed as the optimum condition for 
soluble protein expression. TmuB protein (29.5 kDa) is indicated by yellow arrow. 






2.3.7. TmuB dimerization in vivo 
The Bacterial Adenylate Cyclase Two-Hybrid System was used to test protein-protein 
interaction in vivo. The TmuB protein was fused to both C- and N-terminus of the 
adenylate cyclase domains T25 and T18 as described in 2.2.21 section. The colonies of 
the positive control of the E.coli BTH101 and DHM1 were red and blue on the 
MacConkey and LB/X-gal agars respectively, while the negative control colonies were 
pale color or white on both plates. The E.coli BTH101 and DHM1 colonies, which 
contain constructed vectors, were darker than the negative control but brighter than the 
positive control (Figure 2.29). These colonies were tested to measure the β-
galactosidase enzyme activity to confirm the results. The level of β-galactosidase activity  
Figure 2.27. SDS-PAGE analysis for TmuB protein purification. A: purification by 
Ni-NTA affinity chromatography, the protein was eluted by different imidazole 
concentrations as shown above. The last four fractions (100mM to 250mM) were 
collected and repurified by gel filtration. B: SDS-PAGE for gel filtration fractions 






was below the positive limit which may reveal that this technique provides no evidence 
for protein-protein interaction in vivo (Table 2.8). However, this may contradict the gel 









Figure 2.28. Gel filtration for TmuB protein purification. A: The protein was 
eluted at 180 ml. B: Calibration curve to estimate protein size. The size of TmuB 
(plus His tag) = 31121.16 Da (Log=4.49) which should be eluted around 220ml, 
while elution at 180ml (log 62242.32=4.79) of the shown peak refer it as a 







Table 2.8. The result for in vivo protein-protein interactions using Bacterial 
Two Hybrid system. 
Plasmid 1 Plasmid 2 




pKT25-zip pUT18-zip Red (positive control) 1583 
pKT25 pUT18 Pale red (negative control) 56.7 
pHHM16 pHHM17 Pale red 51.7 
pHHM18 pHHM19 Pale red 56.2 
pHHM16 pHHM19 Pale red 60.74 
pHHM18 pHHM17 Pale red 58.5 
 
 
Figure 2.29. The in vivo protein-protein interaction assay using Bacterial-Two 
Hybrid. pUT18zip and pKT25zip vectors were transformed into BTH101 and 
used as a positive control. The empty pUT18 and pKT25 vector in BTH101 or 
empty BTH101 were used as a negative control. TmuB was inserted to 




2.3.8. TmuB activity in vitro  
Both the native and mutant I109N TmuB protein were tested on PA-A in the presence of 
the co-substrate (α-ketoglutaric acid) and co-factor (Fe+2). As an initial test, the reaction 
was incubated overnight at 25oC. When all the reaction components were included in 
the reaction mixture, the native TmuB generated a new peak at 18.2 min that was well 
separated from the PA-A (20.2min) (Figure 2.30A). The same reaction was repeated 
with the mutant I109N, which showed no activity (Figure 2.30B). To confirm the 
hydroxylation of the product, large-scale reaction was set up, the product peak was 
purified by HPLC, and analyzed by MS and NMR at School of Chemistry, University of 
Bristol, confirming that the new peak is 4-hydroxyl PA-A. This is consistent with the in 
vivo experiments in which the native TmuB showed activity while the mutant I109N did 
not. 
To test the ability of TmuB protein to hydroxylate PA-B in vitro, the same reaction with 
the same conditions except using PA-B as substrate was repeated. A new peak 
generated from TmuB activity on PA-B was detected by HLPC (RT=17.2min) and 
around 43% of the PA-B was converted to the product at 25 oC after overnight 
incubation. The new peak was purified by HPLC and MS detected a peak of MW 532 
(Figure 2.31). The location of the hydroxylation was elucidated by NMR which confirmed 
it as 4-hydroxyl PA-B. In attempt to convert all the substrate in the reaction to 4OH 
product, the reaction was repeated at 23 oC, 25 oC, 30 oC and 37 oC. The proportion of 
PA-B hydroxylated was found to vary, but none of these temperatures enable TmuB to 





Figure 2.30. HPLC analysis to test the activity of purified TmuB protein in vitro. 
The reaction set up in 500µl reaction volume (35µM TmuB protein, 0.2mM FeSO4, 
0.5mM α-keto glutaric acid and 50µM pseudomonic acid A in 20mM Tris-HCl 
buffer, pH7.5 and 500mM NaCl) at 23 oC overnight. A: Activity of purified TmuB on 
PA-A is dependent on all reaction components. When all components included 
(pink line) the PA-A peak shifted from 20.1 min to 18.17 min. B: PM I109N TmuB 
protein showed no activity. (Green line) buffer contains PA-A only as a negative 







Figure 2.31. HPLC and MS analysis of pseudomonic acid B hydroxylated in vitro 
by TmuB activity. The retention time of PA-B shifting from 19.3min to 17.4min and 






2.3.8.1. Reaction condition optimization  
Various reaction conditions were used to optimize TmuB activity. These variations 
included temperature, TmuB concentration, concentrations of the co-factor and co-
substrate, and the incubation time. Reactions were set up at 23oC, 25oC, 30oC and 37oC 
and followed for up to 180 minutes showing that the rate of reaction increased with 
temperature (Figure 2.33). Different concentrations of TmuB protein (17µM, 35 µM, 
Figure 2.32. HPLC analysis of products of TmuB activity using pseudomonic 
acid B (PA-B) at different temperature. About 41% of the substrate hydroxylated 
at 23 oC, 43% at 25 oC, 45% at 30 oC and 36% at 37 oC. The retention time of 




50µM and 85 µM) were used with different concentrations of the substrate (Table 2.9), 
and the reaction was incubated for 1 min at 23 oC. Different concentrations of 
cosubstrate (α-keto glutaric acid) and cofactor (FeSO4) were used. The product peaked 
at 0.5mM and 0.25mM of cosubstrate and cofactor concentration respectively (Figure 
2.34).  
 
The condition that converts small amount of the substrate to the product was identified 
to find the early linear phase of the reaction. The 17µM TmuB protein for 1 min at 23oC 
hydroxylated about 30% of the substrate. From these experiments the optimum 
condition for TmuB activity was identified and used to analyse the enzyme kinetics of 
TmuB using different substrates. A range of PA-A concentrations were run by HPLC to 
plot the calibration curve and calculate the amount of the product in the enzymatic 
reaction (Figure 2.35). 
Table 2.9. The effect of TmuB protein concentration on the reaction. The table 
shows the amount of the product (µM) by each concentration. The reaction 







Figure 2.33. The products of TmuB activity at different temperature using 
PA-A as a substrate. The reaction set up in 500µl reaction volume 
containing 17µM TmuB, 0.25mM FeSO4 (Co-factor), 0.5mM α-keto glutaric 
acid (Co-substrate) and various substrate as shown above in buffer (20mM 
Tris-HCl, pH7.5 and 500mM NaCl).    
[P] 
µM/min 
Figure 2.34. The effect of co-substrate (αKG) and co-factor (FeSO4) on 
the product. The reaction set up for 1 min at 23 oC containing 17µM TmuB 
protein plus 60µM substrate PA-A. The product reached the peak at 









2.3.8.2. Enzyme kinetics 
The enzyme kinetics of the TmuB activity was identified according to Michaelis–Menten 
and Lineweaver-Burk analysis. A range of substrate concentrations (3.75–240 µM) was 
added to the reaction mixture (17µM TmuB, 0.5mM αKG, 0.25mM FeSO4 and buffer 
made up to 500µl) incubated at 23 oC for 1 minute. The initial velocity (V0) of the reaction 
was calculated by dividing the amount of product formed by the time of incubation. The 
initial velocity was plotted versus substrate concentrations [S] to construct a Michaelis–
Menten model. Vmax and Km values for TmuB with PA-A as a substrate were 20.2 
µM/min and 28 µM respectively (Figure 2.36). 
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Figure 2.36. Enzyme kinetics for TmuB using PA-A as substrate. (Top) 
Michaelis- Menten model, Vmax=20.2 µM/min and Km= 28 µM and (Bottom) 





Reactions were set up to obtain the similar Vmax and Km values for TmuB using PA-B as 
substrate. Short time incubation reactions did not show any product, therefore reactions 
were incubated for longer time. After 6 hours of incubation, Vmax and Km were 0.039 




Figure 2.37. TmuB kinetics using PA-B as substrate. (Top)The reaction set up for 
6 hours at 23 oC and (Bottom) The product divided by 360 to find out the product 








The Kcat value for TmuB using PA-A as a substrate was 1986 s
-1 while using PA-B as a 
substrate the Kcat for TmuB was 3.83 s
-1, an approximately 500-fold difference. The 
catalytic efficiency (Kcat/Km) of TmuB for these two substrates are 70.9 and 0.045 
respectively (Table 2.10). 
 




It appears that PA-B still binds reasonably to TmuB but is not a good substrate, so it 
should be a competitive inhibitor of the TmuB reaction on PA-A. The reaction on PA-A 
was therefore carried out at a range of PA-B concentrations (30µM, 60µM and 120µM). 
The result is consistent with this hypothesis which revealed that the Km increased with 














PA-A 20.2 28 1986  70.9 
PA-B 0.039 85 3.83  0.045 






Figure 2.38. The influence of PA-B on TmuB activity while catalysing PA-A 
hydroxylation. The Km increased with the inhibitor concentration increasing (as 
shown above) and Vmax remained unchanged. With adding of 30µM, 60 µM and 
120 µM of PA-B, the Km increased to 28.9 µM, 31 µM and 37 µM respectively.     
0 µM PA-B 
[PA-A µM] 
30 µM PA-B 
60 µM PA-B 




2.3.9. Antibacterial activity of pseudomonic acid derivatives   
The new derivatives of pseudomonic acid (Figure 2.39) produced by TmuB activity in 
vivo and in vitro were assessed for antibacterial activity. Plate bioassay and minimal 
inhibitory concentration (MIC) were achieved using Bacillus subtilis 1064, E.coli DH5α 
and S. aureus MRSA as indicator bacteria. Plate bioassay showed that the antibacterial 
activity of the 4-hydroxy version of pseudomonic acids was reduced against B. subtilis 
1064 when performed on plates supplemented with 0.5 mM IPTG. However, without 
IPTG induction the inhibition zones were bigger than the controls (Figure 2.40). This is 
consistent with the HPLC results which show bigger peaks in the presence of TmuB. 
The 4-hydroxylated versions of PA-A and PA-B were purified by HPLC and the fractions 
were collected and dried using a spin vacuum concentrator. Minimum inhibitory 
concentration was determined and the results revealed a reduction in antibacterial 
activity of the 4-hydroxy version compounds. Against B. subtilis, the MICs for PA-A and 
PA-B were 0.12 µg ml-1 and 8 µg ml-1 respectively while the 4OH PA-A and 4OH PA-B 





Table 2.11. Minimal inhibitory concentration (MIC) of derivatives produced 
in this study. 
Derivatives 






Pseudomonic acid A 0.125 µg. ml-1 128 µg.ml-1 0.25 µg. ml-1 
Pseudomonic acid B 8 µg. ml-1 256 µg.ml-1 16 µg. ml-1 
4OH-pseudomonic acid A 0.5 µg. ml-1 256 µg.ml-1 1µg. ml-1 
4OH-pseudomonic acid B 16 µg. ml-1 256 µg.ml-1 16 µg. ml-1 
Thiomarinol A 15.6 ng. ml-1 4 µg.ml-1 7.8ng. ml-1 





Figure 2.39. Pseudomonic acid and thiomarinol derivatives produced in this study. 





Figure 2.40. Bioassay for the P. fluorescens strains expressing TmuB to test the 
antibacterial activity of the 4-OH version of the products against B.subtilis 1064. A: 
WT P. fluorescens ± tmuB, B: ΔmmpE/OR P. fluorescens ± tmuB and C: ΔmupF 
P. fluorescens ± tmuB. The left hand plates were supplemented with 0.5 mM 





2.3.10. Site directed mutagenesis to deactivate TmuB in Pseudoalteromonas spp 
SANK  
2.3.10.1. Construction of suicide vector 
To create point mutation I109N in TmuB, the pHHM06 plasmid (Table 2.2), used as a 
DNA template and a pair of primers with SalI/XbaI restriction sites were used to amplify 
by standard PCR as stated in the Materials and Methods section. The size of the PCR 
product was checked by gel electrophoresis. The correct size band was cut out, the 
DNA purified digested with appropriate enzymes and then ligated with suicide vector 
pAKE604 (Figure 2.24). The ligation mixture was transformed to E.coli DH5α for 
propagation. The correct clone was checked by digestion followed by sequencing and 
the correct clone transformed to E.coli S17-1.  
The suicide mutagenesis strategy begins by moving the suicide vector (pHHM07) to wild 
type of Pseudoalteromonas SANK 73390. This type of vector is unable to replicate 
independently in the wild type Pseudoalteromonas SANK 73390 unless it integrates into 
host the chromosome via homologous recombination. This vector contains two selection 
markers the Kanr gene, resistant to kanamycin antibiotic, and SacB gene which encodes 
levansucrase hydrolyzing sucrose in the media producing levan which is lethal to the 
cells. The homologous recombination events, which results in either mutant or wild type 
bacterium, can be investigate in two steps. The first step is to investigate the conjugation 
and integration of the vector to the bacterial chromosome by plating on the marine agar 




grow and prevents the growth of the sensitive bacterium (without transformed or 
integrated vector). However, in our lab, the standard kanamycin concentration (50µg/ml) 
was used to select the bacteria that have been transformed with target vectors. In the 
current mutation procedure, a negative control was set up by plating WT SANK on the 
marine agar supplemented with kanamycin (50µg/ml) and tetracycline (15µg/ml).  The 
incubated plates showed reasonable growth of colonies which means that the WT is 
resistant at these concentrations. Therefore, higher concentration of kanamycin (100-
200µg/ml) was used to prevent the growth of the non-transformed bacteria. 
The second recombination event between homologous regions of the DNA results in 
excision of the vector from the host genome. This will produce resistant cells to sucrose 
as the sacB gene is unable to encode levansucrase any more. This can be achieved by 
plating the cells on marine agar containing 5% sucrose. The sucrose resistant colonies 
were checked finally by making patches on marine agar containing kanamycin to confirm 
the plasmid excision. The homologous recombination and plasmid excision generate 
two types of cell with equal probability, either the wild type or mutant of the target gene. 
PCR was used to amplify the target gene (mutant phenotype) using outer primers, and 
the product was sent for sequencing (Figure 2.24 & 2.41). The bases ATA which 





Figure 2.41. Screening the point mutation I109N in SANK. (A) The Kans and Sucr 
patches were used as a DNA template for PCR amplification, (B) purified PCR 
fragments were sent for sequencing, and (C) The sequence result in Chromas 




2.3.10.2. Product characterization from mutant Pseudoalteromonas SANK 
The culture was set up for the I109N mutant in marine broth and the antibiotic was 
extracted as described in material and method section. The extract from this mutant was 
analyzed by HPLC which showed a shifted peak of thiomarinol A from 19.77 min to 
21.91 min. This new peak was purified and subjected to LC-MS and NMR which confirm 


















Figure 2.42. Product characterization of the mutant I109N Pseudoalteromonas 
SANK. A. HPLC analysis of the extract from mutant I109N Pseudoaltromonas 
SANK showed the peak of thiomarinol A (WT) (19.77min) shifted to (21.91min). B. 
Mass spectrophotometer of the new peak MW 624 for mutant which is has a mass 





2.3.10.3. Growth and product rate 
To investigate the role of the tmuB gene in the thiomarinol gene cluster, both the growth 
rate and product profile were monitored. Cultures for the WT and the mutant strain were 
set up in marine broth. This was used to set up a fresh culture with equal OD600 and 200 
µl was aliquoted into 96 well microplates and the growth rate of the WT and the mutant 
strain were monitored overnight at 23 oC (Figure 2.43A). 
To compare the product profile of the mutant and the WT, fresh 25 ml of marine broth 
was seeded with overnight culture, incubated at 23 oC /200 rpm and the supernatants 
were analyzed by HPLC (without opening the cells). The result showed that the 
thiomarinol C product amount is much less than thiomarinol A (Figure 2.43B). 
    
2.3.11. TmuB activity with thiomarinol C 
Enzymatic reactions were set up using thiomarinol C as a substrate to test the activity of 
TmuB protein and its ability to re-hydroxylate it in vitro. The reactions were set up as 
described previously for PA-A replacing the substrate with thiomarinol C. The data 
obtained were fitted to Michaelis–Menten model (Figure 2.44). The Vmax and Km were 








Figure 2.43. Growth rate and product profile of the WT and PM I109N TmuB 
Psuedoalteromonas sp. SANK. The overnight culture seeds were diluted in fresh 
marine broth to obtain the equal OD600 for both strains. A. Growth rate was 
monitored by aliquoting 200 µl into 96 a well microplate and incubated at 23 oC for 
24 hrs in microplate reader, and B. HPLC analysis of the culture supernatant of 
WT and mutant I109N SANK 73390. The samples were from the supernatant (not 
the cell extract) hence the peak size is small for both and the I109N is much 









2.3.12. Antibacterial activity of thiomarinol C 
The antibacterial activity of the thiomarinol C produced by the mutant strain was tested 
using a plate bioassay and by minimal inhibitory concentration (MIC). The bacterial 
strains Bacillus subtilis, Escherichia coli DH5α and Staphylococcus aureus MRSA were 
used as indicator strains. Thiomarinol A was used as a control to compare the 
antibacterial activity. The experiments for the bioassay test for each bacterium were 
carried out separately.  
The amount of antibiotics added to the discs for testing against different bacteria were 
varied from one bacteria to another, for example for B. subtilis, 100µg of thiomarinol A 
and C were added to the discs, while for E.coli and S. aureus only 60 µg was added 
Figure 2.44. Enzyme kinetics for TmuB using thiomarinol C as a substrate.  
Vmax=22.5 µM/min and Km= 29.5 µM. The reaction conditions were similar to 







hence the inhibitory zones look bigger. The aim for the test is to compare the potency 
between thiomarinol A and C against each bacterium not which bacterium is more 
sensitive as this has been done in previous studies.          
Plate bioassay showed that the antibacterial activity of thiomarinol C was reduced 
compared to thiomarinol A (Figure 2.45). However, from the inhibitory zone, it seems 
that the difference is not significant in Gram positive bacteria while in Gram negative 
bacteria, thiomarinol C did not show detectable inhibitory zone around the discs. To 
exclude any difference being due to the diffusion properties of the tested compounds, 
MIC test was carried out with similar bacterial strains. 
Minimal inhibitory concentration test results are consistent with bioassay plate test 
regarding the comparison between thiomarinol A and C potency. As can be noted in the 
Table 2.11, against B. subtilis the MIC of thiomarinol A is 15.6 ng. ml-1 while for 

















Figure 2.45. Plate bioassay to test the antibacterial activity of thiomarinol A and C 
from WT and PM I109N SANK respectively. The discs were soaked with purified 
thiomarinol A and C and tested against B. subtilis 1064, E.coli DH5α and S. 





2.4. Discussion  
The candidate tmuB and tmlZ genes which were identified as a putative phytanoyl-CoA 
dioxygenase and monooxygenase respectively were expressed in the WT and mutant 
strains of P. fluorescens NCIMB 10586. The results showed that only TmuB can 
hydroxylate thiomarinol analogues (pseudomonic acid derivatives) and display a 
specificity to the substrates. The results showed that TmuB action appears to classify 
pseudomonic acid derivatives into two structurally distinct groups. The first group, which 
can be hydroxylated by TmuB, comprises PA-A, PA-C and Mupirocin F while the second 
group, which cannot be modified (or modified very slowly), comprises PA-B, Mupirocin C 
and Mupirocin W suggesting that TmuB does not prefer a substrate with extra groups 
attached to pyran ring (Figure 1.9).  
These results raised a number of questions. Why does TmuB display this kind of 
specificity? Which residues in the active site are responsible for this specificity? Does 
the replacement of these residues modify TmuB specificity and allow it to modify more 
substrates? Therefore, bioinformatic tools were used to predict the protein structure and 
explore how the protein might interact with the substrates and the possible reaction 
mechanism. 
The modelling and docking process identified the possible interactions between the 
protein and the substrate and it’s fitting into the active site (Figure 2.19). As can be 
noticed, the residues around the pyran ring are likely to be responsible for TmuB 




highly conserved residues, His121, Asp123 and His191 coordinating the Fe ion. Gln 
118, Thr154 and Arg202 are located on I/II loop, III/IV loop and βVIII holding the co-
substrate. These six residues have been identified by the Evolutionary Trace Annotation 
(ETA) server as important residues for protein function and are highly conserved. It has 
been reported that mutation most of these residues inactivates the protein (McDonough 
et al., 2005).  
So to modulate substrate specificity while retaining function the only residues that 
interact with substrates can be mutated. These residues are located on βI, βIII and βVIII, 
and form about 50% of the pocket. To explore which residues might be involved in the 
specificity, a hydroxyl group was added manually to the docked PA-A at carbon 8. This 
revealed that the residues Arg69, Lys105, Ile109 and Leu141 are located at the 
entrance to the active site (Figure 2.19C) and potentially close enough to this hydroxyl 
group to generate steric repulsion. These residues were selected for mutation to smaller 
and more hydrophilic amino acids to create more space to accommodate a bulkier 
hydroxylated substrate and interact with it.   
The mutagenesis results suggest that it may not be possible to manipulate the catalytic 
specificity of TmuB or the in vivo hydroxylation of PA-B or may hydroxylate it but the 4-
hydroxylated product may affect thioesterase activity to release it from the PKS, hence 
the product cannot be detected in the culture supernatant. However, it is also possible 
that analogues may be lethal to the producer. To clarify these possibilities, the enzyme 





As mentioned in the Results section, the enzyme activity revealed that TmuB could 
hydroxylate PA-B in vitro but at a low rate in comparison with PA-A. The ability of TmuB 
to hydroxylate PA-B in vitro as a free molecule excludes the hypothesis that TmuB may 
work on the substrate while tethered to ACP domain and the 4-hydroxylated product 
cannot be released by thioesterase from the PKS. In addition, the low antibacterial 
activity of the 4OH PA-B refutes the possibility that it may be lethal to the producer. 
Thus, the mutants of TmuB that did not hydroxylate the PA-B in vivo are more likely not 
to hydroxylate it in vitro. To confirm this, initially one mutant (I109N) was tested in vitro 
and the result showed no activity which is consistent with the in vivo result. The inability 
of TmuB to hydroxylate PA-B and similar derivatives in vivo may be due to the slow 
reaction rate (Kcat = 3.83 s
-1 and Kcat/Km = 0.045), so the product may be released from 
the cell before hydroxylation happens. Alternatively, it may be that the very low level of 
hydroxylated product is just below the HPLC detection limit. 
The docking result showed clearly the difference between PA-A and PA-B binding with 
TmuB model. The docking conformations were compared with the homology crystal 
structures to estimate the distance between the target site (C4) on the substrate and 
Fe+2 ion in the active site of the protein which may be necessary for the catalytic 
process. Although the conformation binding energy and the inhibitory constant of the 
PA-A and PA-B docking are similar (but not identical) the distances of C4 to the active 
site (Fe+2) are different (4.38 Å and 6.3 Å respectively, see Figure 2.19 and 2.23C). This 
may explain the in vitro enzyme kinetics where the catalytic efficiency (Kcat/Km) for PA-A 




Although many mutations were carried out based on modelling and docking results, 
TmuB specificity was not modified in favour of PA-B binding. This may be due to some 
uncertainties about this kind of protein which make the docking result unreliable or 
misleading. First, the loops around the active site (particularly helix2/β3 loop in TmuB) 
may play a substantial role in substrate binding. The active sites of phytanoyl CoA 
dioxygenase enzymes are surrounded by flexible elements which undergo conformation 
changes and induced fit mechanism to ensure the binding of the substrates in the right 
position (Clifton et al, 2006). For example, upon the substrate binding, a finger-like loop 
N-terminal to DSBH in PHD2 enzyme folds to form a stable loop that encloses the 
substrate (Chowdhury et al, 2009).          
In addition, the missing of this loop in some crystal structures which have been resolved 
without the substrates may show it to be a flexible loop flapping over the active site and 
may cover the substrate after fitting into the active site. Furthermore, the sequence 
alignment (Figure 2.12 and 2.17) and evolutionary traces (Figure 2.46) identified the 
diversity of the residues in this loop among the homologous proteins which may be 
consistent with the different shape and other prospectives of the substrates.      
It is not clear whether or not this loop plays a role in the substrate binding and catalytic 
activity in TmuB protein. To investigate how the folding of helix2/β3 loop affects the 
docking process, the 15th TmuB model was used as a receptor to dock PA-A and PA-B. 
The conformations that were obtained from this docking did not show similarity to the 
previous conformations which were obtained using the model with the unfolded loop. 




should stay near the Fe(II) (Figure 2.20). In such case, it is difficult to predict in silico the 
substrate binding with the protein and the role of this loop as the loop is more likely to 
fold over the active site after substrate binding.  
Second, the oligomeric state of the protein may play a role in substrate binding. Both N-
terminal and C-terminal regions can be involved in protein dimerization and essential in 
catalytic activity. It has been reported that C-terminal helical region in FIH protein 
involved in dimerization which is essential for substrate hydroxylation (Lancaster et al, 
2004). The gel filtration chromatography showed TmuB protein as a dimer protein which 
contradicts the bacterial-tow hybrid result. The fusion of T18 or T25 protein into N-
terminal or C-terminal may prevent the protein-protein interaction leading to false 
negative results.   
Thus, for further characterization and to figure out the most accurate structure of TmuB 
and the way in which it interacts with the substrates, the crystal structure is needed. The 
crystal structure study of Fumitremorgin B endoperoxidase (FtmOx1) from Aspergillus 
fumigatus revealed that the replacing of the single residues (Y224A or Y224F) diverts 





Figure 2.46. The Evolutionary Trace analysis of the TmuB model and the 
templates showing the conserved residues as red and non-conserved as blue. A 
and B. Lateral and front view of TmuB model respectively, C. EasH, D. AsqJ, E. 
FAHX and F. EctD. The residues in the loop (Dashed circle) are vary in these 
resolved proteins while the six residues in the active site are highly conserved.     
A B C 
D E F 




The inactivation of TmuB (Point mutation I109N) in thiomarinol producer, 
Pseudoalteromonas sp. SANK 73390, shifts the thiomarinol C, which lacks OH group at 
C4, as a minor product to be the major product in the mutant strain leaving no doubt 
about the role of TmuB in 4-hydroxylation. 
The growth rate and product profile of the mutant were examined to address the 
significance of the tmuB gene in thiomarinol cluster. The result showed that the mutant 
strain grows faster than the WT strain and the thiomarinol secretion outside the cell is 
less than the WT strain (Figure 2.43 A&B). However, when the amount of the products 
from both strains were detected from the cell extract (not culture supernatant), there was 
no a significant difference (Figure 2.42 A). In addition, when TmuB was expressed in the 
heterologous hosts, the amount of the products from the culture supernatant was much 
higher than those without TmuB. This may demonstrate that the 4-hydroxylation may 
enhance the ability of the product to pass through the cell membrane, particularly in the 
Gram-negative bacteria. It may reveal that tmuB in the thiomarinol cluster gives a sort of 
balance between the product formation and the growth rate. However, in terms of 
biological interaction, it is difficult to clarify the significance of the tmuB gene to the 
surroundings as the producer is a marine bacterium and there is not enough knowledge 
about the habitat environment and how it interacts with or what is the beneficial effect of 
the product 4-hydroxylation to the surrounding living organisms.   
Rehydroxylation of TMC at C4 by TmuB in vitro with a similar catalytic efficiency to PA-A 
allowed three significant conclusions. First, it appears to confirm the orientation of 




the external groove (see Figure 2.19). If this were not the case, the active site pocket 
should not be able to accommodate the bulky moieties like the pyrrothine which is 
attached to the fatty acid chain. Second, it suggests that TmuB can catalyse 4-
hydroxylation either as a final step before pyrrothine joining to marinolic acid or after 
joining to create thiomarinol C. Third, except around the pyran ring, the modification of 
the substrates (presence of pyrrothine molecule and shorter fatty acid chain in 
thiomarinol C) does not affect TmuB catalytic activity. This gives a possibility to use 
TmuB as a tool to hydroxylate a broad range of substrate analogues. Thus, the 
modification of the hydroxylase enzyme specificity could enable us to recruit it to modify 
a wide range of analogues in vitro. Furthermore, trans expression of such proteins in 
other analogue biosynthesis pathways may result in significant products.  
Based on the crystal structure of the IleRS that was resolved as a complex with 
mupirocin, Marion and co-workers proposed that the 4-hydroxylation may enable 
mupirocin to form extra hydrogen bonds with His64 or Asp557, and may improve the 
antibacterial activity (Marion et al., 2009). However, the results of this study showed a 
lower antibacterial activity of the hydroxylated PA-A and derivatives. 
As an attempt to explain this result, the 4OH PA-A was docked to the crystal structure of 
the isoleucyl-tRNA synthetase (IleRS) (1FFY PDB) (Silvian et al., 1999). First, PA-A was 
docked to the IleRS to determine the docking parameters which should give the 







The same parameters were used to dock 4OHPA-A, but the similar conformation could 
not be obtained. It is not clear whether or not the hydroxyl group on carbon 4 is close 
Figure 2.47. Crystal structure of isoleucyl-tRNA synthetase complex with 
PA-A. The PDB:1FFY was visualized using PyMol, A. Cartoon mode and B. 















enough to the Asp557 residue to cause a steric repulsion and prevents the PA-A fitting 
into the target site. Alternatively, this extra hydroxyl group may impart PA-A more 
hydrophilicity to interact somewhere else on the protein surface or other proteins inside 
the cell. It was reported that amino acid changes in the active site of IleRS with much 
bulkier residues resulted in low level resistant against mupirocin. The mutation of valine 
588 to phenylalanine in the active site of S. aureus IleRS distorts and fills the pocket, 
and prevents mupirocin binding (Antonio et al., 2002; Hurdle et al., 2004). 
Based on the antibacterial activity test and docking results, it seems “theoretically” that 
the lack of hydroxylation of thiomarinol at 4C (thiomarinol C) may make it a more potent 
compound. However, the tests showed that this is not the case as thiomarinol C has 
lower potency compared with thiomarinol A (Table 2.10) and (Figure 2.38). A study in 
our lab proposed that thiomarinol may target some other cell components rather than 
IleRS and display cytotoxicity in eukaryotic cells (Ahmed, 2010 unpublished). The result 
also showed that thiomarinol C is still more potent than PA-A. This raises the question 
whether or not the 4-dehydroxylation of thiomarinol A reduces the cytotoxicity in 
eukaryotic cells which could be confirmed by further analysis. Hydroxylation of the 
analogues at C4 and lack of 4-hydroxylation of thiomarinol A has changed the 
antibacterial activities and may give them novel biological activities. 
According to the results presented here, it can be concluded that TmuB works as a final 
tailoring step to direct 4-hydroxylation of thiomarinol and displays specificity for 
substrates. However, this specificity is mainly restricted to the pyran ring as the catalytic 




convert a wide range of substrate analogous either in vitro or in vivo by expressing it in 
trans in other analogue biosynthesis pathways. Furthermore, the mutagenesis trials in 
the active site of enzymes belonging to the nonheme-iron(II)/2-oxoglutarate-dependent 
dioxygenase superfamily may not change just the specificity but also diverts the 
catalysis function as was reported recently with fumitremorgin B endoperoxidase from 
Aspergillus fumigatus (Yan et al., 2015). This approach may participate in producing 
new diverse derivatives with significant biological activities. The hydroxylation and 
dehydroxylation of the natural products is a vital step in terms of biological activities of 
the products and metabolism profile of the producers. The antibacterial activities of the 
products formed as a result of TmuB expression or inactivation have changed but might 




























3. CHARACTERIZATION OF NON-RIBOSOMAL PEPTIDE SYNTHETASES IN THE 
THIOMARINOL CLUSTER 
3.1. Introduction  
Non-ribosomal peptide synthetases (NRPSs) are responsible for most peptide bonds in 
secondary metabolism. As described in Chapter one, NRPSs are multi modular proteins 
and normally each module is responsible for adding one amino acid to the product 
backbone. Some NRPSs do not follow this general rule in NRP biosynthesis, iterative 
NRPSs re-use the catalytic domain repeatedly and add more than one building block. 
(Mootz et al., 2002; Hur et al., 2012). 
Congocidine is a pyrrole-amide antibiotic produced by an iterative NRPS in 
Streptomyces ambofaciens (Juguet et al., 2009). However, the iterative NRPS types are 
common in many fungal species. Siderophores, high affinity iron chelators, and 
Enniatins, cyclohexadepsipeptides with various biological activities, are among the 
compounds that are produced by iterative NRPS in fungi (Bushley,Ripoll and Turgeon, 
2008; Sy-Cordero, Pearce , Oberlies, 2012).    
Thiomarinol produced by Pseudoalteromonas bacteria contains pyrrothine consisting of 
two cysteine molecules which are proposed to be produced by the NRPS in the 
thiomarinol gene cluster (Figure 3.1). The intriguing feature of the holA gene, which 
encodes the NRPS responsible for pyrrothine biosynthesis, is that encodes only one 
Adenylation (A) domain, Condensation (C) domain and Peptidyl carrier protein (PCP) 




joining two amino acids (Fukuda et al., 2011). This leads to the suggestions that either 
HolA is a dimeric protein or it works as an iterative NRPS in a similar manner to fungal 
NRPS. Further investigations of this unusual NRPS will provide more data that should 
help us to understand the assembly of the products and provide a better understanding 
of biosynthesis by related NRPs.  
 
The aim of this chapter, therefore, is to characterize the Non-Ribosomal Peptide 
Synthetase in the thiomarinol gene cluster and to understand the assembly of the 
pyrrothine molecule. The holA gene possesses 3369 nucleotides encoding 1122 amino 
acid residues (125KDa). The residues of this protein are arranged as a tri-domain 
module consisting of three putative domains, Condensation, Adenylation and Peptidyl 
Carrier Protein (PCP). Both in vitro and in vivo experiments were used to investigate the 
oligomeric state of HolA. The native and mutant purified proteins were subjected to a 
biochemical assay to check the in trans activity and the amount of the substrate that can 
be activated which may give a clue about the oligomeric state of the protein or the 
iterative behavior of the domain.        
Figure 3.1. The thiomarinol structure. The red part is the pyrrothine moiety 






3.2. Materials and Methods 
3.2.1. holA gene amplification and plasmid construction 
A set of primers (Table 3.1) were used to amplify holA and to construct plasmids using 
the standard molecular biology techniques as described in Chapter 2. Forward and 
reverse primers were designed with Ndel and Xohl restriction sites respectively. This 
enabled the gene to be cloned into the expression vector pET28a. The gene was 
amplified using a high fidelity Q5 polymerase from New England Biolabs. The following 
program was set up to run PCR: 
Denaturation step: 98 oC for 2 minutes       
Denaturation step: 98 oC for 30 sec 
Annealing step: 63 oC for 30 sec 
Extension step: 72 oC for 2.5 min 
 
Denaturation step: 98 oC for 30 sec 
Annealing step: 65 oC for 30 sec                   
Extension step: 72 oC for 2.5 min  
Extension step: 72 oC for 7 minutes          1 cycle 
 
The purified PCR product was cloned into pGEM-T Easy vector for DNA sequencing. In 








cover the middle sequence of the gene during the sequencing process (Table 3.1). The 
correct sequence of holA was inserted into pET28a and the protein expression and 
purification were achieved as described in Chapter 2. For the bacterial strains and 
plasmids used in this study see Table 2.1and 2.2 in Chapter 2.          
Table 3.1. Primers designed and used in this study.  


















5' CGAATACTGGGAGAAGAAGC 3'  54 

























G TGGCTG 3' 
Kpnl  57 
HACYR 
Reverse primer 
for C domain in 
B2H 
5'GAAGGTACCTTGACGACTTAAG
A GCTGTG 3' 
Kpnl  63 
PCPF 
Forward primer 
for PCP domain 
in B2H 
5'GTATCTAGAGACAGAGGCGGC
A TTATTGG 3' 
Kpnl  66 
CPMr 
Reverse primer 
to create PM 







to create PM 










to create PM 
S29A in PCP 
domain 
5'TGGAGGTGATGCTCTACATGCG














*The Tm was calculated by online software NetPrimer from primer Biosoft. The PCR annealing 




3.2.2. In vitro protein-protein interactions 
3.2.2.1. Cross linking with Glutaraldehyde 
Chemical cross linking was used to test protein dimerization in vitro. 50 µl of different 
concentrations (mg/ml) of HolA protein sample in 20mM HEPES buffer, 500mM NaCl, 
pH 7.5 was incubated with different concentrations of Glutaraldehyde (2%, 1%, 0.1% to 
0.5% and 0.01% to 0.05%) at 37 oC for five minutes. The reaction was terminated by 
adding 10 µl of 1M Tris pH 8.0. The protein was precipitated by adding 4 volumes of 1:1 
methanol and acetone and incubated at -20 oC for 1 hour. The protein pellet was 
collected by centrifugation at 14000 xg for 20 minutes at 4 Co and the supernatant was 
removed carefully by pipetting. The pellet was resuspended in 20 µl of SDS loading 





3.2.2.2. Analytical Ultra Centrifugation (AUC) 
The protein samples were purified by affinity chromatography, dialysed overnight in 
buffer (50mM NaH2PO4, 200mM NaCl, pH 7.5) to eliminate imidazole and analysed by 
SDS-PAGE before Analytical Ultra Centrifugation (AUC). 400 µl of three samples (0.65 
mg/ml) were loaded into the cells and 420 µl of the dialysed buffer was used as a blank. 
The test was run at 40.000 rpm / 4 oC and the absorbance scanned at 280 nm every 6 
minutes using Proteome Lab Xli machine and the An-50 Ti rotor. The sedimentation 
velocity data were analysed using Sedfit version 15.01b software 
(http://www.analyticalultracentrifugation.com) and 180 scans were analysed for each 
sample. 
 
3.2.3. In vivo protein-protein interactions 
The Bacterial Adenylate Cyclase Two-Hybrid System Kit was used to test protein-protein 
interactions in vivo. To amplify the holA gene, forward and reverse primers were 
designed with Xbal and Kpnl restriction sites (Table 3.1) respectively. This enabled the 
gene to be cloned in the Two-Hybrid System vectors. In addition, primers were designed 
to clone each of Condensation (C), Adenylation (A), and Peptidyl Carrier Protein (PCP) 
separately to the system vectors (Table 3.2). The details of the procedure were 





3.2.4. Domain inactivation by point mutation 
The modified overlap extension technique, which was described in Chapter 2, section 
2.2.15, was used to create point mutations in HolA domains. The target residues in the 
active site were determined depending on the analogues protein sequence alignment 
and activity. New primers were designed (Table 3.1) to introduce the point mutations 
using the recombinant holA-pET28a as a DNA template. Standard molecular biology 
techniques were used to clone the mutant holA gene to pET28a and the protein 
expression and purification were achieved as described previously. 
 




Features  Usage Source 
pHHM20 
holA cloned to pGEM-T 
easy as A-tail insert  
Sequencing of the holA 
gene 
This study  
pHHM21 
holA cloned to pET28a as 
Ndel/XohI insert  




holA cloned to pKT25 as 
Xbal/KpnI insert 




holA cloned to pUT18 as 
Xbal/KpnI insert 




holA cloned to pKNT25 as 
Xbal/KpnI insert 




holA cloned to pUT18C as 
Xbal/KpnI insert 




C domain cloned to pKT25 
as Xbal/KpnI insert  




C domain cloned to pUT18 
as Xbal/KpnI insert 




A and PCP domains 
cloned to pKT25 as 
Xbal/KpnI insert 









A and PCP domains 
cloned to pUT18 as 
Xbal/KpnI insert 




holA with PM H202A in C 
domain cloned to pET28a  




holA with PM K1003T in A 
domain cloned to pET28a  




holA with PM S1072A in 
PCP domain cloned to 
pET28a  




holA with double PM  in A 
and PCP domains cloned 
to pET28a 




TmlN gene cloned to 








3.2.5. In vivo phosphopantetheinylation of HolA  
The phosphopantetheine moiety was added in vivo to the serine residues of PCP 
domain by co-expression of tmlN gene with holA gene. This enzyme converts the apo-
PCP to holo-PCP by transferring the 4- phosphopantetheine group from CoenzymeA. 
The tmlN gene was cloned into pJH10 and co-transformed with constructed pHHM21 
into BL21 E.coli. The phosphopantetheinylation of HolA was checked by mass 
spectrometry in the genomic lab, School of Bioscience, University of Birmingham. Three 
types of HolA protein samples were sent for mass spectrometry to check for post 
translational addition of the phosphopantetheine arm by PPTase. These include: WT 




expressed with TmlN (holo form) and the mutant HolA protein in which the serine 
residue in the active site was replaced by alanine in the PCP domain. 
 
3.2.6. ATPase assay 
Malachite green ATPase assay was used to test protein activity depending on the 
pyrophosphate (PPi) that is released by the enzymatic activity. The adenylation domain 
activates the amino acid through a reaction with ATP to form an aminoacyl-AMP 
intermediate. This reaction releases inorganic pyrophosphate (PPi) from ATP. In the 
assay, inorganic pyrophosphatase (PPase) (provided by New England Biolabs) was 
added to catalyse the hydrolysis of PPi to two phosphate ions which can be detected by 
Malachite green.  
To prepare malachite green solution, 340mg of Malachite green crystal was dissolved in 
75ml of distilled water and 10.5g of Ammonium molybdate was dissolved in 250ml of 4N 
HCl. These two were mixed and the volume was made up to 1000ml, stirred on ice for 1 
hour and filtered through Whatman filter paper. To prepare the assay solution, 50 ml of 
malachite solution was mixed with 250 µl of 20% Triton X-100. The initial reaction was 
set up by adding 40 µl of different concentrations of protein mg/ml (0.09, 0.187, 0.375, 
0.75 and 1.5), 2 µl of 100mM L-cysteine, 2 µl of (50mM ATP, 100mM magnesium 
acetate) and 10 µl of PPase (100units/ml). The mixture was incubated at room 
temperature for 1, 5, 10 and 20 minutes, 800 µl of assay solution was added, incubated 




incubated at room temperature for 40 minutes. Different amount of HolA and PPase 
protein were used to optimumize the reaction. A calibration curve was made using 
different concentrations of KH2PO4 (0.0 µM, 50 µM, 100 µM, 150 µM and 200 µM) to 
measure the amount of pyrophosphate released by protein activity. The optical density 
(OD) was measured at 640nm using a spectrophotometer. A set of controls were set up 
















3.3.1. HolA-His tag expression and purification 
To express HolA protein as an N-terminal His-tag fusion, a pET28-holA (pHHM21) 
vector was constructed (Figure 3.2) as described in Chapter 2. Escherichia coli BL21 
DE3 was used to over express the target protein at different temperatures and IPTG 
concentrations to check the initial expression. In small scale expression, all the 
temperatures and IPTG concentrations induced sufficient production of HolA protein 
when analysed by SDS-PAGE. However, it was found that the optimum expression of 
the soluble protein can be achieved at 18 oC with 1mM IPTG (Figure 3.3). Therefore, 
this optimum growth condition was used for large scale expression. 
After expression, the protein was purified by affinity chromatography based on 6xHis-tag 
protein as described in Chapter 2. It was found that the majority of tagged protein was 
eluted at 100mM, 200mM and 250mM imidazole. To obtain as much pure protein as 
possible, the last three fractions of the first purification were re-purified again (Figure 
3.4) 
Despite the repeat purification by affinity chromatography, the SDS-PAGE shows 
secondary bands. Therefore, to obtain homogenous pure protein and eradicate 
imidazole, gel filtration was performed which separates the molecules according to their 
size. The absorbance at 280nm showed three peaks after running 120 ml of the volume: 
from 120 to 140, from 140 to 160 and from 160 to 180. According to the calibration 




(Figure 3.5). These variations were either due to the different oligomeric states of the 
protein or different shape and conformation because of the protein folding state. 
Therefore, for simplicity these three peaks were named according to the peak order as 
“1st Peak, 2nd Peak, and 3rd Peak” and used in the rest of this study. The fractions for 






Figure 3.2. Construction of pET28a-holA. (A) PCR amplification of holA gene 
3.4kb, (B) recombinant pGEMT+holA gene digested with EcoRl restriction 
enzyme which cuts the holA gene into 2kb & 1.4kb bands and 3kb for the vector. 
(C) Recombinant pET28a vector digested by Ndel & Xhol restriction enzymes 



























Figure 3.4. SDS-PAGE analysis of HolA protein purified by affinity 
purification. PL: Prestained Protein Marker 170kDa. –V: Negative control, 
FT: Flow through, W: Wash buffer, 50 to 250: Imidazole concentrations. A: 
First purification, B: Repeated purification by gel filtration of the last three 
fractions. The 125kDa of HolA protein is indicated by the arrow     
Figure 3.3. SDS-PAGE analysis of small scale expression of HolA protein. PL: 
Prestained Protein Marker 170kDa. 1,2,3 & 4: IPTG concentrations 0 Mm, 0.1 
mM, 0.5 mM & 1 mM respectively. A: Insoluble protein, B: Soluble protein. The 
soluble HolA protein (125 kDa) was seen at 18 oC. 
 











Figure 3.5. Gel filtration for HolA protein purification. A: The protein was 
separated into three peaks: 1:1st Peak eluted with void volume at 120 ml, 2: 2nd 
Peak at 140 ml and 3: 3rd Peak at 170. B: Calibration curve to estimate protein 














3.3.2. In vitro protein-protein interactions 
3.3.2.1. Cross linking with glutaraldehyde  
HolA protein sample was tested before and after gel filtration in vitro using 
glutaraldehyde. The result for the sample purified only by affinity purification revealed 
that the protein molecules appeared to interact with each other at low concentration of 
glutaraldehyde. The SDS-PAGE showed a large molecule of around 650-700 kDa at 
0.1-0.5% while at higher concentrations (1-2%), the protein made aggregrates and stuck 
in the wells and could not run even through stacking gel (Figure 3.6A). It looks like the 
slowly moving band disappears at the lower protein concentration which might be non-
specific cross-linking – and this would not be surprising at 1 mg/ml (Figure 3.6B). 
 
 
Figure 3.6. Cross linking of HolA with glutaraldehyde before gel filtration. A: 
Different concentrations of glutaraldehyde (%) with (1mg/ml) protein, and B: 
different concentrations of protein (mg/ml) with 0.5% of glutaraldehyde. PL: protein 







After gel filtration, the test was repeated using the 1st and the 3rd Peaks of protein 
(0.5mg/ml) (see Figure 3.5) treated with a range of glutaraldehyde (concentrations from 
0.01% to 1%). For 3rd Peak protein, the SDS-PAGE showed that the protein was able to 
cross linked as a dimer, particularly from 0.03% to 0.5% of glutaraldehyde. At higher 
concentration of the cross linking reagent (0.1%, 0.5% and 1%) larger molecules were 
formed which stuck in the well and consumed all the protein (Figure 3.7A). For the 
sample from the 1st Peak of gel filtration, the reaction produced complexes protein and 
couldn’t run through the gel and the result was consistent with sample reaction before 




Figure 3.7. Cross linking of HolA with glutaraldehyde after gel filtration. A: 3rd Peak 
protein (0.5mg/ml) with different concentrations of glutaraldehyde % shown. The 
proposed dimer (250kDa) protein bands indicated by arrows. B: The 1st Peak protein 
with different concentration of glutaraldehyde % shown. With the glutaraldehyde 
increasing, the protein mobility is reduced and sticks in the wells.  PL: protein ladder. 








3.3.2.2. Analytical Ultra Centrifugation (AUC) 
The data were analysed using sedfit software at friction ratio 2.39 and rmsd 0.008. The 
result showed HolA protein in a monomer state as a single peak. As illustrated in Figure 
3.8, the data fitting result showed the majority of HolA as a monomer protein with MW 
125KDa. However, there were some minor peaks which were estimated to be in the 
higher oligomeric state or due to the sample impurity. The result appears to contradict 
with the gel filtration chromatograph but this could be due to different conformations of 



















































































































































































3.3.3. In vivo protein-protein interactions 
The Bacterial-Two hybrid system was used to test protein-protein interactions in vivo as 
described in Chapter2. HolA protein was fused with the C-terminus of T25 using pKT25 
plasmid, and with N-terminus and C-terminus of T18 using pUT18 and pUT18C 
plasmids respectively. The two compatible recombinant vectors were co-transformed 
into competent E.coli BTH101(-cya) and plated out on MacConkey plus 1% maltose and 
on LB agar plus IPTG and X-gal. After three days of incubation at 30 oC, the result 
showed red colonies for positive controls on MacConkey and blue colonies on X-gal LB 
plates while the test protein was negative (pale colonies) and more similar to the 
negative controls as shown in Figure 3.9. Thus the bacterial two-hybrid experiments 
suggest that this protein cannot interact in vivo or at least cannot reconstitute a 
functional adenylate cyclase. The large size of the protein, which consists of three 
domains, may prevent the physical contact between the two domains (T18 & T25) of 
adenylate cyclase (CyaA) resulting in false negative. To exclude this possibility, 
individual domains of C, A, and PCP were fused separately with T25 & T18 as stated 
previously. The result showed that no interaction between the single domains can be 














C   
F  
Figure 3.9. Protein-protein interactions in vivo using Bacterial Two-Hybrid 
system. BTH101 colonies on MacConky (Right) and X-gal LB agar (left). 
A&B: positive controls, C&D: Hybrid proteins (pHHM22 & pHHM25) and 






3.3.4. Domain inactivation 
An additional way to test the function of the protein was to determine the consequences 
of inactivating the individual domains both in vivo and in vitro. The predicted amino acid 
sequence of HolA protein was aligned against the previously resolved and characterized 
protein structures using COBALT multiple alignment tool from NCBI to identify the 
residues in the active site which are essential for catalytic activity. As illustrated in Figure 
3.10, His202 residue in the condensation domain active site is well conserved which 
may play a key role in the catalytic activity. This was replaced with alanine by site-
directed mutation by converting the CAT to GCT. With respect to the adenylation 
domain, the residue Lys515 was replaced with threonine by converting AAA to ACA. In 
the PCP domain, Ser29 is the only serine which is highly conserved so this was 
replaced with alanine (TCT to GCT) to prevent the phosphopantetheinylation of this 
domain. Two mutant HolA proteins were produced, HolA A with a single mutation K515T 
in A domain and HolA C-T with double mutation H202 and S29A in the C and PCP 







3.3.5.  In vivo phosphopantetheinylation of HolA 
The tmlN gene is proposed to work as phosphopantetheine transferase (PPTase) in the 
thiomarinol cluster. The tmlN gene possesses 780bp encoding 259 residues with high 
identity sequence to phosphopantetheine transferases (PPTase) (55%, 2e-88) including 
MupN from the mupirocin cluster which has been shown to be essential for mupirocin 
biosynthesis and to phosphopantetheinylate to a number of the mup ACPs (Shields et 
al., 2010). Thus, HolA was co-expressed in the presence of TmlN in an attempt to obtain 
the holo form of the protein. As a result, the phosphopantetheine transferase should add 
a 4- phosphopantetheine moiety to the highly conserved serine residue in the peptidyl 




Figure 3.10. Multiple sequence alignment of HolA domains with homologous 
proteins. The target residues H202 in C domain, Lys515 in A domain and Ser29 




protein samples were subjected to trypsin digestion (Figure 3.11B). Therefore, the 
molecular weight of the digested peptide of PCP domain was calculated to see the 
modification of the three samples (see Section 3.2.4). The theoretical MW of each 
peptide was calculated by ExPASy (Compute pI/Mw tool) and compared with the result. 
The native apo PCP domain is 3255.63 Da and the MW of 4'-phosphopantetheine is 
358.348282 Da. This means that the MW of the digested peptide of the holo PCP 
domain should be 3595.963 Da. A similar signal (3595.43 Da) was detected by the MS 
analysis for holo form protein only. The same signal was missed for the other two 





Table 3.3. The MS result of HolA phosphopantetheinylation showing 
the MW of digested PCP domain. 
*TMW: Theoretical molecular weight. 
*AMW: Analytical molecular weight. 
HolA protein samples TmlN TMW* of PCP AMW* of PCP 
WT HolA protein - 3255.63 Da 3254.66 Da 
WT HolA protein + 3595.963 Da 3595.43 Da 








Figure 3.11. Phosphopantetheinylation of HolA by TmlN. A: The process 
catalysed by PPTase, converting the apo protein to holo form. B: The trypsin 
digestion process prior to MS analysis, the green highlighted residues are the 
site for trypsin digestion, the yellow highlighted serine is the active site of the 






PCP domain seq:  AALLEIWIKQLQHSSLDVTSGFFDIGGDSLHAVALIGTIRERFG 
 
 
MW = 3255.63 Da.    QLQHSSLDVTSGFFDIGGDSLHAVALIGTIR 









3.3.6. ATPase assay 
The initial assay was set up for 20 minutes to measure the endpoint of the enzymatic 
activity by reading the optical density for different protein concentrations. The Holo and 
Apo forms of 2nd and 3rd Peaks of HolA protein, which are shown in Figure 3.5, were 
tested to check the amount of the PPi released by each form. Four controls were set up 
to measure the natural hydrolysis of ATP, auto dissociation of PPi and to show that the 
PPi release by HolA protein depends on the presence of substrate and ATP (Figure 
3.12A). The results showed that the ATP auto hydrolysis and PPi dissociation (Control 1 
and 2 respectively) increased slightly over time. The amount of the phosphate released 
by the protein activity was calculated by subtracting the controls OD640nm, then 
comparing the OD with the calibration curve of standard concentration of KH2PO4 
(Figure 3.12B).  
The test shows that in the presence of cysteine and ATP each 10µmole of Apo form of 
the 3rd Peak protein can release about 20µmole of phosphate. This indicates that the 
Adenylation domain is functional and can activate the substrate releasing one PPi 
molecule (Figure 3.13). The assay was repeated for the 2nd Peak and the result showed 
that there was not a significant difference between the two Peaks of HolA protein. As 
showing in these Figures, the optical density declined with the lowering of protein 








Figure 3.12. Controls and calibration curve for malachite green ATPase. A. Four 
controls at different time in which one or more components were omitted,       
Cnt1(-HolA & PPase), Cnt2(-PPase), Cnt3(-ATP) and Cnt4(-Cys); B. Calibration 






Figure 3.13. Malachite green ATPase test for Apo HolA protein. A. The total 
OD640 for each concentration of HolA protein, and B. The amount of phosphate 
(µM) released by each concentration was calculated by subtracting the total 
OD640 from the control OD640 and comparing the net OD640 with the calibration 





The test was repeated using the Holo form protein which interestingly showed about 
two-fold higher OD reading. According to the calibration curve, 40µmole of phosphate 
can be released by 10 µmole of Holo form protein (i.e. two PPi molecules were 
released) as shown in Figure 3.14.   
The assay was repeated using the Holo form protein concentration (10µM) at different 
time course (1, 5 and 10 minutes) to check the auto dissociation of PPi and to confirm 
that the OD reading is due to the HolA activity, not the PPase activity. The HolA activity 
is nearly flat after 10-20 minutes which means that HolA reached the maximum activity 
and the measured OD is due to its activity, not the PPase (Figure 3.15). 
The activity of the mutant protein, HolA A and HolA C-T (see section 3.3.4) was tested 
by this assay. The HolA A showed reduced OD by 75%, while the OD of the HolA C-T 
was similar to the Apo form protein (Figure 3.16). To test whether or not the adenylation 
domain of HolA C-T can complement the HolA A and recover the OD as in the Holo 
form, both with equal amount were mixed and tested by ATPase assay. The OD could 
not be recovered to the Holo form level which may explain that the proteins are not able 








Figure 3.14. Malachite green ATPase test for Holo HolA protein. A. The total 
OD640 for each concentration of HolA protein, and B. The amount of phosphate 
(µM) released by each concentration was calculated by subtracting the total 
OD640 from the control OD640 and comparing the net OD with the calibration curve 


























































Figure 3.15. Malachite green ATPase test for Holo HolA protein at different time. 
A. The total OD640 for 10µM HolA protein within the time shown, and B. The 
amount of phosphate (µM) released was calculated by subtracting the total OD640 
from the control OD640 and comparing the net OD640 with the calibration curve of 














































Mutant protein  
Figure 3.16. Malachite green ATPase test for mutant HolA proteins (A & C-T).  
Top: The total OD640 for 10µM HolA protein within 20 min, and Bottom: The 
amount of phosphate (µM) released was calculated by subtracting the total OD640 
from the control OD640 and comparing the net OD640 with the calibration curve of 
standard concentration of KH2PO4 in Figure 3.12B. The proteins were tested 
separately as shown in A and C-T column. In A+C-T column, equal amount of 





3.4. Discussion  
The gel filtration chromatograph showed three distinct peaks which might be three 
different oligomeric forms of the protein (Figure 3.5A). However, when the 1st and 2nd 
Peaks of the protein were rerun separately through the gel filtration column using the 
buffer with different salt concentrations, the protein could not reform the same three 
peaks and the vast majority kept the same conformations (Figure 3.17). This may mean 
that the protein samples in these peaks have different conformations or different folding 
state rather than the different oligomeric state. The elution of the protein with the void 
volume may be due to the extended protein molecules which have a linear shape being 
unable to diffuse into the gel pores. However, the globular proteins may penetrate the 
pores to varying degrees based on their size and therefore elute more slowly. The 
different conformation of the protein might either due to the natural conformational 
change of the domains to catalyse the joining of two cysteines or might due to improper 
folding of the protein. The holA gene from the marine bacteria SANK may need specific 
chaperones which might not be provided by E.coli BL21 (DE3) leading to improper 
folding of the protein. 
This framework of hypotheses may explain the glutaraldehyde crosslinking results. The 
protein from the first peak interacts aggressively producing complexes that couldn’t run 
through the gel. This may be that the extended protein exposes more amine groups on 
the surface which can be interconnected by glutaraldehyde making a sort of lattice sheet 
(Figure 3.18). The properly folded (globular) protein may expose fewer amine groups on 




on three different NRPS proteins revealed large interfaces between the NRPS domains 
particularly between C and A domains. The interface area ranges from 780Å to 1,097Å, 
forming a catalytic platform (Drake et al., 2016). Thus, the third peak protein from the gel 
filtration may be a properly folded (globular) monomer protein. These suggestions can 
be supported by the analytical ultracentrifugation results which showed the protein as a 

















Figure 3.17. Gel filtration rerun for the separate 1st and 2nd Peaks of HolA protein. 
The peaks in Figure 3.5 were collected separately and reapplied to the gel filtration 
column. Top: The 1st Peak was eluted with void volume as the first time run, 
Bottom: The 2nd Peak eluted around 140ml. Note that the peaks location may be 
slightly different depending on the injection time. The generated shoulders of the 
peaks may be due the peaks overlapping of the first run or slow conformational 




   
 
 
The bacterial two hybrid system showed that HolA protein interaction cannot be 
detected in vivo. There are some possibilities which may lead to this result. The size of 
the HolA protein, which consists of three domains and about 125 KDa, may prevent the 
physical contact of adenylate cyclase fragments T25 (fused to N-terminus of HolA 
protein) and T18 (fused to the C-terminus of HolA protein) resulting in a negative 
outcome. This was addressed by fusing HolA protein to the same terminus for both T25 
and T18 fragments using pUT18C vector which enables fusion of T18 to the N-terminus 
of HolA protein. Another solution for this problem is to fuse a short fragment or single 
Figure 3.18. Proposed reaction of HolA proteins with glutaraldehyde. A. The 
extended shape of the protein (1st Peak) increases exposure of the amine groups 
on the surface of the protein interacting with the crosslinking reagent (Red zigzag 
line) and forming a lattice sheet and big particles. B. The globular protein exposes 
less amine groups forming smaller particles (2nd Peak).     






domain of HolA protein to T25 and T18. The results for both of these approaches were 
also negative confirming that the protein size should not be the problem. One of the Two 
Hybrid system drawback is the high possibility of false positive and false negative results 
(Deane et al, 2002). The fusion of T25 and T18 with the target protein may alter its 
properties leading to false results. In addition, this approach cannot detect weak protein-
protein interactions in vivo. Finally, the improper post-translational modification of protein 
when expressed in different species is among the possibilities that result in false 
negative results (Stynen et at, 2012). In spite of these facts, however, this result is 
consistent with gel filtration, AUC and ATPase assays (see below).  
The protein samples purified by gel filtration were used to test the catalytic activity of the 
adenylation domain. The malachite green ATPase assay was used to test both the 
protein of the 3rd and 2nd Peaks. The results showed that the phosphate precipitation by 
malachite green depends on protein concentration and there is no significant difference 
between the protein from the “3rd” and “2nd” Peaks. After calibration with KH2PO4, the 
assay shows that in the presence of cysteine each 10 µmole of Apo protein can release 
about 20µmole phosphate. This indicates that the Adenylation domain is active and 
activates only one cysteine molecule releasing one molecule of PPi. The HolA protein 
was co-expressed with TmlN to ensure the 4-phosphopantetheinylation of the PCP 
domain (Holo protein) as the E.coli PPTase is not guaranteed. When the test was 
repeated with Holo protein, the phosphate released was twice as much as released by 
the Apo protein. This may mean that the A domain activates two molecules of cysteine 




cysteine as cysteinyl-adenylate followed by nucleophilic attack of the 4-
phosphopantetheine arm leaving A domain to activate the second cysteine (i.e. A 
domain works in an iterative way). This unique feature of an iterative adenylation domain 
was reported in congocidine assembly by the cognate NRPS in Streptomyces 
ambofaciens (Juguet et al., 2009) and the adenylation domain from Acinetobacter 
baumannii (Drake et al., 2016). In Apo protein, A domain activates only one cysteine as 
the 4-phosphopantetheine arm is missing.  
Based on the amount of the PPi released by A domain, the ATPase assay could be 
used to determine the oligomeric state of the protein and to test the ability of the 
monomers to interact with each other in trans. Thus, mutations in the active sites of the 
domains were created to produce two HolA proteins (see Section 3.3.4), HolA A with 
inactive A domain (i.e active C and PCP) and HolA C-T with inactive C and PCP 
domains (active A). Both these mutant proteins were tested by ATPase separately which 
showed a reduction in the amount of PPi released by each. As shown in Figure 3.16 
HolA A releases about 25% of the PPi compared to the native Holo protein. This means 
that the point mutation K515T does not inactivate the A domain completely. This 
conserved Lys515 is located in the active site and according to the alignment with 
homologous proteins (Conti et al., 1997), it interacts with both the substrate and the 
ATP.  However, the binding site for the substrate may vary depending on the substrate 
shape and size while the binding site for ATP is highly conserved in these proteins. 
Previous study identified the conserved residues (SGTTGxPKG) in ATP binding site and 




tyrocidine synthetase I (TycA) from Bacillus brevis leads to complete loss of activity 
(Gocht and Maraheil, 1994). Thus, the conserved residues SGSTGEPKG in the ATP 
binding site in HolA protein would be a better target to inactivate A domain and the 




HolA C-T exhibited similar activity to the Apo protein which means that HolA lost the 4-
phosphopantetheine arm because the serine residue in the active site of PCP was 
replaced with alanine. HolA A and HolA C-T were mixed to test the ability of the A 
domain of HolA C-T to load cysteine to the PCP domain of HolA A in trans. As shown in 
Figure 3.16, this mixture could not restore the activity to the same level as the WT Holo 
HolA protein. This may mean that the monomers cannot interact with each other and the 
ability of the native Holo HolA protein to release 40µM phosphate is due to internal 
monomer reactions (i.e. A domain activates two cysteine). Thus, the ATPase assay 
result is consistent with other assays that showed HolA as a monomer protein.         
Figure 3.19. Multiple sequence alignment of A domain with homologous proteins. 
The highly conserved residues in the ATP binding site are shown. The Lys180 in 




According to the results presented here, some specific features of HolA protein can be 
outlined which enable assembly of the pyrrothine molecule by one module of the NRPS 
in the thiomarinol gene cluster. The A domain may work iteratively and introduce two 
cysteine molecules to the C and PCP domains. Phylogenetic analysis subdivided the C 
domain in NRPS into six different functional subtypes: Cyclization, starter Condensation, 
LCL, 
DCL, E, dual E/C domains (Rausch et al., 2007). The conserved residues in the 
active site are different depending on the catalytic function. The C domain possesses 
the His-motif HHXXXDG in the active site that catalyses peptide bond formation. The Cy 
domain catalyses the cyclodehydration of its own generated peptide bond and the His 
motif replaced by DXXXD (Grünewald and Marahiel, 2013). The multiple sequence 
alignment revealed that the C domain in HolA belongs to Cy subtype and possesses a 
unique conserved sequence, DLIFVD. In congocidine biosynthesis from Streptomyces 
ambofaciens, one of its C domain accepts CoA- activated substrate rather than 
substrate introduced by the PCP-Ppant arm (Juguet et al., 2009).  
The linker region between Cy and A domain in HolA consists of twelve residues which 
facilitate the conformational change during the catalytic process between these two 
domains creating a platform to deliver the substrate as reported in the recent structural 
study (Drake et al., 2016). The linker region between A and PCP domain consists of 
fifteen residues which may allow more flexibility to move and make different 
conformations to visit both C and A catalytic sites. 
These features suggest possible initial steps of pyrrothine biosynthesis by HolA as 




first cysteine and transfers it to the 4-phosphopantetheine arm on the PCP domain. The 
activated cysteine is covalently bound as a thioester to the free thiol of 4-
phosphopantetheine arm. The next step involves the activation of the second cysteine 
either by A domain or may be by a stand-alone Acyl-CoA synthetase provided either by 
pTML1 or chromosomal DNA as reported in congocidine biosynthesis. The cysteine 
activation as a CoA-thiolester depends on the C domain ability to accept such 
substrates as reported in the congocidine system. To catalyse the peptide bond 
formation and cyclization, all the three domains should undergo a conformational 
change to guarantee the delivery of the substrates to the catalytic site of the C domain 
which accepts the substrates from two sides.    














Figure 3.20. The proposal pathway for pyrrothine biosynthesis. (i) Activation of the 1st 
cysteine as AMP by A domain; (ii) Transferring of the activated cysteine to 4-Ppnt (wave 
line) on PCP; (iii) The loaded Ppnt moves to C domain active site (dash line); (iv) Either 
C domain accept activated CoA-cysteine or A domain activates the 2nd cysteine in the 
iterative manner and (v) Conformational change of the domains to deliver both cysteines 























4. GENERAL DISCUSSION, CONCLUSION AND FUTURE WORKS 
4.1. Overview   
Polyketides are structurally diverse natural compounds produced in many bacteria and 
fungi by polyketide synthases (PKSs). Because of the pharmacological activities, 
polyketides have occupied a significant area in the drugs industry and become a subject 
for intensive research and studies to produce novel derivatives with improved properties. 
Many approaches of genetic engineering have been applied to manipulate the enzyme 
machinery responsible for polyketides assembly. In general, these approaches either 
target the enzymes responsible for the backbone assembly or target tailoring enzymes 
which direct post-assembly modifications. Post-PKS enzymes add significant functional 
groups to the polyketides backbone such as glycosyl, methyl and hydroxyl groups. 
These impart the produced compounds structural diversity and alter biological activities 
(Rix et al., 2002; Weissman and Leadlay, 2005). 
The enzymes that introduce hydroxyl groups to the product backbone have received 
considerable interest and become the subject of many studies. Mutation and 
heterologous expression experiments have been used to exploit such enzymes to 
generate novel derivatives (Rix et al., 2002; Wu et al., 2016). Site-directed mutagenesis 
of Ala245 to Thr in the active site of 6-hydroxyerythonolide B hydroxylase altered the 
substrate specificity of this enzyme (Xiang et al., 2000). Inactivation of nonheme-




pneumocandin A0 production and increased the yield of pneumocandin B0, the 
semisynthetic precursor of the antifungal drug, caspofungin acetate (Chen et al., 2015). 
The characterization of tailoring enzymes not only contributes to the generation of new 
products with altered biological activities but also provides a significant tool to study the 
biosynthetic pathways. Many genetic manipulation studies in our lab which targeted the 
mup cluster and the studies that targeted the tailoring enzymes revealed quite important 
facts about the biosynthesis of mupirocin and genetic manipulation allowed the 
production of many derivatives (Gurney and Thomas, 2011; Gao et al., 2014). However, 
quite a few such studies were carried out about the thiomarinol cluster because of the 
genetic manipulation difficulties (See below), and the majority of the proposed genes 
function and biosynthesis pathway is based on the sequence similarities of the 
mupirocin and thiomarinol clusters (Fukuda, et al., 2011). As an alternative strategy, the 
in trans expression of the genes between the heterologous hosts and the 
characterization in vitro of purified enzymes have been carried out to investigate gene 
function. For example, in vitro analysis revealed that both TmlU and HolE are necessary 
to join pyrrothine molecule with marinolic acid (Dunn et al., 2015). The same strategy 
was used to investigate TmuB responsibility in the thiomarinol cluster.  
In modular type I PKSs such as deoxyerythronolide B synthase (DEBS) which catalyses 
erythromycin biosynthesis, the gene order is consistent with the biosynthetic order 
(Donadio et al., 1991). However, the mup cluster doesn’t follow this rule as revealed by 
mutational analyses (some of examples are shown in: Hothersall et al., 2007, Cooper et 




cluster is consistent with its function to hydroxylate the product as a final step as 
revealed by the experiments in this study. Some of the tailoring enzymes in the mup 
cluster work together to achieve single tailoring step and deletion of one of these 
abolishes the PA-A production (Cooper et al., 2005a). Contrariwise, TmuB 
independently catalyses the product hydroxylation and gene inactivation didn’t block the 
biosynthesis machinery.  
Both thiomarinol C and G (Figure 1.14) were isolated as minor products from the WT 
producer (Shiozawa, et al., 1997). Thiomarinol C lacks a hydroxyl group at C4, while 
thiomarinol G lacks hydroxyl groups at C4 and C6 with an extra hydroxyl group at C8. 
From these facts, one can suggest two important points about these hydroxylations in 
the thiomarinol system. First, the presence of hydroxyl group at C8, prevents both the 
C4 and C6 hydroxylation which means that the enzyme responsible for 6-hydroxlation 
might display the same substrate specificity as TmuB does. Second, the un-
hydroxylated intermediate precursor of thiomarinol G could be accepted by all the 
enzymatic assembly line through the thiomarinol cluster which might mean that the 6-
hydroxylation is a final tailoring step either before or after 4-hydroxylation.  
The inactivation of TmuB (Point mutation I109N) in the thiomarinol producer, 
Pseudoalteromonas sp. SANK 73390, is among the few successful mutations that were 
achieved in this bacterium in our Lab. The site directed mutagenesis strategy used in 
our lab to introduce mutations has worked properly in other bacteria such as 
Pseudomonas fluorescens NCIMB 10586. However, the same strategy doesn’t seem to 




mutagenesis and complementation analyses to characterize and manipulate many 
genes in the thiomarinol cluster as was done in the mup cluster in P. fluorescens NCIMB 
10586.         
Pseudoalteromonas spp SANK 73390 is a marine bacteria and many features have not 
been characterized yet which might make the genetic modifications difficult. These 
include the efflux pump system which makes the bacteria resistant to antibiotics. This 
feature is a very critical issue as antibiotic selection steps during mutation procedure is 
an important step to distinguish between transconjugant and non-transconjugant 
phenotypes (Higher antibiotic concentration was used in this study, see below). The 
second feature is the barriers mechanism such as surface exclusion and restriction 
systems that could be used by bacteria against foreign DNA which might reduce the 
transformation efficiency. 
Previous studies reported many successful mutagenesis experiments in 
Pseudoalteromonas species, but all the mutations in all these species were targeted 
chromosomal genes (Wang et al., 2015). However, the thiomarinol gene cluster in 
Pseudoalteromonas spp SANK 73390 is encoded by circular plasmid pTML1 rather than 
chromosomal genome which may make the mutation difficult. As an attempt to 
overcome these difficulties, many strategies have been used to mobilise pTML1 from 
SANK, but unfortunately, none were successful due to unclear reasons (Omer-Bali, 




Our enthusiasm for the TmuB story, encouraged us to carry out a mutational experiment 
in the original producer, Pseudoalteromonas spp SANK 73390, to deactivate tmuB as 
described with required modifications. Four remarkable points were the differences 
between the current mutation (TmuB I109N) with the previous successful and 
unsuccessful trials. First, the current mutation is a point mutation replacing only two 
bases (Figure 2.41) while the previous experiments involved gene knockout. Second, in 
the previous experiments, the constructed vector was carried out by cloning two 
separate inserts (500bp) flanking the target gene, while in TmuB mutation about 800bp 
was cloned into the suicide vector which might give more chance to integrate into the 
target DNA. Third, the yellow pigment of the colonies worked as an indicator for the 
integration and excision of the suicide vector. This narrowed down the search to focus 
on particular colonies with a high possibility of successful plasmid integration. The 
integration of the suicide vector upstream of holA-H in the thiomarinol cluster, interrupted 
the formation of the pyrrothine molecule and generated white colonies. When the suicide 
vector has excised, the yellow pigment restored and the massive screening of the 
colonies identified the mutant phenotype from these colonies. Fourth, a high 
concentration of antibiotics, which might be the most important point, was used for 
transconjugant selection to overcome any possibility of antibiotic resistance problem 
(see Section 2.3.10.1 in Chapter 2). 
According to the principle of the mutation strategy, the proportion of the generated 
mutant phenotype should be equal to the wild type (i.e. 50% of the growing colonies). 




NCIMB 10586, while with Pseudoalteromonas spp SANK 73390, the vast majority of the 
transconjugated cells reverted to the wild type. In conclusion, it is really not clear yet why 
the gene manipulation in this species is quite difficult. Therefore, more studies are 
required to discover the mysterious features of the producer or to characterize the 
pTLM1.  
Since non-ribosomal peptides are structurally diverse products, the biosynthesis system 
responsible for the product assembly should possess the same diversity. The product 
diversity either comes from the unusual building units or from the unusual features of the 
system. Therefore, more biochemical and structural studies are required to predict the 
dynamic interactions between modules and domains that mediate the enzymatic 
processes. Characterization of more NRPS proteins from diverse origin might broaden 
our knowledge and understanding of non-ribosomal peptide biosynthesis and exploit this 
complex machinery. Investigating the NRPS from marine bacteria such as HolA protein 
which exhibited some unusual behavior might add new aspect in this regard.   
 
4.2. Conclusion 
Within the context of the above general points the key conclusions that can be drawn 




1- TmuB in the thiomarinol cluster catalyses C-4 hydroxylation of thiomarinol as a 
tailoring step. In addition to C9-10 epoxide and pyrrothine, this uncovers one more 
difference between mupirocin and thiomarinol structure assembly at the genetic level.  
2- TmuB expression in heterologous hosts catalyses analogous substrates efficiently 
except those with a different pyran ring (with extra groups attached). The mutagenesis 
based on the modelling and docking results couldn’t change the specificity of the TmuB 
to catalyse such substrates.      
3- In vitro analysis revealed that TmuB is able to catalyse analogues with extra groups 
on the pyran ring but with much lower efficiency.  However, apart from the pyran ring the 
analogues with different C-terminal structure such as thiomarinol C doesn’t affect TmuB 
catalytic efficiency. 
4- The hydroxylation or absence of hydroxylation of the natural product backbone plays 
a substantial role in antibacterial potency and may give it new biological activities.  
5- TmuB works independently to add a hydroxyl group to thiomarinol in the sense that its 
inactivation doesn’t cause a defect in the rest of the biosynthesis system suggesting that 
the hydroxylation occurres as a final step either before or after the pyrrothine joining to 
the marinolic acid. 
6- The successful of the mutation experiment in Pseudoalteromonas spp SANK 73390 




required modifications. On the other hand, more research is required to uncover the 
unknown features of the producer which are needed to achieve successful mutagenesis.    
7-  HolA, which assembles two cysteines to form the pyrrothine molecule, possesses 
some unusual features which facilitate the joining and cyclization of two cysteine 
molecules. The protein produced in heterologous bacteria appear to exhibit three distinct 
conformations or folding states. The results showed HolA as monomer protein and the 
conformational change of the domains may be necessary to achieve the catalytic 
activity. 
                
4.3. Future work 
4.3.1. TmuB project 
In an attempt to change the TmuB specificity, many mutations of the residues in the 
active site were carried out depending on the bioinformatic analyses which predict the 
homology model and substrate docking. However, the homology model of TmuB was 
generated depending on the other resolved proteins which catalyse substrates that are 
structurally different from PA-A. Therefore, the orientation of residues in the active site 
may slightly differ from reality. In addition, the interactions between the substrates and 
the protein structures in the docking process depend on the parameters that have been 
used (i.e. different parameters resulted in different conformations). Finally, the correct 




right position. Therefore, to obtain a correct and accurate structure of the protein and 
identify the critical residues in the active site, the protein should be crystalized as a 
complex with the substrate. Many studies have identified the crystal structure of 
nonheme-iron(II)/2-oxoglutarate-dependent hydroxylase successfully (Hausinger, 2004). 
Mutagenesis experiments based on a determined crystal structure can not only facilitate 
specificity changes but could also allow modification of the catalysis of the protein (Yan 
et al., 2015). Therefore, the future work for TmuB specificity should include 
crystallography trials followed by mutagenesis experiments according to the obtained 
crystal structure. Work carried out by colleagues in Bristol, specifically in the laboratory 
of Paul Race did obtain crystals but apparently the diffraction data obtained did not allow 
structure determination and so this was not included in this Thesis. The pseudomonic 
acid derivatives produced in this study should be subject for further studies to explore 
the biological activities which might be useful. Thiomarinol C was produced as a major 
product from the mutant (I109N) SANK and the antibacterial potency was lower than 
thiomarinol A but still higher than PA-A. Therefore, the cytotoxicity test of this compound 
in eukaryotic cells might explain the role of 4-hydroxylation.                    
 
4.3.2. HolA project 
As an initial test to check the activity of the A domain, the malachite green ATPase test 
was used which is the indirect method to measure the amount of the pyrophosphate 




added to convert PPi to phosphate ion which can be detected by the test. Therefore, the 
amount of the phosphate measured by this test may represent the activity of the second 
enzyme (PPase) rather than HolA A domain. To overcome this possibility, a higher 
concentration of PPase was used and incubated for a longer time to allow conversion of 
all of the PPi released by the A domain into phosphate ions. A more accurate test could 
be used to directly measure pyrophosphate released by the A domain such as 
Pyrophosphate Assay Kit (Fluorometric) which provides the most robust 
spectrophotometric method.  
Mass spectrometry (MS) experiment could be used to test the ability of HolA to both 
activate and condense cysteine. To confirm that these two are loaded as a cys-cys 
dimer on the PCP domain, the protein should be subjected to proteolytic digest and the 
molecular mass of the peptide should increase by the expected amount. Both 
pyrophosphate assay kit and MS could be used with the mutant proteins to check the 
oligomeric state of HolA protein as described in Chapter 3. For this purpose, the 
complete inactivation of individual domains should be created by targeting the critical 
residues in the active site as determined in Chapter 3.   
Structural studies revealed intermolecular interactions and the conformational changes 
between NRPS domains which are necessary to achieve the catalytic activity. Therefore, 
the crystal structure of HolA protein might tell us the significance of the different peaks 
shown on the gel filtration chromatography in terms of catalytic activity and this might 
provide fundamental insights into the way in which NRPSs work which is an area of 























Appendix C. The NMR for, PA-B, 4-hydroxylated PA-
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